Carbohydrate-Active enZYmes: functional and applicative aspects of glycoside hydrolases by Ferrara, Maria Carmina
CARBOHYDRATE-ACTIVE ENZYMES: 
 FUNCTIONAL AND APPLICATIVE ASPECTS  
OF GLYCOSIDE HYDROLASES 
Maria Carmina Ferrara 
DOCTORAL THESIS 

The important thing in science is not so much to obtain new facts  
as to discover new ways of thinking about them. 
[Sir William Henry Bragg] 
 
!TABLE OF CONTENTS 
Keywords ................................................................................................................. 1 
List of abbreviations ................................................................................................ 2 
Chapter 1 
General Introduction ............................................................................................ 3 
1.1 Glycoside hydrolases: general features and classification .......................... 5 
1.2 CAZy database ............................................................................................. 7 
1.3 Glycoside hydrolases: catalytic mechanisms ........................................... 10 
1.4 Glycoside hydrolases: biological roles and applications ......................... 13 
1.5 Post-genomic era: what’s about function and structure? ........................ 16 
1.6 Purpose of the thesis ................................................................................. 19 
1.7 References ................................................................................................. 21 
Chapter 2 
Identification and molecular characterization of a 
N-acetyl-β-glucosaminidase from the crenarchaeon S. solfataricus ............. 24 
2.1 General overview ......................................................................................... 25 
2.2 N-acetyl-β-hexosaminidases: structural and functional features ................. 26 
2.3 N-acetyl-β-hexosaminidases: biological roles and applications .............. 35 
2.4 Sulfolobus solfataricus: a hyperthermophilic archaeon ............................... 39 
2.5 Purpose of the work ................................................................................... 46 
2.6 Experimental procedures ........................................................................... 48 
2.7 Results and Discussion ............................................................................. 59 
2.8 References ................................................................................................. 87 
Chapter 3 
Pharmacological enhancement of acid alpha-glucosidase  
by the allosteric chaperone N-acetylcysteine .................................................. 99 
3.1 General overview ..................................................................................... 100 
3.2 acid alpha-glucosidase: structure and function ...................................... 101 
3.3 Lysosomal storage dieases ..................................................................... 108 
3.4 Pompe disease ......................................................................................... 113 
3.5 Therapeutic approaches .......................................................................... 117 
3.5.1 Enzyme Replacement Therapy in Pompe disease .......................... 119 
3.5.2 Pharmacological Chaperone Therapy .............................................. 122 
!3.5.3 Other therapeutic approaches .......................................................... 128 
3.6 Purpose of the work ................................................................................. 131 
3.7 Experimental procedures ......................................................................... 133 
3.8 Results and Discussion ........................................................................... 137 
3.9 References ............................................................................................... 161 
List of Publications .............................................................................................. 172 
Conferences ........................................................................................................ 173 
Acknowledgments ............................................................................................... 176 
! 1 
KEYWORDS 
Glycoside hydrolases 
Archaea 
Sulfolobus solfataricus 
N-acetyl-glucosaminidase 
Alpha-glucosidase 
Lysosomal storage disease 
Enzyme replacement therapy 
Pharmacological chaperones 
 
! 2 
LIST OF ABBREVIATIONS 
 
2- or 4-NP 2- or 4-nitrophenyl 
2-ME 2-mercaptoethanol 
aa amino acids 
CAZy Carbohydrate-Active enZYme  
CBE conduritol b-epoxide 
Cys cysteine 
DNJ 1-deoxynojirimycin 
ER endoplasmic reticulum 
ERT enzyme replacement therapy 
FCE free cell extract 
GAA acid α-glucosidase 
Gal galactopyranoside 
GalNAc N-acetylgalactosaminide 
GH glycoside hydrolase 
Glc glucopyranoside 
GlcNAc N-acetylglucosaminide 
Gly glycine 
His histidine 
LSD lysosomal storage disease 
M molar 
mM millimolar 
MPS  mucopolisaccharidosis 
MU 4-methylumbelliferyl 
NAC N-acetylcysteine 
NAG N-acetylglycine 
NAS N-acetylserine 
NB-DNJ N-Butyldeoxynojirimycin 
ORF open reading frame 
PCR polymerase chain reaction 
PCs pharmacological chaperones 
PCT pharmacological chaperone therapy 
PD Pompe disease 
Ser serine 
v/v volume/volume 
!! 3 
Chapter 1 
 GENERAL INTRODUCTION
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Carbohydrates constitute one of the four fundamental classes of 
biopolymers, along with nucleic acids, proteins, and lipids. In contrast to DNA, 
RNA, and proteins that are linear polymers containing only one basic type of 
linkage between monomers, carbohydrates can form branching structures and 
the multiple monosaccharide building blocks can be linked to various regio- and 
stereochemistries. Accordingly, a relatively simple set of sugars can form a 
huge number of complex structures. Moreover, the resulting oligosaccharides 
can be assembled on various scaffolds such as protein, nucleic acids, lipids, 
antibiotics, etc. generating the so-called glycoconjugates. The carbohydrates 
alone or linked to other biomolecules constitute an “information-rich” system 
capable of participating in a wide range of biological functions. These molecules 
can serve as intermediates in generating energy and as signalling effectors, 
recognition markers, and structural components. They constitute the main 
structural element of the plant cell walls such as cellulose, one of the most 
abundant organic compounds in the biosphere, and are the major constituents 
of the outer covering of insects and crustaceans, such as chitin, a polymer of N-
acetylglucosamine (Khor, 2001). In addition, carbohydrates can constitute a 
nutritional reservoir, such as glycogen in animal cells and starch in plants. 
Glycans are also important in infections (Hooper and Gordon, 2001): bacteria, 
viruses and parasites may use lectins on their cell surface as a ‘key’ to open a 
sugar ‘lock’ on a host cell surface. For instance, influenza virus begins its 
infection cycle through the binding to sialic acid on host cell surface (Sauter et 
al., 1992). 
Although glycans are found in all organisms, considerable diversity of their 
structure and expression exists in nature, both within and between evolutionary 
lineages (Varki, 2006). Sufficient data are available, however, to indicate that 
there is no universal “glycan code” akin to the genetic code. Unlike protein 
sequences, which are primary gene products, glycan chain structures are not 
encoded directly in the genome and are secondary gene products. The glycan 
chains represent numerous combinatorial possibilities, generated by a variety of 
competing and sequentially acting enzymes, glycosidases and 
glycosyltransferase. 
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1.1 GLYCOSIDE HYDROLASES:  
GENERAL FEATURES AND CLASSIFICATION
Glycoside hydrolases: general features and classification 1.1!
!
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Glycoside hydrolases (GHs), also known as glycosidases or glycosyl 
hydrolases, are enzymes that catalyze the hydrolysis of glycosidic bonds 
between two or more carbohydrate residues or a carbohydrate unit linked to an 
aglycon group. This class of enzymes is ubiquitous in nature, about 1% of the 
genome of any organism encodes for GHs (Vocadlo and Davies 2008), and is 
involved in several biological processes. Selective hydrolysis of glycosidic 
bonds is crucial for energy uptake, cell wall expansion and degradation, and 
turnover of signalling molecules. As a consequence of saccharides diversity, 
there is a great variety amongst GHs. The IUBMB (International Union of 
Biochemistry and Molecular Biology) nomenclature of GHs is based on their 
substrate specificity and molecular mechanism: the Enzyme Commission (EC) 
number corresponding to GHs is EC 3.2.1.x, where x represents substrate 
specificity.  According to the two catalytic mechanisms proposed by Koshland in 
1953, GHs are classified in inverting or retaining (see section 1.3 for details). 
They can be further classified on the basis of their action mode on long sugar 
chains: exo-glycosidases catalyze the hydrolysis of the glycosidic bond from the 
reducing or the non-reducing termini of carbohydrate polymers, while the endo-
glycosidases act in the middle of a poly- or oligosaccharide (Fig. 1.1.1).  
Another classification of GHs is based on the amino acid sequence similarities 
among the various enzymes and is reported in CAZy database, which will be 
described in more details in the next section. 
 
 Figure 1.1.1: Mechanism of action of exo- and endo-glycosidases 
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1.2 CAZY DATABASE
CAZy database 1.2!
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IUBMB enzyme classification does not reflect the structural and mechanistic 
features of GHs. To meet these needs, in the 1991 Henrissat proposed the 
classification of GHs based on protein sequence and structure similarities that 
correlates with enzyme mechanisms more than enzyme specificity (Bernard 
Henrissat 1991). CAZy database is founded on this type of classification and is 
available on the web since September 1998 at URL http://www.cazy.org 
(Cantarel et al., 2009). This resource includes not only GHs, but also other 
enzymes involved in the synthesis, degradation and modification of 
carbohydrates and glycoconjugates, collectively known as Carbohydrate-Active 
enZymes (CAZymes).  
Each family is annotated with information regarding known enzyme activities 
and includes catalytic and structural features. At present, CAZy covers 
approximately 300 protein families in four classes of enzyme activities (Tab. 
1.2.1).  
Enzymatic Class No of families 
Glycosyde hydrolases (GHs) 132 
Glycosyltransferases (GTs) 94 
Polysaccharide lyases (PLs) 22 
Carbohydrate esterases (CEs) 16 
Table 1.2.1: CAZy families, updated to March 2013 
Members of the same family have the same protein fold and closely related 
catalytic mechanism. Furthermore, the GH families with similar tertiary structure 
are grouped into clans which are thought to have evolved from a common 
ancestral gene; to date there are 14 clans (Henrissat and Bairoch, 1996). In 
addition to enzymes, CAZy database also includes Carbohydrate-binding 
modules (CBMs) that have no enzymatic activity per se, but potentiate the 
activity of many CAZymes by targeting to and promoting a prolonged interaction 
with the substrate.  
The CAZy database is a convenient tool to derive mechanistic informations. It is 
regularly update through addition of new sequences, new families and further 
information related to the families. New sequences lacking biochemical and 
enzymatic information that cannot be included in an existing family or grouped 
in a new family are included in the GH0 family.  
1.2 CAZy database !
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The principal structural and functional features of each CAZyme family can be 
retrieved by CAZypedia (http://www.cazypedia.org), a comprehensive 
encyclopedia of the CAZymes. In particular, each page of this resource cites 
primary literature which reports on the first identification of enzyme active site 
residues, catalytic mechanism, three dimensional structure, or other important 
works which define catalysis in a GH family or subfamily. This project is inspired 
by, and closely connected with, the CAZy database. All contributors to 
CAZypedia, from the Authors to the Board of Curators, are selected experts in 
the field.  
In definitive, glycoscience is a field in continuous development and ongoing 
efforts are directed towards structural and biochemical characterization of novel 
GHs in order to expand our understanding in this field. 
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1.3 GLYCOSIDE HYDROLASES:  
CATALYTIC MECHANISMS
1.3 Glycoside hydrolases: catalytic mechanisms !
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Glycoside hydrolases carry out cleavage of glycosidic linkages in a 
stereospecific manner. According to the two catalytic mechanisms proposed by 
Koshland in 1953, GHs can be classified in inverting or retaining, depending on 
the stereochemistry at the anomeric center of the product generated.  
The inverting enzymes hydrolyze the glycosidic bonds generating a product 
with anomeric carbon inverted with respect to that of substrate. The catalysis 
proceeds through a single-displacement mechanism (Fig.1.3.1).  
The catalytic machinery of these enzymes involves two catalytic carboxylates 
normally glutamic or aspartic acids: one functions as general acid, and the other 
as a general base that assists the nucleophilic attack by a water molecule.  
The retaining mechanism leads to a net retention of the configuration at the 
anomeric carbon of the substrate after cleavage. This reaction proceeds via a 
double displacement mechanism with the assistance of two catalytic 
carboxylate residues and involves the formation of a covalent glycosyl-enzyme 
intermediate (Fig.1.3.2). In the first step (glycosylation), one of the two 
carboxylic groups functions as a general acid catalyst by protonating the 
glycosidic oxygen, simultaneously the second carboxylate acts as a nucleophile 
by attacking the anomeric carbon of the glycosidic bond. This step leads to the 
formation of glycosyl-enzyme intermediate. In the second step 
(deglycosylation), the first carboxylate residue now functions as a general base 
and activates an incoming water molecule by deprotonation. The water 
molecule acts as nucleophile and hydrolyses the glycosyl-enzyme intermediate 
resulting in the release of the sugar molecule. 
Figure 1.3.1:!Catalytic mechanism of an inverting β-glycoside hydrolase 
Glycoside hydrolases: catalytic mechanisms 1.3!
!
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Figure 1.3.2:!Catalytic mechanism of a retaining β-glycoside hydrolase 
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BIOLOGICAL ROLES AND APPLICATIONS
Glycoside hydrolases: biological roles and applications 1.4!
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Glycosidases play an important role in a wide range of biological process, 
from primary metabolism through glycoprotein glycan maturation. Therefore, it 
is not surprising that their function or dysfunction is implicated in a number of 
different diseases, leading to an interest in glycosidases as potential 
therapeutics per se or as drug targets. For instance, intravenously 
administration of the recombinant GHs is at the basis of the Enzyme 
Replacement Therapy (ERT) (for details see paragraph 3.5.1), a therapeutic 
approach aimed to restore the defective metabolic function in Lysosomal 
Storage Disorders (LSDs) (see paragraph 3.3 for a detailed description). In 
addition, several pharmaceutical treatments exploit the GHs as therapeutic 
targets modulating their synthesis and/or activity. For example, neuraminidase 
has been the target for the development of two influenza drugs (Relenza™, 
GlaxoSmithKline, and Tamiflu™, Roche). These compounds are synthetic 
structural analogues of neuraminic acid that bind specifically to the 
neuraminidase active site, and thus inhibit the transmission of the virus. The 
therapy for diabetes mellitus type 2 takes advantage of competitive inhibitors of 
α-glucosidase (GlucobayTM, Bayer, and GlysetTM, Pfizer) to delay the 
digestion and absorption of carbohydrates in the small intestine and hence 
reduces the increase in blood-glucose concentrations after a carbohydrate load. 
Iminocyclitols (also known as azasugars or iminosugars) are particularly well-
studied glycosidase inhibitors that have shown to be promising in the treatment 
of cancer (Goss et al., 1994; Sun et al., 2009), LSDs (Valenzano et al. 2011) 
and viral infections such as HIV (Gruters et al., 1987), and hepatitis B and C 
(Mehta et al., 1998). 
The great deal of attention for GHs can be also attributed to their role in a 
variety of industrial and biotechnological applications. The current efforts are 
directed to optimize the role of GHs in the emerging field of renewable energies. 
The last 15 years have seen a massive growth of so-called first-generation 
processes that are based upon hydrolysis by amylases, pullulanases and 
glucoamylases of polysaccharides extracted from biomasses of crops like corn, 
wheat and sugar cane. However, these plants are also important components 
of the human food web, so using them for ethanol production has the potential 
to affect the price and availability of these basic commodities (Naik et al., 2010). 
By contrast, the production of second generation bioethanol exploits 
1.4 Glycoside hydrolases: biological roles and applications !
!
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lignocellulosic materials, deriving from abundant and underutilized biological 
resources such as forestry crops (poplar, willow and eucalyptus), and perennial 
grasses (miscanthus, switch grass and reed canary grass). Cellulases and 
hemicellulases, such as xylanases, β-glucosidases, β-xylosidases, endo- and 
exo-glucanases, have been investigated as means to hydrolyze cellulose and 
hemicellulose in the lignocellulosic materials to fermentable reducing sugars 
(Sun and Cheng, 2002). 
GHs are “friendly” catalysts also in other industrial process. For instance, 
xylanases constitute a major group of industrial enzymes with significant 
application in paper industry: the hydrolysis of xylan facilitates release of lignin 
from paper pulp and reduces the level of usage of chlorine as the bleaching 
agent (Shoham et al., 1992). The hydrolytic activity of the amylases is 
harnessed in the fermentation processes at the bases of baking and brewing 
industries or for production of high-fructose corn syrup. In the dairy industry, β-
galactosidases are used to hydrolyze lactose from milk products to minimize 
effects on lactose-intolerant individuals (Perotti et al., 2012). Finally, GHs such 
as β-N-acetylgalactosidase and β-galactosidase are able to hydrolyze the A and 
B blood antigens respectively and so they are exploited for the production of the 
common H structure found in the universal O group (Liu et al., 2007).  
These are only some examples that delineate the role of GHs in a variety of 
biological and industrial processes and unveil the importance to study the 
structure and function of this class of enzymes. Understand how these enzymes 
function and what is their functional structure is essential to increase our 
knowledge in this field and to expand their biological and industrial implications. 
! 16 
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Over the last decade, genome sequencing projects have provided a huge 
amount of data that need to be interpreted and integrated with functions. Many 
of the presently available annotations are inferred by bioinformatic analysis that 
predict the functions of newly sequenced genes on the basis of their similarity to 
genes or gene products of known or predicted function. This method displays at 
least two issues: 1) the small size of the genes set with experimentally 
established functions and 2) difficulties to define which level of identity or 
similarity is required to establish that two proteins have the same function or 
otherwise related functions. To date, a significant fraction of every genome 
sequenced, from bacterial to human, is composed of uncharacterized proteins. 
Additionally, one gene can code for different proteins as a result of post-
transcriptional and post-translational processing and modification, so the 
number of proteins requiring characterization greatly exceeds the number of 
genes in the genome (Walsh 2006). Thus, genome sequences alone offer only 
limited biochemical and structural insights.  
The post-genomic era shows great challenges and opportunities in the field 
of glycobiology. The content of genomes from a glycobiological perspective can 
be analyzed (e.g., by listing candidate GHs or GTs in a genome) and compared 
across genomes to see whether families have expanded or disappeared during 
evolution. The genomic sequences have unveiled a plethora of open reading 
frames (ORFs) likely to be involved in the synthesis, modification and 
degradation of sugars. The CAZy classification provides an efficient tool for the 
competent annotation of ORFs found during genome sequencing (e.g. 
prediction of the general function, fold and mechanism). However, progress on 
the biochemical, physiological and structural characterization of unknown ORFs 
are much more slower than sequencing. In CAZy database, the number of 
sequences has increased 14-fold in eight years, while the number of proteins 
with enzymatic and structural characterization has barely doubled (Fig. 1.5.1). 
Therefore, it is essential to understand how the sequences are related to 
structure, mechanism and specificity of the encoded enzyme. Future efforts 
should be directed to translate the data acquired by the genomic sequencing 
projects into the detailed structural and biochemical informations so as reducing 
the current gap between the genome sequencing and the proteomic 
characterization. 
Post-genomic era: what’s about function and structure? 1.5!
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!
Figure 1.5.1: The number of CAZymes noted in December of the years 1999-2007 
(Cantarel et al., 2009) 
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Carbohydrates play an important role in a variety of biological and industrial 
process. Elucidate the structure/function relationship of enzymes involved in 
their modification, CAZymes, can help us to understand the implication of this 
class of enzymes in various biological phenomena and how we can exploit their 
catalytic features, for example in pharmacological therapies or to optimize 
industrial process. 
Starting from these observations my thesis work is dedicated to the study of 
GHs structure/function relationship as common denominator and can be 
subdivided in two principal sections, chapter 2 and 3, respectively. In chapter 2, 
the research plan is focused on the identification and biochemical 
characterization of novel glycosidases activities in the hyperthermophilic 
crenarchaeon Sulfolobus solfataricus, in particular N-acetylglucosaminidase 
activities. This study allows to increase our knowledge on the phylogeny of this 
class of enzymes and to achieve additional data concerning their structural and 
functional features. In chapter 3, the study of structure/function of lysosomal α-
glucosidase is aimed to understand what are the factors responsible of the 
enzyme stabilization and the gained informations are exploited to identify novel 
pharmacological chaperones for the therapy of the lysosomal storage disorder 
known as Pompe disease. 
! 21 
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Chapter 2 of this thesis work describes the identification and molecular 
characterization of a N-acetyl-β-glucosaminidase from the crenarchaeon S. 
solfataricus. This section begins with a brief introduction on the 
structural/functional features and on the biological relevance of this class of 
enzymes (paragraphs 2.2 and 2.3). The chapter keeps on with the description 
of the model organism adopted in my thesis work, S. solfataricus, in which no 
such activity has been described so far (paragraph 2.4). The purpose of this 
work is shown in paragraph 2.5, while the experimental part is described in the 
last two paragraphs; in particular paragraph 2.6 reports on experimental 
procedures and paragraph 2.7 shows results and discussion. At last, the 
paragraph 2.8 reports the literature references included in this chapter. 
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N-Acetyl-β-hexosaminidases (β-HexNAcase, systematic name 2-acetamido-
2- deoxy-β-D-hexopyranoside acetamidodeoxyhexohydrolase, EC 3.2.1.52) are 
exo-glycosidases catalysing the removal of β-D-N-acetylglucosamine (GlcNAc) 
or β-D-N-acetylgalactosamine (GalNAc) from the non-reducing ends of a variety 
of N-acetyl-β-D-hexosaminides.! The activity on both gluco- and galacto-
configurations is a typical feature of this class of enzymes (Muramatsu, 1968; 
Slámová et al., 2010). Generally, D-gluco-structures are preferred and the 
GlcNAcase/GalNAcase activity ratio is commonly in the range of 1.5-4.0 
(Horsch et al., 1997). Nevertheless, in some limited cases, the 
GlcNAcase/GalNAcase ratio is much higher or inverted. For instance, the 
Xenopus laevis enzyme showed a GlcNAcase activity 167-fold higher than 
GalNAcase (Greve et al., 1985) or N-acetyl-β-hexosaminidase from Penicillium 
oxalicum clearly preferred the axial hydroxyl at C-4 position, with a GalNAcase 
activity 2.5-fold higher than GlcNAcase (Weignerová et al., 2003). According to 
the CAZy database (http//:www.cazy.org), N-acetyl-β-hexosaminidases, as 
defined above, are classified into three families: GH3, GH20 and GH84. GH3 
and GH84 β-HexNAcases recognize only GlcNAc derivatives and thus are 
usually named β-N-acetyl-D-glucosaminidases. Since most of the GH20 
enzymes recognize both GlcNAc and GalNAc, they are usually named β-N-
acetyl-D-hexosaminidases (Liu et al., 2012). Although the enzymes grouped in 
these three distinct families possess no sequence homology, they share some 
basic structural and catalytic features. 
GH3 N-acetyl-β-hexosaminidases 
The CAZy family GH3 includes N-acetyl-β-hexosaminidases (EC 3.2.1.52), 
β-glucosidases (EC 3.2.1.21), and, among other enzymatic activities, xylan 1,4-
β-xylosidase, EC 3.2.1.37; glucan 1,3-β-glucosidase, EC 3.2.1.58; glucan 1,4-
 β-glucosidase, EC 3.2.1.74; exo-1,3-1,4-glucanase, EC 3.2.1.-; and α-L-
arabinofuranosidase, EC 3.2.1.55 (Fig.2.2.1). GH3 β-GlcNAcases constitute a 
small group of bacterial enzymes, also known as NagZ; no! eukaryotic β-
HexNAcases have been described in this family so far.  
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Three dimensional structures have been solved for NagZ from Vibrio cholerae 
(Stubbs et al., 2007), Bacillus subtilis (Litzinger et al., 2010), and Salmonella 
typhimurium (Bacik et al., 2012). These enzymes are single domain proteins 
that adopt a TIM barrel fold with the strands of the barrel forming several loops 
at the C-terminal end delimiting the active centre (Fig. 2.2.2). 
The peculiar architecture of the GH3 active site promotes catalysis via the 
classical double-displacement mechanism of retaining glycosidases which 
involves a covalent α-glycosyl-enzyme intermediate (Fig. 2.2.3 A) (see 
paragraph 1.3 for details) (Vocadlo et al., 2000; Vocadlo and Withers, 2005). 
The substrate binding pocket is larger in the area accommodating N-acetyl 
moiety of the substrate and this extra space is occupied by a molecule of water. 
The catalytic nucleophile for NagZ Vibrio furnisii has been identified 
experimentally as Asp242, which is conserved throughout family GH3 (Vocadlo 
Figure 2.2.2: 3D structure of GH3 NagZ from Vibrio cholerae in complex with the 
inhibitor PUGNAc (PDB ID 2OXN) 
Figure 2.2.1: Principal structural and functional features of CAZy family GH3!
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et al., 2000). A general acid residue has not been identified and a conserved 
histidine has been proposed as the general acid/base (Litzinger et al., 2010).! 
An unusual N-acetyl-β-hexosaminidase was also reported, Nag3 from 
Cellulomonas fimi. This enzyme showed a broad substrate specificity, 
hydrolysing both β-N-acetylglucosaminides and β-glucosides (Mayer et al., 
2006).!
GH20 N-acetyl-β-hexosaminidases 
Family 20 contains the highest number of N-acetyl-β-hexosaminidases in 
CAZy classification and is also the most studied, mainly for the presence of the 
human lysosomal β-HexNAcases, HeXA and HexB, whose deficiency leads to 
GM2 gangliosidoses (see the paragraph 2.3 for more details) (Fig. 2.2.4).!!
Figure 2.2.3: Double-displacement retaining mechanism for β-N- 
acetylhexosaminidases; A) classical mechanism utilised by GH3; 
B) substrate-assisted mechanism of GH 20 and 84 
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The catalytic mechanism of GH20 β-HexNAcases is a modification of the 
classical double-displacement process used by retaining glycosidases (Mark 
and James 2002) and is known as substrate-assisted mechanism (Fig. 2.2.3 B). 
In particular, such a catalysis, also called anchimeric assistance, involves, 
rather than an enzyme residue as a nucleophile, the 2-acetamido substrate 
moiety to form an oxazolinium ion intermediate (Mark et al., 2001; Tews et al., 
1997). The N-acetyl group of the substrate is bound in a hydrophobic pocket 
defined by three conserved tryptophan residues. A detailed bioinformatic study 
of some GH20 hexosaminidases revealed a conserved sequence motif 
His/Asn-Xaa-Gly-Ala/Cys/Gly/Met-Asp-Glu-Ala/Ile/Leu/Val surrounding the 
catalytic residues (Gutternigg et al., 2007). The active site contains a highly 
conserved pair of catalytic residues Asp-Glu. The glutamate acts as a proton 
donor, while the aspartate, not functioning as nucleophile, could stabilize the 
oxazoline transition state and assist the correct orientation of the 2-acetamido 
moiety during catalysis (Prag et al., 2000; Williams et al., 2002). The crystal 
structures of several bacterial N-acetyl-β-hexosaminidases have been solved, 
such as Hex1T from Paenibacillus sp. strain TS12 (Sumida et al., 2009), 
chitobiase from Serratia marcescens (Tews et al., 1996), StrH from 
Streptococcus pneumoniae R6 (Jiang et al., 2011) (Fig. 2.2.4). The eukaryotic 
kingdom is represented by the structures of human lysosomal 
hexosaminidases, HexA and HexB (Lemieux et al., 2006; Maier et al., 2003; 
Mark et al., 2003).  
Figure 2.2.4: Principal structural and functional features of CAZy family GH20 
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The common features of all known structures are the (β/α)8-barrel architecture 
of the!catalytic domain and the location of the active site at the C-terminal end 
of the third of the four protein domains. Bacterial enzymes are monomeric, 
while the human β-HexNAcases form active dimers with two catalytic sites. 
Moreover, the subunits of human HexA and HexB are post-translationally 
cleaved, yielding the mature enzyme. 
GH84 N-acetyl-β-glucosaminidases 
The N-acetyl-β-glucosaminidases belonging to family GH84 have recently 
gained great attention, primarily for the presence of human O-GlcNAcase (or 
HexC) which is involved in Alzheimer’s disease (Yuzwa et al., 2008) (Fig. 
2.2.5). 
Figure 2.2.4: 3D structure of GH20 N-acetyl-β-hexosaminidase from Paenibacillus sp. 
TS12 in complex with GlcNAc (PDB ID 3GH5) 
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Although GH20 and GH84 enzymes differ in their amino acid sequence, they 
share the substrate-assisted catalytic mechanism (Fig. 2.2.3 B) and the (β/α)8-
barrel architecture of the!catalytic domain (Macauley et al., 2005). The catalytic 
residues are two aspartates (vs. Asp and Glu in GH20), actively involved in 
catalysis, while a tyrosine stabilizes the transition state (Dennis et al., 2006; 
Rao et al., 2006). Two bacterial enzymes of this family have been successfully 
crystallized and their structures resolved: the β-HexNAcases from the pathogen 
Clostridium perfringens (Fig. 2.2.6) and from the human gut symbiont 
Bacteroides thetaiotaomicron (Dennis et al., 2006). These structures serve as 
good models of both the active site and catalytic domain of human O-
GlcNAcase.  
Figure 2.2.6: 3D structure of GH84 N-acetyl-β-hexosaminidase from Clostridium 
perfringens in complex with the inhibitor PUGNAc (PDB ID 2CBJ) (Rao 
et al., 2006) 
Figure 2.2.5: Principal structural and functional features of CAZy family GH84 
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N-acetyl-β-glucosaminidases inhibitors 
The inhibition of β-HexNAcases is useful both for elucidating the role of these 
enzymes in biological processes as well as for developing therapeutic tools. 
The principal issue in the generation of β-HexNAcases inhibitors relies on the 
design of highly selective molecules for the various forms of human enzymes. 
Promiscuous inhibitors acting on both lysosomal (HexA and HexB) and nuclear 
(O-GlcNAcase) β-HexNAcases generate complex phenotypes and are poorly 
useful in studying the physiological roles of individual enzymes.  
In the past few years, two main inhibitor platforms have been studied: NAG-
thiazoline (2’-methyl-α-D-glucopyrano-[2,1-d]-Δ2’-thiazoline) and PUGNAc (O-
(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate). The 
structural scaffolds of these compounds mimic the transition state of the 
substrate-assisted reaction mechanism shared by GH20 and 84 enzymes. 
NAG-thiazolines are highly potent inhibitors of human HexA and HexB (GH20) 
as well as O-GlcNAcase (GH84). The active sites of GH84 enzymes tolerate 
moderately bulky substituents attached to the substrate acetamido group 
compared to those of GH20 enzymes. Exploiting these structural differences, 
new inhibitors highly selective for human O-GlcNAcase were developed. 
Indeed, the inhibition of HexA and HexB rapidly decreases with increasing N-
acyl chain length of the inhibitor, while O-GlcNAcase tolerates longer chains. 
On these bases, functionalized NAG-thiazolines have been prepared, such as 
aliphatic, azide and fluoride derivatives, which showed outstanding selectivity 
for O-GlcNAcase. For instance, an aliphatic chain linked to the thiazoline ring 
allowed to increase 3100-fold the selectivity for O-GlcNAcase over the 
lysosomal forms (Macauley et al., 2005).  
PUGNAc, a molecule that is thought to mimic the geometry of the dissociative 
transition states of most glycosidases, is another poorly selective inhibitor of β-
GlcNAcases (Macauley et al., 2005). As in the case of NAG-thiazoline, the 
problem of the selectivity was addressed by the! design and preparation of 
PUGNAc derivatives. Exploiting the ability of GH20 enzymes to accommodate 
substrates with the D-galacto-configuration, it has been possible to develop 
highly selective inhibitors of lysosomal N-acetyl-β-hexosaminidases, such as 
Gal-PUGNAc, which is inactive on O-GlcNAcase (Stubbs et al., 2009).!
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However, the overall inhibition and selectivity of PUGNAc-derived compounds 
are somewhat poorer than NAG-thiazoline derivatives (Stubbs et al., 2006). 
Moreover, some PUGNAc derivatives, such as N-valeryl-PUGNAc and N-
butyryl-PUGNAc, act as inhibitors also of NagZ (GH3) (Balcewich et al., 2009; 
Stubbs et al., 2007). 
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N-acetyl-β-hexosaminidases are commonly involved in the degradation of 
polysaccharides and glycoconjugates containing N-acetylhexosamine residues. 
They are universally distributed among most types of organisms, both 
prokaryotes and eukaryotes, but not archaea, in which no such activity has 
been described so far. These enzymes show a very broad range of functions 
depending on the organism source and on the cellular localization. For 
instance, bacterial β-HexNAcases play an important role in recycling the cell 
wall. N-acetyl-β-glucosaminidases from Gram-negative bacteria (NagZ, GH3), 
participate in the peptidoglycan recycling pathway hydrolysing the β-1,4-
glycosidic bond between N-acetylglucosamine and N-acetylmuramic acid 
(Cheng et al., 2000). The resulting 1,6-anhydro-N-acetylmuramic acid peptides 
can induce the transcription of AmpC β-lactamase, and consequentially extend 
the resistance of Gram-negative bacteria to a broad spectrum of β-lactam 
antibiotics. The selective inhibition of NagZ represents an approach intensively 
investigated to attenuate/suppress the resistance to many β-lactam antibiotics 
(Stubbs et al., 2007). 
Insect cells usually express several N-acetyl-β-hexosaminidases, which are 
important for the turnover of the chitin exoskeleton (Hogenkamp et al., 2008), 
but also in N-glycan trimming producing paucimannosidic-type N-glycans that 
are different from the glycans produced by higher eukaryotes (Altmann et al., 
1995; Gutternigg et al., 2007). It has been demonstrated that the inactivation of 
this class of enzymes in insect expression cell lines (Sf9, Drosophila S2 cells) 
could represent a useful tool to improve the production of eukaryotic 
glycoproteins in recombinant form via baculovirus expression systems (Geisler 
et al., 2008; Kim et al., 2009; Léonard et al., 2006).!
The physiological role of β-HexNAcases is mainly studied in mammals, 
especially in humans, where a deficiency of these enzymes causes severe 
disorders.! Mammalian cells express three distinct types of N-acetyl-β-
hexosaminidases:  
1. HexA, HexB and HexS (GH20) 
2. HexC or O-GlcNAcase (GH84) 
3. HexD (GH20)  
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These enzymes differ in their physiological roles and structures.  
HexD is a nucleocytoplasmic N-acetyl-β-hexosaminidase discovered recently, 
which prefers N-acetylgalactosaminides as substrates, but its biological 
significance remains unclear (Gutternigg et al., 2009). 
O-GlcNAcase (OGA) is another nucleocytoplasmic N-acetyl-β-hexosaminidase, 
with a strict specificity to N-acetylglucosamine (GlcNAc) (Comtesse et al., 
2001). It catalyzes the removal of GlcNAc moieties from post-translationally 
modified serine and threonine residues of nucleocytoplasmic proteins (Gao et 
al., 2001). This post-translational modification is abundant in mammalian cells 
(Torres and Hart, 1984) and is found on many cellular proteins involved in a 
wide range of vital functions, including transcription (Lamarre-Vincent and 
Hsieh-Wilson, 2003), proteasomal degradation (Zhang et al., 2003), and cellular 
signaling (Vosseller et al., 2002), and is also found on many structural proteins 
(Cole and Hart, 1999). This form of glycosylation has been implicated in various 
pathological states including cancer, type II diabete, and Alzheimer’s disease 
(Hart et al., 2007). 
Lysosomal β-HexNAcases belong to the GH20 family and are composed of two 
subunits, α and β, which are approximately 60% identical in their amino acid 
sequence. The two subunits are synthesized as precursor proteins and 
subsequently processed and assembled in a dimer form in the endoplasmic 
reticulum. The dimerization is essential for the enzymatic activity and yields 
three isoforms: HexA (αβ), HexB (ββ) and HexS (αα). Each subunit possesses 
an active site characterized by its own substrate specificity (Kytzia and 
Sandhoff, 1985). The β-subunit predominantly cleaves uncharged substrates 
like glycolipid GA2 and oligosaccharides with terminal N-acetylhexosamine 
residues, whereas the α-subunit cleaves also negatively charged substrates 
(e.g., 6-sulphated GlcNAc) (Hou et al., 1996). Only the αβ-heterodimer HexA is 
able to degrade ganglioside GM2 at significant rates in the presence of the 
GM2 activator protein (GM2AP), which solubilizes the gangliosides for 
presentation to HexA (Hou et al., 1996). Mutations in the HEXA and HEXB 
genes lead to Tay-Sachs and Sandhoff disease, respectively. These LSDs are 
typically accompanied by increased concentration of the GM2 ganglioside in 
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neuronal lysosomes, which gradually results in serious, or even deadly, 
neurodegeneration (Mahuran 1999). Several therapeutic strategies are 
currently being developed, such as direct gene transfer via brain capsules 
(Martino et al., 2005), pharmacological chaperone therapy based on the use of 
small molecules, primarily inhibitors, that enhance HexA activity (Tropak et al., 
2007; Tropak and Mahuran, 2007) or enzyme replacement therapy with 
recombinant human HexA produced in yeast cells (Akeboshi et al., 2009). 
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Archaea  
In the 1970s the pioneering work of Carl Woese, classifying all life forms 
upon sequence data from the small subunit ribosomal RNA (SSU rRNA), led to 
the surprising discovery of the Archaea (Woese and Fox, 1977). This domain 
represents a third line of evolutionary descent, distinct from Eukarya, and a 
second prokaryotic lineage distinct from the Bacteria (Fig. 2.4.1).! 
Early studies on molecular characteristics and mechanisms of Archaea 
revealed their distinctive nature. They harbour unique traits radically 
distinguishing them from the other two domains, including the incorporation of 
ether-linked isoprenoid lipids in the cytoplasmic membrane, and 
methanogenesis to produce biological methane. In addition, they display 
bacterial-like traits, for example metabolism, and genomic complexity and 
organization, and eukaryal-like traits, such as DNA replication, transcription and 
translation (Tab. 2.4.1).  
Figure 2.4.1: Universal phylogenetic tree based on SSU rRNA sequences (Allers and 
Mevarech, 2005) 
2.4 Sulfolobus solfataricus: a hyperthermophilic archaeon !
!
 41 
 
Trait Archaea Bacteria Eukarya 
Carbon linkage of 
lipids Ether Ester Ester 
Phosphate backbone 
of lipids 
Glycerol-1-
phosphate 
Glycerol-3-
phosphate 
Glycerol-3-
phosphate 
Nucleus and 
organelles No No Yes 
Methanogenesis Yes No No 
DNA topology 
Relaxed or 
positively 
supercoiled  
Negatively 
supercoiled  
Negatively 
supercoiled  
DNA replication, 
transcription and 
translation 
Eukarial-like Bacterial Eukarial 
Table 2.4.1: Comparison of Archaea, Bacteria and Eukarya, adapted from Cavicchioli 
2011 
Initial studies seemed to limit Archaea to various extreme environments, in 
terms of temperature, pH, salinity, and anaerobiosis. Members of Archaea 
domain inhabit a variety of the most hostile environments known to support life 
on earth: highest temperature, e.g. strain 121 grows at 121°C (Kashefi and 
Lovley, 2003), lowest pH, e.g. Picrophilus thrives optimally at pH ~0 (Fütterer et 
al., 2004; Schleper et al., 1995), and highest NaCl concentration, e.g. many 
Halobacteriales tolerate Na+ saturation (~5.2 M NaCl) (Bowers and Wiegel, 
2011).!Typical habitats from which pure cultures of archaeal species have been 
isolated include hot springs, hydrothermal vents, solfataras, salt lakes, soda 
lakes, sewage digesters, and the rumen. However, within the past two decades, 
the use of molecular techniques, including PCR-based amplification of 16S 
rRNA genes, has unveiled a wide distribution of mostly uncultured archaea in 
normal habitats, such as ocean waters, lake waters, and soil.  
Based upon SSU rRNA gene sequence analysis, the archaeal domain can be 
subdivided in five distinct phyla: 
♦ Korarchaeota. A phylum proposed nearly 20 years ago by 16S rRNA 
gene analysis of various environmental samples (Barns et al., 1996) and 
still including exclusively uncultivated species. 
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♦ Nanoarchaeota. The first and sole representative of this phylum is 
Nanoarchaeum equitans, a nanosized hyperthermophilic anaerobe that 
lives in obligate symbiosis on the surface of Ignicoccus (Huber et al., 
2002). From initial 16S rRNA gene sequence analysis, it was proposed 
that Nanoarchaeota form a deep branch in the archaeal phylogenetic 
tree and represents a novel archaeal phylum (Huber et al., 2002). 
However, recent phylogenetic analysis of the completed Nanoarchaeum 
equitans genome, which is the smallest cellular genome to date (480 kb), 
has called into question this placement. Extensive phylogenetic analysis 
comparing Nanoarchaeum sequences with Crenarchaeota and 
Euryarchaeota sequences have indicated that N. equitans branched 
more consistently with the euryarchaeal lineage, with notable ties to the 
Thermococcales (Brochier et al., 2005).  
♦ Thaumarchaeota. Initially classified as mesophilic Crenarchaeota, 
comparative genomics has recently revealed that they form a separate 
and deep-branching phylum within the Archaea (Brochier-Armanet et al., 
2008).!This phylum has rapidly gained much attention after the discovery 
that some members are able to oxidize ammonia aerobically, providing 
the first example of nitrification in the Archaea (Könneke et al., 2005). 
♦ Euryarchaeota. The name derives from the greek term ευρυς, that means 
“broad” and reflects the phenotypic heterogenity of this phylum. Included 
among the Euryarchaeota are various orders of methanogens 
(Methanobacteriales, Methanococcales, Methanomicrobiales, 
Methanosarcinales, and Methanopyrales), as well as extreme halophiles 
(Halobacteriales), sulfate reducers (Archaeoglobales), and various 
thermophiles (Thermococcales and Thermoplasmatales). 
♦ Crenarchaeota. This group of microorganisms shows a limited 
phenotypic heterogeneity with respect to Euryarchaeota. All pure 
cultures of this phylum are thermophiles (optimum growth temperature 
>45°C) and hyperthermophiles (optimum growth temperature >80°C). 
The Bergey’s Manual of Systematic Bacteriology recognizes the cultured 
Crenarchaeota to be composed of four orders: Caldisphaerales, 
Desulfurococcales, Sulfolobales, and Thermoproteales (Chaban et al., 
2006).  
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The study of archaeal microorganisms is important not only for unravelling 
questions about origin of life, but also in applicative perspective. The 
extremophilic properties of many archaea have made them a favourite starting 
point for theories concerning how life may have evolved in the hostile conditions 
of early Earth (Stetter, 2006). Moreover, the enzymes from extremophilic 
archaea, showing an increased stability to extreme conditions of temperature 
and pH, are excellent catalysts for industrial process. Several thermophilic 
archaeal enzymes can be potentially used in industrial biocatalysis, such as 
amidase/γ-lactamase from Sulfolobus solfataricus in the production of optically 
pure γ-lactam, the building block for antiviral carbocyclic nucleotides and alcohol 
dehydrogenase from Aeropyrum pernix in the production of optically pure 
alcohols (Littlechild, 2011). 
Sulfolobus solfataricus 
Sulfolobus solfataricus is a hyperthermoacidophilic archaeon and represents 
one of the best-studied organisms within the phylum Crenarchaeota. It 
colonizes terrestrial volcanic hot springs and was originally isolated from the 
Pisciarelli solfataric field near Naples, Italy. This microorganism grows optimally 
at 80°C and pH 2–4 (Brock et al., 1972; Zillig et al., 1980), but maintains its 
cytoplasmic pH at about 6.5 by generating a large pH gradient across the 
cytoplasmic membrane (Van de Vossenberg et al., 1995). It is a strict aerobe 
and grows heterotrophically on a variety of organic compounds as carbon and 
energy source such as sugars (e.g. glucose, galactose, arabinose, sucrose), 
amino acids, or peptides. Thus, S. solfataricus can be easily maintained in 
laboratory with relatively little special equipment (Grogan 1989).!Its genome has 
been completely sequenced and published in 2001 (She et al., 2001) and a 
proteomic map of this microorganism was also developed leading to the 
identification of 1399 proteins, including 44 insoluble and 32 secreted proteins 
(Barry et al., 2006; Chong and Wright, 2005). Comparative biochemical studies 
on central carbohydrate metabolism revealed that S. solfataricus utilizes a 
modified Entner-Doudoroff (ED) pathway for glycolysis (De Rosa et al., 1984). 
Moreover, Sulfolobus species are well known for their saccharolytic capacity. 
This feature is particularly well reflected by the number of CAZymes that have 
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been found by either purification of their activity or by homology search 
methods (Fig. 2.4.2). 
Enzymes involved in the breakdown of starch have been described, such as 
extracellular surface-layer associated α-amylase (SSO1172, GH57) 
(Worthington et al., 2003) and an intracellular maltase that releases glucose 
from maltodextrins (SSO3051, GH31) (Ernst et al., 2006; Rolfsmeier and Blum, 
1995). The dextrins are also substrate for the GH13 enzymes TreY (SSO2095) 
and TreZ (SSO2093) that convert them to trehalose (Maruta et al., 1996), one 
of the main compatible solute in Sulfolobus spp. (Santos and Costa, 2001). A 
gene cluster involved in glycogen synthesis and breakdown can also be found 
in the S. solfataricus genome. Apart from a glycogen synthase (SSO0987, 
GT5), this cluster contains a glycogen associated α-amylase (SSO0988, GH57) 
(Cardona et al., 2001), a glucoamylase (SSO0990, GH15) (Kim et al., 2004) 
and a putative glycogen debranching enzyme (SSO0991). The ability of 
Sulfolobus to use α-linked galactosides, such as melibiose and raffinose, can 
be ascribed to α-galactosidase activity of GalS (SSO3127, GH36) (Brouns et 
al., 2006). Moreover, the genome of Sulfolobus has also revealed an α-
fucosidase (SSO11867/SSO3060, GH29) encoded by an interrupted gene that 
was correctly translated by the ribosome programmed -1 frameshifting 
(Cobucci-Ponzano et al., 2003) and an α-mannosidase (SSO3066, GH38), that 
seems involved in the process of protein glycosylation (Cobucci-Ponzano et al., 
2010b). A β-galactosidase (SSO3019, GH1) involved in the degradation of 
lactose and cellobiose has been described (Pisani et al., 1990), which not only 
Figure 2.4.2: CAZymes annotated in the genome of S. solfataricus P2 
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has served as a thermostable model protein in engineering studies (Kaper et 
al., 2002), but also has allowed the development of genetic manipulation 
systems for S. solfataricus (Jonuscheit et al., 2003; Worthington et al., 2003). In 
the genomic vicinity of the β-galactosidase, there is an α-xylosidase (SSO3022, 
GH31), and this may suggest a cooperative function of the two enzymes in the 
degradation of xyloglucan oligosaccharides (Moracci et al., 2000). The same 
gene cluster also harbours a bifunctional β-D-xylosidase/α-L-arabinosidase 
(SSO3032, GH3) that is specifically induced in the presence of xylan 
polysaccharides (Morana et al., 2007). Finally, Sulfolobus genome harbours 
cellulases belonging to GH12 family (SSO1949, SSO1354 and SSO2534) that 
could operate in the extracellular environment characterized by extreme acidity 
and high temperature (Huang et al., 2005; Limauro et al., 2001; Maurelli et al., 
2008). 
In conclusion, S. solfataricus is of high interest for industry and biotechnology 
for various reasons: broad physiological versatility, unique properties of its 
thermostable proteins, and a model organism for physiology, biochemistry, and 
comparative and functional genomics. 
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Glycosyl hydrolases plays a key role in a wide range of biological processes 
as well as in many industrial applications. Accordingly, unveil the structural and 
functional features of this class of enzymes is useful to increase our knowledge 
in this field and to expand the applicability of these catalysts. In particular, the 
enzymes isolated from hyperthermophilic microorganisms have elicited great 
interest in the scientific community for their unique features, such as 
thermostability and optimal activity at high temperatures. The efforts are 
focused on the study of the molecular basis of the resistance of these enzymes 
to extreme conditions of pH and temperature. In addition, their increased 
stability with respect to mesophilic enzymes makes them more suitable for 
harsh industrial processes. 
On the basis of these observations, one part of my PhD project was aimed to 
identify novel extremophilic glycosidases from the hyperthermophilic 
crenarchaeon S. solfataricus. To date no enzymatic activities involved in the 
hydrolysis of N-acetyl-hexosaminides have been described in the archaeal 
organisms, although these sugars have been identified in archaeal 
glycoproteins (Zähringer et al., 2000) and exopolysaccharides (Zolghadr et al., 
2010). These premises prompted us to seek N-acetyl-hexosaminidase activities 
in the extracts of S. solfataricus, strain P2. The first part of my work was 
focused on the isolation and identification of N-acetyl-β-glucosaminidase from 
S. solfataricus P2. In the second part, the biochemical characterization of the 
recombinant form of this enzyme has allowed to unveil its catalytic features. 
The biochemical data associated to the phylogenetic analysis have provided 
major clues about the CAZy family GH116, in which N-acetyl-β-
glucosaminidase is included. 
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Bacterial Strains 
E. coli strains used in this work are listed in the Table 2.6.1. 
Archaeal Strains 
Sulfolobus solfataricus P2 (She et al., 2001) 
Sulfolobus solfataricus 98/2 (Hochstein and Stan-Lotter, 1992) 
Sulfolobus solfataricus PBL2025 (Schelert et al., 2004) 
Culture media 
LB (Luria-Bertani Broth) (1 liter): 
10 g NaCl 
5 g yeast extract 
10 g tryptone 
S. solfataricus media 
Brock medium (Brock et al., 1972) adjusted to pH 3.5 with sulfuric acid and 
supplemented with yeast extract, sucrose and casaminoacids (0.1 % each) as 
carbon source. 
Reagents 
All commercially available substrates were purchased from Sigma-Aldrich 
and Carbosynth unless otherwise designated.  
Strain Genotype Reference or 
Source 
DH5α  F- lacZΔM15 recA1 endA1 hsdR17 phoA 
supE44Δ (lacZYA argF) glnV44 thi-1 relA1 
gyrA96 deoR nupG  
Hanahan 
1983 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZ ΔM15  ΔlacΧ74 recA1 araD139 
Δ(ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG 
Invitrogen 
BL21 star (DE3)! F- ompT hsdSB (rB– mB–) gal dcm rne131 
(DE3) 
Invitrogen  
BL21 Ril (DE3)! F- ompT hsdS (rB– mB–) dcm+ Tetr gal λ 
(DE3) endA Hte [argU ileY leuW Camr]!
Invitrogen !
Rosetta (DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pRARE (CamR) 
Novagen 
Table 2.6.1:!E. coli strains used in this work!
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Isolation of a N-acetyl-β-glucosaminidase from S. solfataricus P2 
N-acetylglucosaminidases activities were searched in free cell extract (FCE) of 
S. solfataricus P2. The enzymatic activities were followed through assays on 
the chromogenic substrates 4-nitrophenyl-N-acetyl-β-glucosaminide (4Np-β-
GlcNAc) and 4-nitrophenyl-N-acetyl-α-glucosaminide (4Np-α-GlcNAc). In 
addition, N-acetyl-β-glucosaminidase (β-GlcNAcase) activity was monitored by 
activity gel staining with 5-Bromo-4-Chloro-3-Indolyl 2-acetamido-2-deoxy-β-D-
glucopyranoside (X-β-GlcNAc) (see below for details).  
S. solfataricus cells, strain P2, were grown at 80°C and the growth was 
monitored spectrophotometrically at 600 nm. When the culture reached an 
A600nm of 0.7-1.0 optical densities, cells were harvested by centrifugation at 
5,000 xg for 15 min at 4°C. The resulting cell pellet was resuspended in 2 mL 
g-1 cells of PBS buffer (20 mM sodium phosphate buffer, pH 7.4, 150 mM 
NaCl) supplemented with 0.1% (v/v) Triton X-100. The cells were lysated with 
three cycles of freeze thawing (5 min at -70°C; 5 min at 37°C), and centrifuged 
for 30 min at 10,000 xg.  
FCE was applied on a High Load 16/10 Q-Sepharose High Performance 
column (GE-Healthcare) equilibrated with Buffer A (20 mM phosphate buffer, 
pH 7.5) at a flow rate of 3 mL min-1. The run was performed with an initial step 
of extensive wash with Buffer A (3-column volumes) followed by a linear ionic 
strenght gradient from 0 to 1 M NaCl in Buffer A (3-column volumes) and a 
final step with 1 M NaCl in Buffer A (2-column volumes).  
At these conditions, β-GlcNAcase activity was found primarily in the fractions 
eluted at about 150 mM NaCl.  Active fractions were pooled, equilibrated with 
1 M ammonium sulphate, and applied on a HiLoad 26/10 Phenyl Sepharose 
High performance (GE-Healthcare), which was equilibrated with Buffer A 
supplemented with 1 M ammonium sulphate at a flow rate of 3 mL min-1.  After 
1-column volume of loading buffer, the protein was eluted with a two-step 
gradient of water (0-80%, 2-column volumes; 80-100%, 3-column volumes) 
followed by a final step at 100% of water (2-column volumes); the protein 
eluted in about 85% water. 
Active fractions were pooled, dialyzed against PBS buffer and!concentrated by 
ultrafiltration on an Amicon YM30 membrane (cut off 30,000 Da). The resulting 
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sample was loaded on a Superdex 200 HR 10/300 gel filtration column (GE-
Healthcare), run at a flow rate of 0.5 mL min-1 in PBS buffer. Active fractions 
were pooled and concentrated. The protein concentration was determined with 
the method of Bradford (Bradford, 1976). The native enzyme was about 85% 
pure by SDS-PAGE and was stored at 4°C. 
Activity assays of native N-acetyl-β-glucosaminidase on X-β-GlcNAc and 
on 4Np-β-GlcNAc 
The activity on X-β-GlcNAc was analysed by loading the non heat-denatured 
samples on 8% SDS-PAGE gel. After the run, the gel was washed with water 
and then equilibrated in 50 mM phosphate pH 6.5. The activity assay was 
carried out by incubating the gel at 65°C for 16 hours in 50 mM phosphate pH 
6.5 with 2 mg ml-1 of X-β-GlcNAc and 10% methanol.  
The hydrolysis of 4Np-β-GlcNAc was analysed by incubating FCE or FPLC 
fractions in 50 mM phosphate pH 6.5 at 60°C for a suitable time (2-5 minutes). 
The reactions, performed on 12 mM substrate, were blocked in ice by adding 
1M sodium carbonate pH 10.2. The release of nitrophenol group was 
monitored spectrophotometrically at 420 nm and the extinction coefficient to 
calculate enzymatic units was 17.2 mM–1 cm–1. In all assays, spontaneous 
hydrolysis of the substrate was subtracted by using appropriate blank 
mixtures without enzyme. 
Cloning of sso3039 gene in E. coli 
Cloning of sso3039 gene was performed by using Champion™ pET 
directional TOPO® expression kit (Invitrogen). 
Genomic DNA strain was extracted from S. solfataricus P2 cells by 
Nucleospin Tissue kit (Macherey Nagel). The sso3039 gene was amplified 
by PCR from the genome of S. solfataricus P2 using the synthetic 
oligonucleotides 3039TOPO5’ and 3039TOPO3’His (Tab. 2.6.2). 
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Table 2.6.2: Sequence of oligonucleotides used for amplification of sso3039 gene.  
Sequence indicated in red is introduced to pair with the overhang 
sequence, GTGG, in pET 101/D-TOPO vector 
The amplification reaction was performed with the PfuUltra II Fusion HS 
DNA Polymerase (Stratagene) by using the program reported in Fig. 2.6.1.!
  
The PCR product obtained was verified by electrophoresis on 1% agarose 
gel, purified by PCR Kleen spin columns (Biorad) and then cloned in the 
expression vector pET101/D-TOPO (Invitrogen), according the 
manufacturer. Briefly 50 ng of DNA fragment were incubated in salt 
solution with 1 µl vector (15-20 ng) at room temperature for 30 minutes. 
The TOPO cloning reaction was used to transform One Shot TOP10 
chemically competent cells according to the protocol of the manufacturer 
(see below for more details). Positive clones were selected through PCR 
colony and the absence of mutations was verified by sequencing. This 
procedure allowed to obtain the recombinant plasmid pET101/D-TOPO-
SSO3039, in which the SSO3039 ORF is under the control of the 
isopropyl-1-thio-β-D-galactopyranoside (IPTG) inducible T7 RNA 
polymerase promoter and the C-terminal of the protein was fused to V5 
epitope and 6xHis tag (Fig. 2.6.2).  
Primer 5’-sequence-3’ N° of bases Tm (°C) 
3039TOPO5’ CACCATGAAATACAAATACTCTTA
 
25 57.60 
3039TOPO3’His AAATTCAATCTCTTCATTTTCCC 23 55.60 
Figure 2.6.1:! Schematic representation of PCR protocol used to amplify sso3039 
gene 
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Transformation of One Shot TOP10 chemically competent cells 
The recombinant plasmid pET101/D-TOPO/SSO3039 obtained by TOPO 
cloning reaction described above was transformed into competent One 
Shot® TOP10 chemically competent E. coli cells provided by the kit. The 
entire TOPO cloning reaction mixture has been added into a vial of cells. 
After incubation on ice for 30 minutes, the cells were subjected to a heat-
shock at 42°C for 30 seconds and then immediately transferred to ice and 
supplemented with 250 µL SOC medium.  The cells were incubated at 
37°C for 1 hour; then 200 µL of culture were spread on LB-agar plates 
containing 50 µg mL-1 ampicillin and incubated at 37°C for 16 hours. 
Expression trials of rSSO3039 
To determine which strain allows to obtain the better yield of the recombinant 
SSO3039 (rSSO3039), expression trials were performed in three different 
E.coli strains:! BL21 star (DE3), BL21 Ril (DE3) and Rosetta (DE3). For each 
strain, E. coli cells transformed with the construct pET101/D-TOPO-SSO3039 
were used to prepare 100 mL cultures. The cells were incubated at 37°C and 
when reached an A600nm of 0.6, each culture was divided in two aliquots: one 
was treated with 0.6 mM IPTG (I), while the other one was not treated (NI). 
The growth was allowed to proceed for 16 h and the cells were harvested by 
centrifugation at 5,000 xg for 30 minutes. The cell pellet was resuspended in 
50 mM sodium phosphate buffer, pH 8.0, 300 mM NaCl (Buffer B) with a 
ratio of 5 ml g−1 cells and then was incubated at 37°C for 1 h with lysozyme 
(Fluka) and 25 U g-1 cell of Benzonase (Novagen). The cell lysis was 
performed by three cycles of freeze/thawing and the cell debris were removed 
by centrifugation at 14000 xg for 30 minutes. The rSSO3039 was partially 
Figure 2.6.2:!pET101/D-TOPO/SSO3039 features 
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purified by one step of thermal precipitation: incubation at 80°C for 20 minutes 
followed by centrifugation at 16000 xg for 30 minutes. The resulting samples 
was used to evaluate rSSO3039 expression by two different approaches: 
- SDS-PAGE 
- Activity on 4Np- β-GlcNAc 
Purification of rSSO3039 
The SSO3039 ORF was expressed in E. coli cells, strain BL21 star 
(DE3) (Invitrogen) transformed with pET101/D-TOPO-SSO3039 according 
to the manufacturer. Cells were grown at 37°C in 4.5 liters of Luria-Bertani 
(LB) broth supplemented with ampicillin (50 µg mL-1). Growth was allowed 
to proceed for 16 h without addition of IPTG, and cells were harvested by 
centrifugation at 5,000 xg. The resulting cell pellet was resuspended in 
Buffer B with a ratio of 5 ml g−1 cells and then was incubated at 37°C for 1 
h with 20 mg of lysozyme (Fluka) and 25 U g-1 cell of Benzonase 
(Novagen). The cells were lysed by French cell pressure treatment and cell 
debris were removed by centrifugation at 10,000 xg for 30 min. FCE was 
loaded on a His Trap FF crude column (GE-Healthcare) equilibrated with 
Buffer B at a flow rate of 1 mL min-1. After an initial wash-step (20-column 
volumes) with buffer B, the protein was eluted with a two-step gradient of 
imidazole in Buffer B (250 mM imidazole, 20-column volumes; 500 mM 
imidazole, 15-column volumes). 
The protein eluted at 250 mM imidazole. Active fractions were pooled, 
dialyzed against PBS buffer and then heat-fractionated for 20 min at 80°C. 
The resulting supernatant was concentrated to about 3 mg mL-1 and 
applied on a HiLoad 16/60 Superdex 200 gel filtration column (GE-
Healthcare) equilibrated with PBS buffer at a flow rate of 0.5 mL min-1. 
Active fractions were pooled, concentrated and stored at 4°C. After this 
procedure rSSO3039 was more than 95% pure by SDS-PAGE. 
Molecular mass determination 
The molecular mass of native and recombinant SSO3039 was determined 
by gel filtration on a Superdex 200 HR 10/300 FPLC column (GE-
Healthcare) performed as described above. Molecular weight markers were 
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apoferritin (443 kDa), amylase (200 kDa), alcohol dehydrogenase (150 
kDa), albumin (66 kDa) and ribonuclease A (13.7 kDa).  
Temperature and pH influence on rSSO3039 activity 
The temperature profile of rSSO3039 activity was determined in the range 
of 40-70°C in the standard assay conditions.  
Thermal stability was evaluated by incubating pure rSSO3039 (0.33 mg 
mL-1) in PBS buffer, pH 7.3, at the indicated temperatures. At intervals, 
aliquots of 6 µl (2 µg enzyme) were withdrawn, transferred in ice and 
assayed at standard conditions. The residual activity was expressed as a 
percentage of the maximal enzymatic activity measured before the 
incubation at indicated temperatures. 
Optimal pH and buffered saline were determined by assaying rSSO3039 in 
50 mM of the indicated buffers and pHs in standard conditions. 
Enzymatic assays of rSSO3039 
The standard assay for rSSO3039 activity was performed in 50 mM citrate 
phosphate buffer, pH 4.0 on 4Np-β-GlcNAc at the final concentration of 12 
mM. Typically, in each assay, we used about 2–5 µg of rSSO3039 in the 
final volume of 0.2 mL. After 2 min of incubation at 60°C, the reaction was 
blocked in ice by adding 0.8 mL of 1 M sodium carbonate pH 10.2. The 
absorbance was measured at 420 nm at room temperature and the 
millimolar extinction coefficients of 4-nitrophenol and 2-nitrophenol were 
17.2 and 4.7 mM–1 cm–1, respectively. In all the assays, spontaneous 
hydrolysis of the substrate was subtracted by using appropriate blank 
mixtures without the enzyme. The specific activity, indicated as U mg-1, 
was determined with the formula reported in Fig. 2.6.3. 
One enzymatic unit is defined as the amount of enzyme catalysing 
the conversion of 1 µmole of substrate into product in 1 min, at 
Figure 2.6.3:!Formula applied to calculate specific activity 
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the indicated conditions. All kinetic data were calculated as the average of 
at least two experiments and were plotted and refined with the program 
GraphPad Prism.  
The enzymatic activity on 4-Methylumbelliferyl-β-D-glucoside (MU-β-Glc) 
and 4-methylumbelliferyl N-acetyl-β-D-glucosaminide (MU-β-GlcNAc) was 
assayed in standard conditions with slight modifications; the reaction was 
performed in 0.25 mL with 0.3 µg rSSO3039 and was blocked by adding 
0.5 mL of 0.1M Glycine-NaOH rather than sodium carbonate. The release 
of 4-methylumbelliferone has been followed by fluorescence spectroscopy 
(Tab. 2.6.3). A standard curve of the free fluorophore, 4-
methylumbelliferone, in the same conditions of assay was generated for 
the calculation of enzyme product.  
Kinetic constants of rSSO3039 were measured at standard conditions by 
using concentrations of substrate ranging between 0.5 and 20 mM for 4Np-
β-GlcNAc, 0.1 and 15 mM for 4Np-β-Glc, 0.05 and 4 mM for MU-β-Glc, 
0.25 and 15 mM for MU-β-GlcNAc. 
Parameter Set(value 
λex 384(nm 
λem 450(nm 
Band(width(ex 2.5(nm 
Band(width(em 5(nm 
Table 2.6.3: Setting of parameters for the measurements on the spectrofluorometer 
JASCO FP-8200 
The substrate specificity of rSS3039 was determined by analysing the 
activity on different aryl-glycosides (final concentration 12 mM) in standard 
conditions (Fig. 2.6.4).  
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The activity of rSSO3039 on tetra- and pentasaccharides of glucose and N-
acetylglucosamine (Glc4, Glc5, GlcNAc4 and GlcNAc5), 2Np-β-cellobioside 
(2Np-β-Cel) and 4Np-N,N'-diacetyl-β-chitobioside (4Np-β-Chit) was 
measured by assaying the enzyme (5 µg) at standard conditions. Aliquots 
were withdrawn at indicated times and stored at -20°C. The analysis of the 
reaction products was performed on a silica gel 60 F254 TLC or by High-
Performance Anion-Exchange chromatography with Pulsed Amperometric 
Detection (HPAEC-PAD) equipped with a PA200 column (Dionex, USA). 
TLC analysis of the gluco-oligosaccharides was carryed out by using 
acetone/isopropanol/ water (60:30:15) as the eluent and 5% sulfuric acid in 
methanol for the detection. HPAEC-PAD analyses of the reactions on 2Np-
β-Cel and gluco-oligosaccharides were performed at a flow-rate of 0.5 mL 
min-1 in 100 mM NaOH/10 mM sodium acetate for 6 min followed by a two-
step gradient of sodium acetate in 100 mM NaOH (10-100 mM in 10 min; 
100-150 mM in 4 min); instead, an isocratic protocol (10 mM NaOH for 40 
Figure 2.6.4: Structure of the β-aryl-glycosides used in the assays 
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min) was applied for the analysis of the enzymatic reactions on N-acetyl-
chitooligosaccharides and on 4Np-β-Chit. 
Inhibition of rSSO3039 
To evaluate the inhibition of rSSO3039 by N-butyldeoxynojirimycin (NB-
DNJ) and conduritol β-epoxide (CBE) (Fig. 2.6.5), the enzyme (0.08 mg mL-
1) was incubated in the presence of 0.1–50 µM NB-DNJ or 2-15 mM CBE in 
50 mM phosphate buffer, pH 7.0, in a final volume of 60 µl. After incubation 
at 45°C for 30 min, aliquots of 25 µl were withdrawn and the residual 
activity was measured in standard conditions. Residual activity was 
expressed as a percentage of the maximum activity measured with enzyme 
incubated in the same conditions described above with the exception of the 
inhibitor.  
Figure 2.6.5: Structure of the inhibitors CBE and NB-DNJ 
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Isolation of a N-acetyl-β-glucosaminidase from S. solfataricus P2 
According to the CAZy classification, N-acetyl-β-glucosaminidase activities 
(EC 3.2.1.52) are classified in the GH families 3, 20 and 84. Although these 
families include archaeal GHs, no enzymatic activity involved in the hydrolysis 
of N-acetyl-β-hexosaminides has been described in the archaeal organisms to 
date. In Archaea, only chitinase (EC 3.2.1.14) belonging to GH18 have been 
characterized, in particular the chitinolytic enzymes from Pyrococcus furiosus 
(Nakamura et al., 2008; Oku and Ishikawa, 2006; Tsuji et al., 2010), 
Thermococcus kodakarensis (Tanaka et al., 1999, 2001) and Thermococcus 
chitinophagus (Andronopoulou and Vorgias 2003, 2004).! N-acetyl-β-
hexosaminides have been identified among the monosaccharides constituents 
of archaeal glycoproteins (Abu-Qarn et al., 2008; Namboori and Graham, 2008) 
and exopolysaccharides (Zolghadr et al., 2010). In addition chitobiose is the 
glycan linker to the N-glycosylation site, as observed in cytochrome b558/566 and 
in the S-layer proteins of the thermoacidophilic archaea S. acidocaldarius and 
S. solfataricus (Peyfoon et al., 2010; Zähringer et al., 2000). These premises 
prompted us to seek N-acetyl-β-hexosaminidase activities in the extracts of S. 
solfataricus, strain P2. 
Free cell extracts (FCE) were prepared from a cell culture of S. solfataricus P2 
stopped in the early stationary phase and assays on the chromogenic 
substrates, 4Np-β-GlcNAc or 4Np-α-GlcNAc, allowed to reveal low, but 
detectable N-acetylglucosaminidase activities: 4.6×10-3 U mg-1 and 5.5×10-3 U 
mg-1 on 4Np-α-GlcNAc and 4Np-β-GlcNAc, respectively. A purification 
procedure was set up to isolate the native enzymes involved in these catalytic 
processes. After three chromatography steps (anionic exchange, hydrophobic 
and gel filtration chromatographies), it was not possible isolate the N-acetyl-α-
glucosaminidase activity. Consequently our efforts were focused on the 
isolation and identification of N-acetyl-β-glucosaminidase. To this aim we 
adopted the purification procedure summarized in Tab 2.7.1, that allowed to 
isolate the enzyme of interest through three chromatographic steps. Although 
the protein preparation was not pure to homogeneity (Fig. 2.7.1), SDS-PAGE 
activity stained with X-β-GlcNAc revealed a clear band of high molecular weight 
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(Fig. 2.7.2A and 2.7.2B), indicating that a single N-acetyl-β- glucosaminidase 
activity was present in S. solfataricus extracts.  
Fraction Volume (mL) 
Protein 
(mg/mL) 
Total Protein 
(mg) 
Acitvity 
(U/mL) 
Total Activity 
(U) 
Specific Activity 
(U/mg) 
Yield 
(%) 
Fold 
Purification 
Free cell extract 4 53 212 0.3 1.2 5.5 10-3 100 1 
Anionic exchange 13 1.4 18.2 0.05 0.6 0.03 50 5.5 
Hydrophobic 
chromatography 2.5 0.32 0.8 0.06 0.16 0.2 13 36 
Gel filtration 0.5 0.04 0.02 0.05 0.03 1.3 2.5 236 
!
Table 2.7.1: Purification table of native β-GlcNAcase from S. solfataricus P2 extracts. 
Enzymatic assays were performed in 50 mM phosphate pH 6.5 at 60°C 
on 12 mM 4Np-β-GlcNAc  
Figure 2.7.1: SDS-PAGE of native β-GlcNAcase: Coomassie staining of denaturated 
native samples 
!
Figure 2.7.2: SDS-PAGE of native β-GlcNAcase. (A) Coomassie staining of non-
denaturated native samples. (B) activity staining with X-β-GlcNAc of 
non-denaturated native samples 
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To identify the ORF encoding for this enzymatic activity, we have employed two 
complementary approaches: the use of a natural mutant and mass 
spectrometry analysis.  
First, we assayed for N-acetyl-β-glucosaminidase activity in extracts of a 
deletion mutant of S. solfataricus strain 98/2, named PBL2025, which lacks a 
chromosomal fragment of about 50 Kb, including the ORFs from SSO3004 to -
3050 (Schelert et al., 2004). Interestingly, we could not detect any activity in 
PBL2025, while FCE of 98/2 strain, used as parental control, showed specific 
activity comparable to that observed in the P2 strain (3×10-3 U mg -1). SDS-
PAGE activity stained with X-β-GlcNAc confirmed the absence of N-acetyl-β-
glucosaminidase activity in FCE of PBL2025 strain and its presence in the 
parental strain 98/2 (Fig. 2.7.3).  
These data strongly indicate that the N-acetyl-β-glucosaminidase activity is 
encoded by an ORF deleted in PBL2025. The chromosomal region deleted in 
this strain includes a diverse set of genes possibly involved in sugar 
degradation and metabolism (Zolghadr et al., 2010), such as GHs, 
carbohydrate transporters and glucose dehydrogenases. Among GHs deleted 
in PBL2025, there are either already characterized enzymes, such as α-
mannosidase (Ssα-man, SSO3006, GH38) (Cobucci-Ponzano et al., 2010b), β-
glycosidase (LacS, SSO3019, GH1) (Moracci et al., 1994), α-xylosidase (XylS, 
SSO3022, GH31) (Moracci et al. 2000), β-xylosidase/ α-L-arabinosidase (XarS, 
SSO3032, GH3) (Morana et al., 2007), or other still hypothetical, like putative 
endo-glucanase (SSO3007, GH5), β-glucuronidase (SSO3036, GH2), α-
Figure 2.7.3: SDS-PAGE activity of FCE from S. solfataricus 98/2 (596 µg) and 
PBL2025 (434 µg) stained with X-β-GlcNAc  
!
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glucosidase (SSO3037-3038, GH122), and bile-acid β-glucosidase (SSO3039, 
GH116).! Taking into account only the characterized enzymes, GHs potentially 
involved in the hydrolysis of 4NP-β-GlcNAc might be LacS and XarS, which are 
specific for β-O-anomeric substrates. Thus, the two purified enzymes and FCE 
of 98/2 strain (positive control) were assayed on 4Np-β-GlcNAc and X-β-
GlcNAc. Assays on 4Np-β-GlcNAc revealed that neither LacS nor XarS were 
able to hydrolyze this chromogenic substrate and SDS-PAGE activity stained 
with X- β-GlcNAC confirmed this results for LacS (Fig. 2.7.4A) and XarS (Fig. 
2.7.4B). Accordingly, these data fostered our hypothesis that S. solfataricus 
expresses another GH with N-acetyl-β-glucosaminidase activity. 
Figure 2.7.4: SDS-PAGE of the GHs LacS and XarS. (A) Coomassie and activity 
staining with X-β-GlcNAc (left and right panels, respectively) of 98/2 
FCE (434 µg) and purified LacS (2 µg). (B) Coomassie and activity 
staining with X-β-GlcNAc (left and right panels, respectively) of 98/2 
FCE (434 µg) and purified XarS (4.74 µg)  
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Mass spectrometry analysis of N-acetyl-β-glucosaminidase partially 
purified from S. solfataricus P2 
To identify the ORF encoding for N-acetyl-β-glucosaminidase activity we used a 
mass spectrometry approach. This study was performed by Dr. A. Amoresano 
and Dr. A. Carpentieri of the University of Naples “Federico II”. Mass 
spectrometry analysis was performed on the sample deriving from the final step 
of the purification procedure described above (gel filtration chromatography, 
Table 2.7.1). A gel free proteomic approach was carried out to identify the 
proteins in the sample showing N-acetyl-β-glucosaminidase activity. The protein 
sample was reduced and alkylated and then hydrolyzed in solution using trypsin 
as a proteolytic enzyme. The peptide mixture obtained by this procedure was 
fractionated by nano LC and analyzed by tandem mass spectrometry (MS/MS). 
The MS/MS spectra submitted to MASCOT search led to the identification of at 
least 19 proteins occurring in the same fraction (Table 2.7.2). Among the 
identified proteins, only three ORFs (SSO3006, SSO3032 and SSO3039) 
resided in the chromosomal region deleted in PBL2025 strain, in which no N-
acetyl-β-glucosaminidase activity was revealed. SSO3006 encodes for an α-
mannosidase extensively characterized by Cobucci-Ponzano and colleagues 
(Cobucci-Ponzano et al., 2010b). SSO3032 encodes for the β-xylosidase/ α-L-
arabinosidase XarS, which, as shown above, has no β-GlcNacase activity (Fig. 
2.7.4B). SSO3039, with a sequence coverage of 55% and a MASCOT score of 
474, has never been characterized so far and it is annotated in the genome of 
S. solfataricus P2 (http://www-archbac.u-psud.fr/projects/sulfolobus/) as a 
predicted bile acid β-glucosidase. It is worth to mention that SSO3039 is 
classified as GH116 in the CAZy database (http://www.cazy.org/GH116.html). 
This CAZy family, previously created in our laboratory by Cobucci-Ponzano and 
co-workers (Cobucci-Ponzano et al., 2010a), includes only acid β-glucosidase 
(EC 3.2.1.45), β-glucosidase (EC 3.2.1.21) and β-xylosidase (EC 3.2.1.37) and 
not β-GlcNAcase ( EC 3.2.1.52). These premises prompted us to explore the 
functional features of SSO3039 in more detail. 
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Cloning, expression, and characterization of SSO3039 
To unequivocally confirm that the ORF SSO3039 encodes for the N-acetyl-β-
glucosaminidase revealed in FCE of S. solfataricus P2, we produced and 
characterized the recombinant form of this enzyme. To this aim, sso3039 gene 
was cloned in the expression vector pET101/D-TOPO obtaining the 
recombinant construct pET101/D-TOPO-SSO3039, which allowed to express 
a recombinant SSO3039 (rSSO3039) fused to the V5 epitope and to a 6xHis 
tag at the C-terminal end. To determine which strain allowed to obtain the better 
yield of rSSO3039, expression trials were performed in three different E. coli 
strains: BL21 star (DE3), BL21 Ril (DE3) and Rosetta (DE3) (see section 2.7 for 
details about the experimental procedures). SDS-PAGE analysis and activity 
assays on 4Np-β-GlcNAc showed that the best yield of rSSO3039 can be 
obtained in E. coli BL21 (Star) DE3 strain without induction with IPTG or in 
Rosetta DE3 in which the protein expression was induced with 0.6 mM IPTG 
(Fig. 2.7.5). 
Table 2.7.2: ORFs identified by mass spectrometry analysis in the protein sample 
showing β-GlcNacase activity !
!
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The levels of rSSO3039 expression in E. coli BL21 star (DE3) and Rosetta 
DE3 were comparable, and we decide to use the former strain for the 
expression and purification of rSSO3039, that is also the strain recommended 
by the manufacturer of the expression kit, Invitrogen. The purification 
procedure consists of three steps (Ni-affinity chromatography, thermal 
precipitation and gel filtration) (Tab. 2.7.3) and led to an enzyme preparation 
>95% pure (Fig. 2.7.6). The low final yield (~0.4 mg per liter of E. coli) 
demonstrated that the levels of rSSO3039 expression in E. coli were not high 
and were much lower than those obtained with another GH116 enzyme from S. 
solfataricus, the β-xylosidase/glucosidase SSO1353, whose yield was 1.5 mg 
per liter of E. coli (Cobucci-Ponzano et al., 2010a). Assays on 4Np-β-GlcNAc 
revealed that the purified rSSO3039 showed a thermophilic N-acetyl-β-
glucosaminidase activity, confirming that SSO3039 ORF encodes for the 
enzyme involved in hydrolysis of N-acetyl-β-glucosaminides in S. solfataricus 
P2. 
Figure 2.7.5: SDS-PAGE of the partially purified rSSO3039 expressed in three 
different E. coli strains with (I) or without (NI) the induction with IPTG. 
Yellow circles highlight rSSO3039 protein band!
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The initial biochemical analyses of rSSO3039 have been aimed to unveil the 
optimal conditions for the catalysis, such as pH and temperature optima, and 
thermal stability. To determine the pH optimum of rSSO3039 activity, the 
enzyme was assayed in 50 mM of different buffers in the range of pH 3.0-8.0. 
As illustrated in Fig. 2.7.7, rSSO3039 was optimally active in citrate phosphate 
or sodium acetate buffer at pH 4.0.  
!
 Volume (mL) 
[Protein] 
(mg/mL) 
Total 
Proteins 
(mg) 
Acitvity 
(U mL-1) 
Total Activity 
(U) 
Specific Activity 
(U mg-1) 
Yield 
(%) 
Purification folds 
 
FCE 116 20.6 2390 0.37 43 0.018 100 1 
His Trap 15 4.6 69 2.7 40 0.58 93 32 
Heat-fractionation 14 1.07 15 2.5 34.5 2.3 80 128 
Gel filtration 5 0.33 1.65 2.5 12.4 7.5 29 417 
Table 2.7.2: Purification of rSSO3039 from E. coli BL21 star (DE3) strain transformed 
with pET101/D-TOPO-SSO3039. Assays were performed on 12 mM 4Np-
β-GlcNAc, in 50 mM citrate phosphate buffer, pH 4.0, at 60°C for 2 
minutes!
Figure 2.7.6: SDS-PAGE of rSSO3039 purification steps!
Figure 2.7.7: pH dependence of rSSO3039 activity on 12 mM 4Np-β-GlcNAc!
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As expected for an enzyme from thermophilic source, the temperature profile 
assessed in the range of 40-70°C indicated the maximal activity (∼ 25 U mg-1) at 
70°C (Fig. 2.7.8).  
Moreover, rSSO3039 showed a noticeable stability at 65 and 85°C (Fig. 2.7.9). 
On the basis of this initial characterization, the standard assay used in all the 
following study was performed on 12 mM 4Np-β-GlcNAc, in 50 mM 
citrate/phosphate buffer, pH 4.0 at 60°C.  
Figure 2.7.9: Thermal stability of rSSO3039 at 65°C and 85°C!
The molecular weight of the recombinant enzyme in solution was of 313 kDa ± 
10 kDa (Fig. 2.7.10A) comparable to that observed for the native enzyme in the 
same conditions (271 ± 18.5 kDa) (Fig. 2.7.10B). Since the denatured monomer 
is 93.4 kDa for the native form and 96.4 kDa for the recombinant one (the 
Figure 2.7.8: rSSO3039 activity monitored in the range of 40-70°C!
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additional 3kDa derive from the fusion to V5 epitope and 6xHis tag), these data 
indicated that SSO3039 was a trimer in solution. 
Substrate specificity of rSSO3039 
To determine the substrate specificity of rSSO3039, the enzyme was assayed 
on various aryl-glycosides as described in the Experimental procedures, section 
2.7. Enzymatic assays on these substrates indicated the highest specificity for 
aryl-N-acetyl-glucosaminides, followed by aryl-glucosides and -galactosides, 
while the activity on aryl-xylosides, and -fucosides was only barely detectable, 
and no activity was observed on aryl-mannosides (Fig. 2.7.11) and 
glucocerebrosides (data not shown). The specific activity measured on 4Np-β-
GlcNAc corresponds to 7.5 U mg-1, a value much higher than that observed with 
SSO1353 on 4Np-β-xylopyranoside (0.8 U mg-1), another GH116 enzyme 
(Cobucci-Ponzano et al., 2010a). 
!
Figure 2.7.11: Substrate specificity of rSSO3039!
Figure 2.7.10: Molecular weight of rSSO3039 (A) and native β-GlcNAcase (B) 
determined by gel filtration 
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The steady state kinetic constant of rSSO3039 on 4Np-β-GlcNAc, 4Np-β-Glc, 
MU-β-Glc and Mu-β-GlcNAC were measured in standard conditions and listed 
in Tab. 2.7.4. This kinetic analysis confirmed that rSSO3039 is a N-acetyl-β-
glucosaminidase/β-glucosidase as the specificity constant for 4Np-β-Glc is 
about 10-fold higher than that for 4Np-β-GlcNAc (11.5 and 1.65 s-1 mM-1, 
respectively) and for MU-β-Glc is about 2-fold higher than that for MU-β-GlcNAc 
(9.9 and 4.9 s-1 mM-1, respectively), because of the lower KM.!!
The hydrolytic activity of rSSO3039 was evaluated also on longer substrates, in 
particular on β-1,4 oligosaccharides of glucose (Glc) and N-acetylglucosamine 
(GlcNAc), namely cellotriose (Glc3), cellotetraose (Glc4), cellopentaose (Glc5), 
tetra-N-acetylchitotetraose (GlcNAc4) and penta-N-acetylchitopentaose 
(GlcNAc5). The enzyme was active on all these substrates. The reaction 
mixtures with Glc3, Glc4 and Glc5 were first analysed by thin layer 
chromatography (TLC) showing in all the cases the progressive hydrolysis of 
the initial substrates with the accumulation of glucose after an overnight 
incubation (Fig. 2.7.12). 
Substrate kcat  (s-1) 
KM  
(mM) 
kcat/KM 
 (s-1 mM-1) 
4NP-β-GlcNAc 19.2±0.46 4.15±0.27 1.65 
4NP-β-Glc 9.15±0.19 0.8±0.08 11.4 
MU-β-GlcNAc 5.4±0.14 1.1±0.13 4.9 
MU-β-Glc 8.8±0.5 0.9 ±0.14 9.9 
Table 2.7.4: Steady state kinetic constants of rSSO3039 
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HPAEC-PAD analysis of the enzymatic reactions on Glc4 and Glc5 showed the 
release of glucose and of the oligosaccharide product shortened of one unit 
(cellotriose and cellotetraose from Glc4 and Glc5, respectively) after 10 min of 
incubation at 60°C (Fig. 2.7.13). 
Figure 2.7.12: TLC analysis of the enzymatic assays on Glc3 (A), Glc4 (B) and Glc5 
(C). The reaction mixtures were stopped in ice at the indicated times 
(minutes). C is the negative control. Glucose (Glc), cellobiose (Glc2), 
cellotriose (Glc3), cellotetraose (Glc4) and cellopentaose (Glc5) were 
used as markers!
Figure 2.7.13: HPAEC-PAD analysis of the enzymatic assays on Glc4 (A) and Glc5 
(B). The reaction mixtures were stopped in ice at the indicated times 
(minutes) and in all runs, C is the negative control, while R is the 
reaction mixture with rSSO3039. Glucose (Glc), cellobiose (Glc2), 
cellotriose (Glc3), cellotetraose (Glc4) and cellopentaose (Glc5) were 
used as markers 
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Similarly, rSSO3039 hydrolyzed GlcNAc4 and GlcNAc5 producing GlcNAc (Fig. 
2.7.14) and the production of monosaccharides observed in the early times of 
the reaction strongly suggested that rSSO3039 was an exo-glycosidase acting 
from one of the ends of the substrates.  
This hypothesis was confirmed also by the analysis of the catalytic activity of 
rSSO3039 on 2Np-β-cellobioside and 4Np–N,N'-diacetyl-β-chitobioside (2Np-β-
Cel and 4Np-β-Chit, respectively). HPAEC-PAD analysis of the enzymatic 
reactions on these substrates indicated that rSSO3039 released the 
corresponding monosaccharide (either Glc or GlcNAc) after 2h incubation (Fig. 
2.7.15), unequivocally demonstrating that rSSO3039 is an exo-glucosidase 
acting from the non-reducing end of the substrate. 
Figure 2.7.14: HPAEC-PAD analysis of the enzymatic assays on GlcNAc4 (A) and 
GlcNAc5 (B). The reaction mixtures were stopped in ice at the 
indicated times (hours) and in all runs, C is the negative control, while 
R is the reaction mixture with rSSO3039. N-acetylglucosamine 
(GlcNAc), chitobiose (GlcNAc2), tetra-N-acetylchitotetraose (GlcNAc4) 
and penta-N-acetylchitopentaose (GlcNAc5) were used as markers.!
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NB-DNJ and CBE inhibition profile  
One of the peculiarities of GH116 enzymes is their sensitivity to known 
competitive inhibitors, such as conduritol β-epoxide (CBE) and N-
butyldeoxynojirimycin (NB-DNJ) (Cobucci-Ponzano et al., 2010a). The inhibition 
profile of rSSO3039 revealed that the enzyme is inhibited by both NB-DNJ and 
CBE, but with different sensitivity. The IC50 values calculated for both inhibitors 
differ of almost one order of magnitude: 5.15 µM for NB-DNJ and 9 mM for CBE 
(Fig. 2.8.16). This sensitivity spectrum makes rSSO3039 different from other 
two characterized GH116 enzymes, the archaeal β-glycosidase SSO1353 and 
the human non-lysosomal glucosylceramidase (NLGase or GBA2). SSO1353 
was inhibited by both NB-DNJ and CBE, like SSO3039, but it is worth noting the 
differences in term of sensitivity. In particular, both enzymes showed 
comparable mM sensitivity to CBE, but SSO3039 resulted more sensitive to 
NB-DNJ than SSO1353 (IC50= 5.15 µM for SSO3039 and 1.5 mM for 
SSO1353) (Cobucci-Ponzano et al., 2010a). The comparison with GBA2 
delineated a different picture as, conversely to SSO3039, the human enzyme is 
Figure 2.7.15: HPAEC-PAD analysis of the enzymatic assays on 4Np-Chit (A) and 
2Np-Cel (B). The reaction mixtures were stopped in ice at the 
indicated times (hours) and in all runs, C is the negative control, while 
R is the reaction mixture with rSSO3039. 4Np–N,N'-diacetyl-β-
chitobioside (4Np-Chit), 4Np-β-N-acetylglucosaminide (4Np-GlcNAc), 
N-acetylglucosamine (GlcNAc), chitobiose (Chit), glucose (Glc), 2Np-
β-glucoside (2Np-Glc), cellobiose (Cel) and 2Np-β-cellobioside (2Np-
Cel) were used as markers!
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insensitive to CBE and showed nM sensitivity to NB-DNJ (Boot et al., 2007). 
The different spectrum of sensitivity to NB-DNJ and CBE could represent an 
useful tool to distinguish and classify these enzyme within GH116. 
Phylogenetic analysis of GH116 enzymes 
The CAZy family GH116 was created after the paper by Cobucci-Ponzano and 
co-workers reporting on the identification and characterization of a new β-
glycosidase encoded by SSO1353 ORF of the hyperthermophilic crenarchaeon 
S. solfataricus P2 (Cobucci-Ponzano et al., 2010a). Presently this family 
includes β-glucosidases (EC 3.2.1.21), β-xylosidases (EC 3.2.1.37) and 
glucocerebrosidases (EC 3.2.1.45) from the three domains of life. The catalytic 
features were experimentally demonstrated for SSO1353 and indicate that the 
enzymes belonging to this family are retaining GHs following the classical 
Koshland double-displacement mechanism (see section 1.3 for a detailed 
description). The phylogenetic analysis (Fig. 2.7.17) has indicated that 
Figure 2.7.16: Inhibition of rSSO3039 by NB-DNJ (A) and CBE (B)!
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sequences included in the GH116 family can be subdivided into two major 
groups, one containing archaeal sequences and another one comprising mostly 
sequences from Cyanobacteria and Eukaryotes. Based on homology extent 
with SSO1353, the authors identified two other subgroups in the archaeal 
group: one includes SSO1353 homologs with identity >80% and the other one 
contains SSO1353 homologs with identities in the range of 21-33%, such as 
SSO2674 and SSO3039 from S. solfataricus P2. This family can be further 
subdivided into several subgroups according the organism source of sequences 
(Fig. 2.7.17). It is worth to note the presence of human non-lysosomal 
glucosylceramidase or β-glucosidase (GBA2) in the animal subgroup.! 
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Figure 2.7.17: Phylogenetic tree of family GH116 proposed by Cobucci-Ponzano and 
co-workers (Cobucci-Ponzano et al., 2010a) 
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Following the biochemical characterization of SSO3039, a new phylogenetic 
analysis of GH116 enzymes was performed in collaboration with Dr. B. 
Henrissat, the curator of CAZy database. From this study it emerged that the 
CAZy family GH116 can be organized in three subfamilies (Fig. 2.7.18). The 
subfamily 1, indicated in blue, contains the human GBA2 (Boot et al., 2007), the 
subfamily 2, in green, includes SSO3039 described in this work and the 
archaeal β-glucosidase/xylosidase SSO1353 (Cobucci-Ponzano et al., 2010a) 
resides in the subfamily 3 depicted in yellow. Remarkably, the molecular 
characterization of the novel β-glucosidase/N-acetyl-glucosaminidase SSO3039 
described here, gives experimental support to this phylogenetic analysis, 
demonstrating that the three subfamilies are functionally different. GH116 
enzymes share the specificity for β-O-glycosides and the same reaction 
mechanism which is retaining-like (Cobucci-Ponzano et al., 2010a). However, 
we can recognize a different substrate specificity in each of the three 
subfamilies: enzymes included in subfamily 1 are specific for 
glucosylceramides, such as GBA2, those in subfamily 2 for N-acetyl-
glucosaminides, such as SSO3039, and, lastly, those in subfamily 3 for 
xylosides, such as SSO1353. Additionally, as anticipated above, GH116 
enzymes showed a different sensitivity to the competitive inhibitors NB-DNJ and 
CBE, and this feature further support their subdivision in three subfamilies. In 
particular, the subfamily 1 is insensitive to CBE and is inhibited by nM 
concentrations of NB-DNJ, while the subfamily 2 is inhibited by both 
compounds even if with a different sensitivity (IC50 corresponds to 5.15 µM for 
NB-DNJ and 9 mM for CBE). Instead, the subfamily 3 is sensitive to CBE 
conversely to subfamily 1 and differs from subfamily 2 for its lower sensitivity 
(mM) to NB-DNJ. The characterization of additional GH116 enzymes might be 
interesting to validate the effectiveness of this classification criterion. 
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Figure 2.7.18: Phylogenetic tree showing the organization of GH116 enzymes in three 
subfamilies with different functions 
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Further bioinformatic studies were performed to predict potential active site 
signatures of the sequences grouped in the three subfamilies, namely amino 
acids surrounding the catalytic residues that may determine functional 
specificity.  
The catalytic nucleophile and the general acid/base of SSO1353, belonging to 
subfamily 3, were identified experimentally as Glu335 and Asp462, respectively 
(Cobucci-Ponzano et al., 2010a). Multi-alignment of the sequences included in 
the subfamily 3 revealed the conserved sequence motifs 
GRFAX(I,V)YEX(A,D)P (Fig. 2.7.19A) and DNX(S,A)X(F,Y)D(X(G,A)T (Fig. 
2.7.19B), surrounding the nucleophile Glu335 and the acid/base Asp462, 
respectively. 
Figure 2.7.19A:!Multi-alignment of sequences included in the subfamily 3 showing the 
conserved motif surrounding the nucleophile. Red star indicates 
Glu335!
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Multi-alignment of putative glucocerebrosidases from mammals, plants, and 
tunicates belonging to subafamily 1 of GH116 family allowed to predict GBA2 
catalytic residues, Glu527 and Asp677 that act as nucleophile and acid/base, 
respectively (Cobucci-Ponzano et al., 2010a). Sequence analysis of subfamily 1 
revealed the motifs GX(Q,R)FX(G,A,L)X(V,Y)LEX(C,G)X(L,I,V)X(D,E)Y (Fig. 
2.7.20A) and PDQTX(F,Y)DX(D,A)W (Fig. 2.7.20B), surrounding the 
nucleophile and the acid/base, respectively. 
Figure 2.7.19B:!Multi-alignment of sequences included in the subfamily 3 showing the 
conserved motif surrounding acid/base residue. Red star indicates 
Asp462!!
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Figure 2.7.20A: Multi-alignment of sequences included in the subfamily 1 showing the 
motif surrounding the nucleophile. Red star indicates Glu527!!
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Figure 2.7.20B:! Multi-alignment of sequences included in the subfamily 1 showing the 
motif surrounding acid/base residue. Red star indicates Asp677!
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In SSO3039 the nucleophile and the acid/base of the reaction were predicted to 
be Glu321 and Asp539, respectively, as observed in a multi-alignment of all 
GH116 enzymes (data not shown) and of SSO1353 with enzymes belonging to 
subfamily 2 (Fig. 2.7.21). 
Figure 2.7.21: Multi-alignment of SSO1353 with enzymes belonging to subfamily 2. 
The residues corresponding to the nucleophile Glu335 (A) and 
acid/base Asp462 (B) are indicated with a red star 
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Multi-alignment of the sequences included in the subfamily 2 revealed the 
almost conserved motif DGX(F,R)FX(G,Y)X(I,G)WEG surrounding the putative 
nucleophile Glu321 (Fig. 2.7.22A), while the putative acid/base residue is 
located in a region showing a more variable sequence pattern (Fig. 2.7.22B). 
Moreover, it is worth to mention that the putative acid/base Asp539 is followed 
by another aspartate, Asp540, conserved among the enzymes belonging to the 
subfamily 2. Detailed biochemical studies are required to determine 
unequivocally the catalytic residues of these enzymes and to elucidate a 
possible role of Asp540. 
Figure 2.7.22A:!Multi-alignment of sequences included in the subfamily 2 showing the 
motifs surrounding the putative nucleophile Glu321, which is 
indicated with a red star !
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Comparing the motifs identified in the three subfamilies, it is possible to disclose 
an almost conserved sequence pattern surrounding the nucleophile (Fig. 
2.7.23A). In addition, highlighting the residue preceding the nucleophilic 
glutamate, it is possible to note that its nature varies among the different 
subfamilies (Fig. 2.7.23A). In particular, the enzymes in subfamily 1 carry a 
leucine, an hydrophobic amino acid, while those in subfamily 2 a tryptophan, an 
aromatic amino acid and, lastly, a hydrophilic tyrosine precedes glutamate of 
subfamily 3 enzymes. Nevertheless, detailed biochemical analyses are required 
to establish an eventual role of this residue. Conversely, the sequence pattern 
surrounding the acid/base residues of the three subfamilies is more 
heterogeneous (Fig. 2.7.23B). Our findings can now allow the planning of more 
detailed site-directed mutagenesis studies to better understand the molecular 
bases of the substrate recognition of enzymes belonging to the three different 
subfamilies. 
Figure 2.7.22B:! Multi-alignment of sequences included in the subfamily 2 showing the 
motif surrounding the putative acid/base residue Asp539, which is 
indicated with a red star !
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In conclusion, our study, which for the first time identified an N-acetyl-
glucosaminidase from archaea, demonstrated that the detailed biochemical 
characterization of enzymes from natural sources is of utmost importance to 
functionally support genomic data, to increase our knowledge on enzyme 
classes, and to complete the information provided by bioinformatic data banks. 
In order to elucidate the function in vivo of these enzymes, it is needed a more 
detailed functional and structural characterization of this family. For instance, 
understanding the role of GBA2 and its interplay with the lysosomal counterpart, 
if there is, could be useful to set up new therapeutic strategies for Gaucher 
disease. But the production of GBA2 in abundant and homogenous form is 
difficult to achieve. These limits might be overcame by using GBA2 homologs 
from hyperthermophilic archaea that are easly produced in recombinant form 
and are stable in various conditions. The structural and functional studies on 
hyperthermophilic enzymes can provide useful informations that might be easily 
extended to the human counterpart. 
Figure 2.7.23:! Comparison of the sequence patterns surrounding the nucleophile (A) 
and the acid/base (B) residues of the three GH116 subfamilies. The 
catalytic residues are indicated in green, while the invariant amino 
acids are indicated in red 
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Chapter 3 
Pharmacological  enhancement  
of  acid a lpha-glucosidase  
by the al loster ic  chaperone  
N-acetylcysteine  
3.1 General overview !
!
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Chapter 3 focuses on pharmacological enhancement of acid α-
glucosidase (GAA), whose deficiency leads to Pompe disease (PD), 
belonging to lysosomal storage diseases (LSDs), by the allosteric 
chaperone N-acetylcysteine. This chapter starts with four introductive 
paragraphs (from 3.2 to 3.5) reporting the literature on the topic. In 
particular, in section 3.2 the functional and structural features of GAA will be 
exposed while the molecular aspects at the basis of LSDs will be discussed 
in the paragraph 3.3, followed by a deep description of PD in the section 
3.4. The section 3.5 is further subdivided in three sub-paragraphs, each one 
highlighting a type of therapeutic approach adopted or under investigation 
for PD treatment. The purpose of this study is illustrated in the paragraph 
3.6; while the experimental procedures and the results achieved are 
presented in sections 3.7 and 3.8, respectively. The references, instead, are 
reported in paragraph 3.9.!
!
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3.2 ACID ALPHA-GLUCOSIDASE:  
STRUCTURE AND FUNCTION
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Acid α-glucosidase (lysosomal α-glucosidase, acid maltase, glucoamylase or 
GAA; EC 3.2.1.20) is an exo-glycosidase that catalyzes the hydrolysis at acidic 
pH (pH 4.0-5.0) of both α-1,4 and α-1,6 linkages in the natural substrate 
glycogen (Fig. 3.2.1) (Jeffrey et al., 1970a, 1970b).  
Information on the primary structure of GAA has been obtained via molecular 
cloning and analysis of cDNA and genomic sequences (Hoefsloot et al., 1990; 
Martiniuk et al., 1991). The gene encoding for human GAA is located on the 
long arm of chromosome 17 and contains 20 exons and 19 introns spread over 
a distance of about 28 kb (Fig 3.2.2) (Martiniuk et al., 1991).  
The cDNA encodes for a protein of 952 aa with an apparent molecular weight of 
105 kDa (Hoefsloot et al., 1988). The newly synthesized precursor has an 
amino-terminal signal peptide for co-translational transport into the lumen of the 
endoplasmic reticulum (ER), where it is N-glycosylated at seven glycosylation 
Figure 3.2.1:!Breakdown of glycogen catalyzed by GAA 
Figure 3.2.2: Organization of GAA gene 
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sites (Fig. 3.2.3), resulting in a glycosylated precursor with an apparent 
molecular mass of 110 kDa.  
During trafficking to the lysosome, the 110 kDa form is subject to several post-
translational modifications involving both the N-glycan chains and the protein 
backbone (Fig. 3.2.4) (Moreland et al., 2005). The first processing step is the 
cleavage between aa 28 and 29 by a signal peptidase, followed by a proteolytic 
cleavage between aa 56 and 57. After transport through the Golgi complex and 
targeting to the endosome/lysosome, it is further proteolytically processed at the 
amino terminus, resulting in a 95 kDa intermediate with a sequence beginning 
at aa 122 (intermediate 1). Interestingly, almost all of the reduction in molecular 
mass from 110 to 95 kDa is attributed to the loss of part of the carbohydrate 
moiety due to extensive glycan trimming. This suggests that the processing 
yielding intermediate 1 takes place in a late endosome or lysosome, containing 
multiple glycosidases. In the next step, the 95 kDa intermediate is proteolytically 
cleaved at the carboxyl terminus, between aa 816 and 881, by an unknown 
protease generating the 76 kDa form that represents the major enzymatic 
species. The 76 kDa form is then proteolytically processed at the amino 
terminus, at aa 204, to give the 70 kDa mature form (Wisselaar et al., 1993). 
The nomenclature used for the processed forms of GAA is based on apparent 
molecular mass as determined by SDS-PAGE.  
Figure 3.2.3:!Glycosylation sites of GAA 
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The identities of the proteases involved in the maturation of GAA are unknown. 
GAA has been purified from many different tissues such as bovine testis 
(Reuser et al. 1984), rat liver (Scheibe et al., 1985), pig liver (Tashiro et al., 
1986), human liver (Murray et al., 1978), rabbit muscle (Matsui et al., 1984), 
human heart (Chambers and Williams, 1983), human urine (Oude Elferink et 
al., 1984) and human placenta (Hasilik and Neufeldg, 1980): the predominant 
species observed are the 76- and 70-kDa mature forms. 
The peptides released during proteolytic processing remained tightly associated 
with the major species (Moreland et al., 2005). The first 95 kDa intermediate is 
covalently linked via a disulfide bond to a 3.9 kDa polypeptide (aa 78–113). The 
76 kDa form is associated with peptides of 3.9 kDa (aa 78–113) and 19.4 kDa 
(aa 792–952), while the 70 kDa form contains the 3.9- and 19.4 kDa peptide 
species as well as a 10.3-kDa species (aa 122–199). The association of the 
proteolytically cleaved fragments of GAA is not unique for lysosomal enzymes. 
The lysosomal α-mannosidase enzyme is synthesized as a single chain 
precursor and then is processed into three glycopeptides of 70, 42, and 15 kDa. 
The 70-kDa glycopeptide is further proteolyzed into three peptides that are 
joined by disulfide bridges (Nilssen et al., 1997). 
Figure 3.2.4:!Model for the maturation of GAA 
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Proteolytic processing appears to be required for optimal activity toward the 
natural substrate glycogen. The 76/70-kDa species display an affinity for 
glycogen 7–10-fold higher than the 110 kDa precursor (Tab. 3.2.1) (Bijvoet et 
al., 1998; Wisselaar et al., 1993). 
Source CHO medium 
CHO 
medium 
Mouse 
milk 
Mouse 
milk Placenta 
Isoform (kDa) 110 76 110 76 76/70 
Km (mg/ml) 425.3 43 484.6 54.8 42.2 
Table 3.2.1:!Affinity for glycogen of the recombinant forms of human GAA!
In addition to maturation of the peptide backbone, GAA is subjected to an 
extensive remodelling of the carbohydrate chains (Fig. 3.2.5) (Chen and 
Amalfitano, 2000).  
The newly synthesized GAA harbouring a high-mannose oligosaccharide is 
transferred from ER to the Golgi network where it acquires the mannose 6-
phosphate (M6P) residues through the sequential action of N-
acetylglucosaminylphosphotransferase (GnPT) and N-acetylglucosamine-1-
phosphodiester α-N-acetylglucosaminidase (UCE) (Fig. 3.2.5, pathway 2). M6P 
residues can bind to M6P receptors allowing the transport of the enzyme to the 
lysosome. Alternatively, GAA can undergo trimming of mannose, addition of 
Figure 3.2.5:!Remodelling of GAA N-glycans during trafficking to the lysosomes  
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sugars and formation of a complex oligosaccharide and is secreted (Fig. 3.2.5, 
pathway 1). M6P receptors on plasma membrane can bind extracellular 
enzyme and mediate its internalization and localization to the lysosomes. Thus, 
N-glycans decorating the seven glycosylation sites of GAA are highly 
heterogeneous; they are predominantly high-mannose-type, containing typically 
six to nine mannose residues and one or two M6P residues, but complex-type 
chains are also present (Mutsaers et al., 1987). The functional relevance of 
each of the seven glycosylation sites was determined by site-directed 
mutagenesis (Hermans et al., 1993).!Elimination of six of the seven sites does 
not interfere with enzyme synthesis, lysosomal transport or function; whereas 
removal of the second glycosylation site at Asn-233 hampers dramatically the 
formation of mature enzyme. The mutant precursor is synthesized normally and 
assembled in the ER, but it is not targeted to the lysosomes. 
According to CAZy classification, GAA is included in the family GH31, that also 
contains α-xylosidases (EC 3.2.1.177), isomaltosyltransferases (EC 2.4.1.-), 
maltase/glucoamylases (EC 3.2.1.48) and the α-glucan lyases (EC 4.2.2.13). 
The GH31 enzymes are retaining α-glycosidases following the classical 
Koshland double-displacement mechanism (Koshland, 1953) (see section 1.3 
for more details) and can be found in a wide range of organisms including 
archaea, bacteria, plants and animals. 
With respect to the functional trait, it is worth to note the striking similarities 
found between human GAA and the 2 subunits of intestinal brush border 
sucrase-isomaltase, suggesting that these proteins are derived from the same 
ancestral gene. The major sequence differences are found in the N-terminal 
regions accounting, probably, for the different cellular locations of these 
proteins. Structural conservation of the active site of these enzymes seemed 
likely because of overlapping substrate specificities (Hoefsloot et al., 1988; 
Hunziker et al., 1986).! The catalytic domain of human GAA is folded into a 
(β/α)8-barrel, and the active-site pocket is located at the C-terminal end of the β-
strand. Through two different approaches, the substrate analogue and active 
site-directed inhibitor conduritol β−epoxide (CBE) and site-directed 
mutagenesis, Hermans and colleagues have identified the catalytic nucleophile 
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as Asp-518 (Hermans et al., 1991); by contrast, the catalytic proton donor 
residue, Asp-616, was assigned by similarity (Yoshimizu et al., 2008). 
GAA activity is essential for the catabolism of lysosomal deposits of glycogen 
and the deficiency of this metabolic function is associated to the pathogenesis 
of a lysosomal storage disease (LSD), known as Pompe disease (see below for 
a detailed description). 
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Lysosomes are membrane-bound acidic organelles that contain over 50 
different acid hydrolases responsible for the catabolism of a wide range of 
macromolecules, including glycosphingolipids, glycogen, mucopolysaccharides, 
oligosaccharides, cholesterol, peptides, and glycoproteins. They also play a role 
in cell health by digesting viruses, microbes and other organelles.  
The deficiency of any individual lysosomal enzyme leads to a lysosomal storage 
disorder (LSD), which is characterized by the pathological accumulation of the 
deficient enzyme’s substrate (Fig. 3.3.1). Lysosomal storage diseases (LSDs) 
are a diverse group of hereditary metabolic disorders and, although they are 
individually rare, their overall prevalence is estimated to be 1 in 8000 births 
(Meikle et al. 1999). 
The first description of a lysosomal storage disorder was that of Tay-Sachs 
disease in 1881, even if the lysosome was not discovered until 1955, by 
Christian De Duve (Appelmans et al., 1955). The first demonstration of a link 
between an enzyme deficiency and a storage disorder was achieved for Pompe 
disease by Hers in 1963 (Hers, 1963). To date, over 50 LSDs have been 
described; they tend to be multisystemic and display a progressive course (Tab. 
3.3.1).!!
Most LSDs are autosomal recessive disorders with the exceptions of Hunter 
disease (MPS II) and Fabry disease, that show an X-linked inheritance pattern. 
The pathogenic mutations affect a single gene and can be of various type. 
Nonsense mutations, deletions, insertions and duplications cause premature 
termination and/or frame shifts and frequently lead to absent or truncated 
Figure 3.3.1:! Schematic illustration of the LSDs pathogenesis. A complex substrate is 
normally degraded by a series of lysosomal enzymes (A, B, and C) into 
soluble end products. If there is a deficiency or malfunction of one of the 
enzymes (e.g., B), catabolism is incomplete and insoluble intermediates 
accumulate in the lysosomes 
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proteins, which results in a complete loss of functional enzyme. Several splice-
site mutations have also been identified and, in some instances, they do not 
allow the generation of functional mRNA (Polten et al., 1991).!!
Table 3.3.1: Some known LSDs. OMIM is Online Mendelian Inheritance in Man 
number 
3.3 Lysosomal storage diseases !
!
111 
The effects of missense mutations or small in-frame deletions are less apparent 
and need molecular biological characterization to understand how they lead to 
the enzyme deficiency. However, considering the large number of missense 
mutations identified in LSDs, only a limited number have been investigated from 
a biochemical point of view. The deleterious effect of a missense mutation is 
obvious if the affected amino acid is located in the active site (Garman and 
Garboczi, 2004; Huie et al., 1994) or is important for proper folding. Active-site 
mutations may lead to a complete loss of enzyme activity, but may also result in 
alterations of enzyme kinetics (Zhang et al., 2000). Substitution of cysteine 
residues or charged residues involved in the formation of intramolecular 
disulphide bonds or salt bridges, respectively, is likely to interfere with proper 
folding of the enzyme (Hermann et al., 2000; Saarela et al., 2001). Mutations 
affecting the active centre or intramolecular bonds, however, are in the minority.!
The effects of most missense mutations are still unknown. Thus, it is difficult to 
understand why even very conservative amino acid substitutions can severely 
affect a lysosomal enzyme. In many cases, amino acid substitutions cause 
misfolding of the enzyme, which results in retention of the mutant polypeptide in 
the ER and its subsequent proteasomal degradation (Poeppel et al., 2005; 
Schestag et al., 2002). It has been estimated that degradation is responsible for 
about 50% of protein defects in all genetic diseases and thus represents the 
most frequent cause of deficiencies (Carrell and Lomas, 1997). Alternatively, 
amino acid substitutions allow to pass the ER quality control. One example is 
given by substitution of proline 426 by leucine (P426L) in arylsulphatase A, one 
of the most frequent mutation causing Metachromatic leukodystrophy (Polten et 
al., 1991; Von Bülow et al., 2002).  
Since the synthesis and processing of lysosomal hydrolases involve many 
steps, it is not surprising that the disfunction can originate at different levels: 
synthesis, folding, activation or targeting. The severity of the phenotype is 
closely related to the residual enzyme activity. In general, the lower is the 
residual activity, the earlier is the age of onset, and more severe are the clinical 
manifestations. There was a critical threshold above!of which, enzyme activity is 
still sufficient to prevent accumulation of substrate (Conzelmann and Sandhoff, 
1983). 
Lysosomal storage diseases 3.3!
!
112 
LSDs are not simply a consequence of pure storage, but also result from other 
complex cell signalling mechanisms, which in turn elicit secondary structural 
and biochemical events. The molecular pathways through which the storage 
material causes cellular and organ pathology are largely unknown. A number of 
secondary biochemical and structural events have been reported. For example 
raised concentrations of cytokines or chemokines, deriving from macrophage 
activation, have been found in patients with Gaucher disease (Boot et al., 2004; 
Hollak et al., 1997). Altered homeostasis of calcium, an important intracellular 
mediator, appears to play an important role in the sphingolipid storage 
disorders. There is also evidence that extralysosomal accumulation of substrate 
may take place and have deleterious effects on trans-membrane and 
intracellular signalling. For example, in a mouse model of metachromatic 
leucodystrophy, accumulation of sulphatide was demonstrated in myelin as well 
in lysosomes. There is also the intriguing possibility that lysosomal storage may 
adversely affect mitochondrial function (Jolly et al., 2002; Lücke et al., 2004). 
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Pompe disease (PD, OMIM 232300), also known as glycogen-storage 
disease type II, glycogenosis type II or acid maltase deficiency, is a pan-ethnic 
autosomal recessive myopathy with an estimated incidence of 1:40,000 live 
births. It was described for the first time by the Dutch pathologist Johannes C. 
Pompe in 1932 (Pompe, 1932) and since then, continuous progress has been 
made in the understanding of its biochemistry and genetics (Fig.3.4.1)  
The pathogenesis is associated to mutations in the GAA gene, resulting in 
functional deficiency of acid α-glucosidase (GAA) with consequent lysosomal 
accumulation of!glycogen in several tissues and organs (Fig. 3.4.2).  
Presently, more than 400 different mutations have been identified (missense, 
nonsense, deletions, insertions and splice site mutations) and are listed in the 
PD database of the Erasmus University, Rotterdam, the Netherlands 
(http://www.erasmusmc.nl/klinische_genetica/research/pompe_center/). Some 
of them are recurrent (Hermans et al., 2004) and show an ethnic distribution: 
the c.525del, p.G309R, p.M519T, p.G219R, p.G828_N882del, c.525del, and 
p.E176fsX4 mutations are frequent among Caucasians, the pR854X among 
Africans, the p.D645E among Asians. In Italy the p.L552P mutation accounts for 
8.5% of the alleles in early-onset Italian patients (Pittis et al., 2008), whereas 
the p.W746X mutation has been found in 10.3% of the alleles in late-onset 
patients (Montalvo et al., 2006). Other mutations are pan-ethnic, such as the 
splice site c.-32-13T>G, which is highly prevalent among late-onset PD patients 
Figure 3.4.1: Milestones in the scientific research on PD 
Figure 3.4.2:!PD pathway 
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(Kroos et al., 2007). The nature and combination of the mutations in the two 
GAA alleles dictates the degree of enzyme deficiency. Accumulation of 
lysosomal glycogen starts when GAA activity drops below 30% of average 
normal activity and the disease phenotype is correlated to the extent of enzyme 
deficiency: GAA activity may range from complete deficiency (<1%) in the 
severe forms, to partial (up to 30%) deficiency in milder forms (Fig. 3.4.3) 
(Hermans et al., 2004). 
The genotype/phenotype correlation is not always unequivocal: secondary 
factors can influence substantially the clinical course (De Filippi et al., 2010). 
PD is a multisystemic disease with glycogen storage occurring in almost every 
tissue and cell type. However, clinical manifestations are predominantly related 
to heart and skeletal muscle involvement.!As a consequence, the clinical picture 
of PD shares common features with that of neuromuscular disorders.  
Traditionally, PD has been classified into distinct categories based on the 
phenotype and the age of onset: 
- classic infantile  
- juvenile and adult  
The infantile form manifests with a severe phenotype, characterized by severe 
hypertrophic cardiomyopathy, generalized hypotonia, respiratory infections and 
a rapidly progressive course (van den Hout et al., 2003).!Clinical manifestations 
may appear already in utero, but usually present within the first months of life 
(1.6-2.0 months) and patients with this PD form rarely survive beyond 1 year of 
age. 
Figure 3.4.3: Model depicting the correlation between residual GAA activity and 
phenotype 
!
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The late-onset juvenile and adult forms emerge between the second and fourth 
decade and show a more mild clinical presentation (Hagemans et al., 2005).  
The cascade of events that starts from glycogen storage and leads to cell death 
and muscle atrophy and destruction is still poorly understood. For many years, 
it was assumed that storage per se was responsible for cell and tissue damage. 
The rupture of glycogen-filled lysosomes was considered the major cause of 
muscle destruction in PD. Only in the recent years, emerging evidences 
suggest that secondary factors triggered by storage are likely to concur in tissue 
damage.!The spectrum of such events is wide, including receptor activation by 
non-physiologic ligands, modulation of receptor responses and signal 
transduction cascades, activation of inflammatory responses, impaired 
intracellular trafficking of vesicles, membranes and membrane-bound proteins, 
impairment of autophagy, and others (Ballabio and Gieselmann, 2009).!  
The understanding of the role played by the secondary factors in the 
pathogenetic route of PD!has very important clinical implications, specifically for 
the therapeutic management of the disease. 
 
!! 117 
 !
3.5 THERAPEUTIC APPROACHES
Therapeutic approaches 3.5!
!
118 
The complexity of PD phenotype and pathophysiology makes therapeutic 
interventions particularly challenging. Therapies should be directed towards 
correction of pathology and function in all affected tissues to restore health, or 
to ameliorate patients’ quality of life. The last decade has witnessed 
extraordinary innovation in the treatment of PD with different approaches now 
available or under investigation (Fig. 3.5.1). Currently, the only approved 
therapy for this LSD is the Enzyme Replacement Therapy (ERT) based on 
intravenous infusions of recombinant GAA (see paragraph 3.5.1 for more 
details). Nevertheless, this approach has limitations and important issues 
remain unsolved. Thus, current efforts are being directed towards exploring 
alternative therapeutic approaches based on innovative strategies, such as 
Pharmacological Chaperone Therapy (PCT, which will be described in the 
paragraph 3.5.2), gene therapy, Substrate Reduction Therapy (SRT) and 
modulation of autophagy (described in the paragraph 3.5.3).  
 
Figure 3.5.1: Multiple therapeutic approaches have been used or are under 
investigation to treat PD, targeting different cellular pathways and 
functions 
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Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) 
is currently the only approved pharmacologic treatment for PD. 
ERT is based on the concept that recombinant lysosomal hydrolases, in most 
cases enzyme precursors manufactured on large scale in eukaryotic cells, can 
be administered periodically to patients by an intravenous route. These 
enzymes are internalized by patients’ cells and tissues through the mannose or 
M6P receptors and are ultimately delivered to lysosomes, where they are 
activated and restore the function of the defective hydrolases (Fig. 3.5.1.1). 
In the 1960s, PD was the first LSD for which attempts at ERT were undertaken 
by using enzyme preparations from Aspergillus niger and human placenta. 
However, these attempts had no clinical benefit: inappropriate enzyme source 
and insufficient dosing were the causes of failure (Hug and Schubert, 1967). An 
important step forward was the knowledge that cell-surface receptors are 
required for uptake of extracellular glycoproteins via endocytosis. Efficient 
uptake and targeting to the lysosomes was mediated by the M6P or insulin-like 
growth factor II receptor (Van der Ploeg et al., 1988).!Cloning of the GAA gene 
provided the essential method to explore production of recombinant human 
enzyme in cell culture and in milk of transgenic animals leading to large-scale 
production of rhGAA in milk of transgenic rabbits and in CHO cells (Bijvoet et 
al., 1999; Van Hove et al., 1996; Van Hove et al., 1997; Martiniuk et al., 1986). 
Both products were! tested in a mouse model of PD and showed similar uptake 
characteristics (Bijvoet et al., 1998), but! rhGAA produced in CHO cells has 
proved to be more effective in clearing glycogen stores in heart and muscle 
(McVie-Wylie et al., 2008). For these reasons CHO-derived rhGAA 
(alglucosidase alfa) was selected for future clinical development and 
registration (Van den Hout et al., 2000; Van den Hout et al., 2004; Klinge et al., 
Figure 3.5.1.1: Model depicting the cellular uptake of rhGAA 
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2005). In 2006 alglucosidase alfa (Myozyme®, Genzyme, Cambridge, MA) 
received marketing approval by the European Medicine Agency! and US Food 
and Drug Administration. Myozyme is protected by U.S. Patent No. 6,118,045 
which expires on August 18, 2018. The therapeutic protocol provides 
intravenous administration of doses of 20 mg/kg and 40 mg/kg once every 2 
weeks. The age at which treatment is started constitutes an important factor 
that determines efficacy of therapy: early start leads to the best outcome. 
ERT in PD is, at present, the only cure and had the great merit of improving 
survival of the patients and stabilize the disease course. However, it displays 
several limitations: 
- reduced targeting to skeletal muscle, one of the major sites of disease 
(Raben et al., 2003). Why this happens remains to be fully elucidated, 
even if several factors have been proposed. Most of the recombinant 
enzyme (up to 85%) was taken up by liver and only a small fraction 
reaches heart and even less skeletal muscle. The large mass of this 
tissue and the relative deficiency of the M6P receptors on muscle cells 
(Wenk et al., 1991) also contribute to the poor correction of GAA activity. 
To improve muscle targeting of rhGAA, Zhu and colleagues have 
proposed a glycoengineered rhGAA, that is chemically modified by 
conjugation of a synthetic oligosaccharide harbouring M6P residues (Zhu 
et al., 2005). This modification significantly improved the affinity of the 
enzyme for the M6P receptors and its uptake by muscle cells. 
Administration of this carbohydrate-remodeled enzyme to PD mice 
resulted in an approximately fivefold higher clearance of lysosomal 
glycogen in muscles when compared to the unmodified enzyme. 
Nevertheless, the large production of this form of rhGAA is still difficult.!
- immune response to rhGAA 
- high costs. Initial investments in research and costs related to the 
production of large amounts of good manufacturing practice recombinant 
enzymes contribute to keep the prices of ERT extremely high 
($300,000/year/patient) 
- burdensome for patients 
Therefore, importantly,! the ERT drawbacks point to the need for improved 
therapeutic strategies. 
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Over the past decade, pharmacological chaperone therapy (PCT) has 
attracted much interest as a potential treatment for many genetic diseases that 
result from misfolded and/or unstable proteins, including LSDs (Fan, 2008; 
Parenti, 2009).  
Many of the mutations causing human LSDs are missense and may influence 
mRNA expression, protein folding and stability, intracellular trafficking, substrate 
binding, catalytic competency, and/or enzyme turnover rate. Folding and 
maturation of lysosomal enzymes, like many other proteins, are monitored by 
the quality control system of the ER (Ellgaard and Helenius, 2001). It relies on 
molecular chaperones and folding factors, such as BiP, calnexin, calreticulin, 
thiol-disulfide oxidoreductases, and protein disulfide isomerase, that recognize 
common structural features, such as exposed hydrophobic regions, unpaired 
cysteine residues and so on, to distinguish stable, native protein conformations 
from unstable, non-native ones (Anelli and Sitia, 2008; Ushioda et al., 2008). 
The correctly folded proteins can leave ER and progress through the secretory 
pathway to the lysosome. If the nascent protein is not properly folded, it is 
recognized as aberrant by ER quality control system and targeted to the 
proteasomal degradation (Fig. 3.4.2.1A). ER quality control is highly efficient, 
but, in some cases, mutant enzymes that retain catalytic activity, or that have 
only modestly compromised function may be recognized as aberrant and then 
degraded. Thus, slight modifications in protein stability or conformation, as seen 
with many lysosomal enzymes carrying missense mutations, may prevent 
release from the ER and result in premature degradation and a loss of function.  
PCT is based on the concept that small molecules, such as substrates or 
active-site directed competitive inhibitors, may assist the folding of mutated 
enzymes that retain their catalytic activity, and prevent their recognition by the 
quality control system (Fan and Ishii, 2007). In this way the pharmacological 
chaperones (PCs) increase intracellular pool of active enzyme, improve 
trafficking of the protein towards its final destination and partial restore the 
metabolic functions (Fig. 3.5.2.1B). In addition to lysosomal enzymes, the 
efficacy of PCs has been shown also for other types of mutated proteins, 
including G protein-coupled receptors, secreted proteins, transcription factors, 
ion channels, and transporters, involved in the pathogenesis of diseases such 
as cystic fibrosis, hypercholesteremia, cataracts, Huntington’s, Alzheimer’s and 
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Parkinson’s diseases, retinitis pigmentosa, nephrogenic diabetes insipidus, and 
cancer.  
PCs are distinct from chemical chaperones, such as glycerol, dimethylsulfoxide, 
and trimethylamine N-oxide. Chemical chaperones act non-specifically on many 
proteins and require very high concentrations to exert their effect. By contrast, 
PCs are designed to specifically bind the protein of interest, as a consequence 
therapeutic benefits are achieved at low concentrations. 
Several factors make LSDs excellent candidates for PCT. In most LSDs, 1% to 
6% of normal activity has been estimated to be sufficient to delay or prevent 
disease onset or to yield a more mild form of the disease (Schueler et al., 
2004). Thus, even a minor increase in enzyme activity obtained by PCT could 
have a significant impact on substrate levels, and hence disease severity and 
the rate of disease progression. In addition, the use of PCs has the potential to 
overcome several ERT limitations such as its impact on the patients’ quality of 
life and high costs. These drugs are low molecular-weight molecules, and thus 
can be ingested orally with broad biodistribution and do not require invasive life-
long infusions, as for ERT. 
PCs identified so far interact with the active site and reversibly inhibit enzyme 
activity. In the case of PD, the imino sugars DNJ and derivatives are currently 
Figure 3.5.2.1: A. Folding of lysosomal enzymes in absence of PCs; destiny of wild-
type protein is indicated by green arrows; while red arrows 
delineate the route of mutated misfolded enzyme.  
B. Stabilizing effect of PCs on misfolded lysosomal enzyme indicated 
by green arrows 
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under investigation as PCs (Fig. 3.5.2.2). These compounds contain a 
piperidine ring with an array of hydroxyl groups that closely resembles the 
terminal glucose unit of glycogen: this high level of structural similarity allows 
the binding to the active site and stabilization of GAA, but they also act as 
reversible competitive inhibitors of enzyme. It has been assumed that, once in 
the lysosome, the chaperone is displaced from the enzyme due to the excess of 
natural substrate, with a higher affinity to the catalytic site and that the acidic 
environment of lysosomes favours the dissociation of the chaperone–enzyme 
complex. But all these aspects are not completely clear and will need further 
investigation.  
Although the rationale of PCT is clear, the molecular mechanisms underlying 
the effect of chaperones are still not fully understood.  
Not only mutated enzymes, but also recombinant enzymes used for ERT may 
be prone to mistrafficking and degradation. For instance, in human fibroblasts 
from PD patients and in muscle cells of a PD mouse model, it has been shown 
that a fraction of the rhGAA is mistargeted and is ineffective (Cardone et al., 
2008; Fukuda et al., 2006). Some evidences indicate that PCs can act also on 
wild-type enzymes. The mechanisms underlying the effect of chaperones on 
wild-type enzymes is not clear. The enhancing effects of PCs may take place at 
different levels (Fig. 3.5.2.3): 
? increased uptake  
Figure 3.5.2.2: Structure of the imino sugars that act as PCs of GAA 
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? improved intracellular trafficking to lysosomes 
? enhanced  enzyme stability  
In the case of PD, NB-DNJ has proved to be effective to increase stability of 
rhGAA in vitro and, importantly, also to improve the delivery of the recombinant 
enzyme to the lysosomes. The combination of rhGAA and the PC is more 
efficient in correcting the enzyme activity than rhGAA alone (Porto et al., 2009). 
The synergistic effect of PCT and ERT may be particularly useful in patients 
responding poorly to therapy and in tissues in which sufficient enzyme levels 
are difficult to obtain. Further investigations are required to address questions 
as to where do chaperones and enzymes come in contact and why do they 
confer stability to already properly folded protein.  
Unfortunately PCT, like ERT, displays some drawbacks: 
! inhibitory action of PCs identified to date (Porto et al., 2012; Yoshimizu et 
al., 2008) 
! only missense mutations are amenable to PCT, accounting for about 
15% of mutations leading to PD (Porto et al., 2009) 
! adverse effects and high costs of some PCs, like NB-DNJ (Ficicioglu, 
2008) and DNJ. A first phase 2 clinical trial, started in the US and 
sponsored by Amicus Therapeutics, was performed using DNJ as 
therapeutic agent. The trial was terminated after the appearance of 
Figure 3.5.2.3: Model depicting the synergy between ERT and PCT 
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adverse events in treated patients and needs careful evaluation of the 
treatment protocol (Parenti and Andria, 2011).  
Hence, future efforts should be directed towards the identification of a second 
generation of molecules with a good safety profile and better enhancing 
properties and intracellular distribution. An ideal compound should have a good 
enhancing activity (Wang et al., 2009) without inhibitory effects, and be effective 
on a larger number of mutations. To overcome the inhibitory effect associated 
to the use of compounds directed to active site, one possible scenario could be 
the identification of molecular chaperones directed to allosteric sites. 
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Gene therapy  
Gene therapy is based on the use of vectors delivering the therapeutic 
enzyme!to target organs. Different vectors, including Adenoviruses (Ad), adeno-
associated (AAV) viruses and lentiviruses, have been tested in PD mouse 
model.! AAV-mediated gene therapy was reported to restore therapeutic levels 
of GAA activity, substantially reduce glycogen storage and improve muscle 
morphology both in the heart and in skeletal muscle (Sun et al., 2008).!
Intravenous administration of an Ad vector encoding GAA resulted in secretion 
of high levels of the precursor GAA into the plasma of treated animals 
(Amalfitano et al., 1999). The secreted enzyme was efficiently taken up by the 
neighboring cells through M6P receptors, resulting in a phenotypic rescue and 
correction of glycogen storage. Another gene therapy approach is based on the 
use of a chimeric GAA containing an alternative signal peptide that increased 
the secretion of GAA from transduced cells and enhanced the receptor-
mediated uptake of GAA in striated muscle (Sun et al., 2006). This strategy 
allowed to reduce significantly glycogen content in striated muscle of PD mice.!
The lentiviral vector were used to express GAA in hematopoietic stem cells 
(HSC). PD mouse model transplanted with this genetically engineered HSC, 
showed a clearance of glycogen in heart, diaphragm, spleen and liver (Van Til 
et al., 2010). Although these preclinical studies seem to hold great promise, 
several issues remain to be addressed, such as evasion of immune response, 
possible toxicity of vectors, choice of the appropriate dosage of viral particles 
and of the proper route of administration to achieve sustained corrective 
enzyme levels in target tissues. 
Substrate reduction therapy (SRT) 
Substrate reduction therapy (SRT) is aimed to restore the equilibrium 
between substrate synthesis and degradation, reducing the rate of substrate 
synthesis, instead of enhancing the activity of the degrading enzymes. Since 
2003, this strategy is already in clinical use for mild to moderate forms of 
Gaucher disease and is based on the use of NB-DNJ (miglustat, Zavesca®, 
Actelion Pharmaceuticals, Allschwil/Basel, Switzerland), a small molecule that 
inhibits ceramide glucosyltransferase (Platt and Jeyakumar, 2008).! A SRT-
based approach was also proposed for treatment of PD (Douillard-Guilloux et 
al., 2008, 2010). The strategy is based on the genetic suppression of glycogen 
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synthesis through the use of short hairpin ribonucleic acids (shRNA) targeted to 
the glycogen synthase. In PD mouse model, this approach allowed to deeply 
reduce the amount of glycogen in the heart and skeletal muscles, and to 
significantly decrease lysosomal swelling and autophagic build-up. 
Modulation of the autophagy 
Autophagy is a highly regulated mechanism in the lysosomal pathway by 
which the cells degrade long-lived proteins and damaged or unneeded 
organelles in the cytoplasm (Wang and Klionsky, 2003). Defects in lysosome 
function can lead to autophagic stress (Chu, 2006) characterized by 
accumulation of autophagic intermediates (Kurz et al., 2008). Suppression of 
autophagy alone or combined with ERT, as alternative treatment for PD, can be 
beneficial for the restoration of muscle histology and architecture (Raben et al., 
2010).! Anyway, it is worth to note that the suppression of autophagy in the 
muscles can theoretically also have unwanted consequences, such as 
accumulation of dysfunctional mitochondria and oxidative stress (Wu et al., 
2009). Hence, when considering the manipulation of autophagy as therapeutic 
strategy, it is important to find a correct balance. 
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Acid-α-glucosidase is a glycoside hydrolase whose functional deficiency 
leads to Pompe disease, a lysosomal storage disorder highly debilitating and 
life-threatening. Enzyme replacement therapy (ERT) is the only approved 
therapy, which allows to ameliorate patients’ quality of life and slow the clinical 
course, but it displays several limitations that contribute to reduce its efficacy, in 
addition to be very expensive and burdensome for patients. In the recent years, 
Pharmacological chaperone therapy alone or in combination with ERT has 
proved to be very promising. The pharmacological chaperones (PCs) identified 
to date are directed to active site of target protein and act as its competitive 
inhibitors, limiting their chaperoning action. For these reasons, a second 
generation of PCs with better enhancing effect and effective on a larger number 
of mutants without inhibitory effect is desirable.  
This scenario prompted us to start a project with the goal of identifying new 
molecular chaperones. The first part of work was focused on the biochemical 
characterization of rhGAA and on the identification of the parameters to use for 
testing the efficacy of new PCs. In the second part, we have analysed how the 
new PCs affect the activity and stability of rhGAA. In particular, the effect on 
basal activity has allowed to evaluate if they act or not as inhibitors of rhGAA. 
Instead, the chaperoning action was tested in a cell free system, analyzing the 
effect of the selected compounds on pH and thermal stability of rhGAA. The 
study on cell system and in vivo were performed by Dr. Parenti’s group of 
TIGEM institute, while the computational biology studies were carried out by Dr. 
Colombo of Istituto di Chimica del Riconoscimento Molecolare (ICRM, CNR). 
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Reagents!
rhGAA (algucosidase, Myozyme) was from Genzyme, Cambridge, MA. It is 
a kind gift of the Dr. Giancarlo Parenti and derive from the residual amounts 
of the reconstituted recombinant enzymes prepared for the treatment of PD 
patients at the Department of Pediatrics, Federico II University, Naples, 
Italy. NAC, NAS, NAG, cysteine, serine, glycine, 2-mercaptoethanol, 4-
nitrophenyl-α-glucopyranoside (4NP-α-Glc), DNJ, NB-DNJ, and DGJ were 
from Sigma-Aldrich. !
Enzymatic assay of rhGAA!
The standard activity assay of rhGAA was performed on 20 mM 4NP-α-Glc 
in 100 mM sodium acetate pH 4.0. The reaction was started by adding 5 µg 
of enzyme; after 2 minutes of incubation at 37°C the reaction was blocked in 
ice by adding 800 µl of 1 M sodium carbonate pH 10.2. Suitable blanks, 
containing all the reagents with the exception of enzyme, were always 
prepared to take into account the negligible spontaneous hydrolysis of the 
substrate. Absorbance was measured spectrophotometrically at 420 nm at 
room temperature and the extinction coefficient to calculate enzymatic units 
was 17.2 mM–1 cm–1. One enzymatic unit is defined as the amount of 
enzyme catalyzing the conversion of 1 µmol substrate into product in 1 
minute, under the indicated conditions. All kinetic data were calculated as 
the average of at least two experiments and were plotted and refined with 
the program GraphPad Prism.!
The effect of PCs and other molecules on the basal activity of rhGAA was 
evaluated by performing the standard activity assay in the presence of 0-10 
mM of the compounds indicated in the text.!
Effect of pH and temperature on rhGAA activity!
The effect of different pHs was determined in 50 mM citrate/phosphate in 
the range of pH 3.0–7.0. The reaction mixtures, containing 0.75 mg ml–1 of 
enzyme, were kept at 37 °C and aliquots were withdrawn at the times 
indicated (0–48 hours). The residual GAA activity was measured with the 
standard assay. The effect of PCs and other molecules on the stability of 
rhGAA at pH 5.0 and 7.0 was determined as described above by adding to 
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the reaction mixtures 0.1, 1 or 10 mM of the different compounds indicated 
in the text. !
To test the effect of temperature, rhGAA (0.75 mg ml–1) was incubated in 50 
mM citrate/phosphate pH 5.0 or 7.0 at 60-65°C. At the times indicated (0–40 
min) aliquots were withdrawn and the residual GAA activity was measured 
with the standard assay. !
Differential scanning fluorimetry of rhGAA!
The differential scanning fluorimetry (DSF) (Niesen et al. 2007) was used to 
evaluate the thermal stability of rhGAA in different conditions. The thermal 
denaturation was monitored by measuring fluorescence of SYPRO Orange 
(Invitrogen), a dye that binds to the hydrophobic regions exposed by 
proteins undergoing thermal unfolding (Fig. 3.7.1). !
The measurements were performed in neutral pH buffer (25 mM sodium 
phosphate buffer, 150 mM NaCl, pH 7.4) or acidic pH buffer (25 mM sodium 
acetate, 150 mM NaCl, pH 5.2). The enzyme (2.5 µg) was incubated in the 
absence and in the presence of 5-20 mM of the compounds indicated in the 
results in a final volume of 25 µl. Thermal stability scans were performed at 
1°C/minute in the range 25–95°C in a Real-Time Light Cycler (Biorad, Milan, 
Italy). SYPRO Orange fluorescence was normalized to maximum 
fluorescence value within each scan to obtain relative fluorescence. To 
calculate the melting temperature (Tm), the values of fluorescence were 
processed through an Excel file that determines minimum and maximum 
intensities! within a selected temperature range: these two values delineate 
Figure 3.7.1: Schematic representation of thermal shift assay with SYPRO Orange to 
monitor protein melting profiles 
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the two asymptotes of the melting transition. The processed data were then 
fitted to Boltzmann equation implemented in a GraphPad Prism file. The two 
files used for this calculations are available! for download from 
ftp://ftp.sgc.ox.ac.uk/pub/biophysics (Niesen et al., 2007).!
Inhibition of rhGAA by DNJ!
The inhibition of rhGAA was evaluated with variation of the standard activity 
assay. Briefly, the enzyme (5 µg) was assayed at various substrate 
concentrations (0-30 mM 4Np-α−Glc) in presence of 2, 8 or 16 µM DNJ and 
the activity was measured as described for the standard activity assay.
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Biochemical characterization of rhGAA 
Acid α-glucosidase (GAA) is a lysosomal glycoside hydrolase belonging to 
CAZy family GH31 that catalyzes the hydrolysis of both α-1,4 and α-1,6 
linkages in the natural substrate glycogen. The majority of the biochemical data 
on wild-type or mutant GAA derives from studies in cell-systems, such as 
cultured fibroblasts or transiently transfected COS7 and CHO cells (Flanagan et 
al., 2009; Kakavanos et al., 2006; Okumiya et al., 2007; Parenti et al., 2007; 
Porto et al., 2009). In the literature, biochemical data on the purified GAA are 
very limited (Marugan et al., 2010; Yoshimizu et al., 2008); thus, in an attempt 
to fill this gap we performed a general characterization of the recombinant form 
of human GAA (rhGAA). The enzyme used in our experiments is the 
pharmaceutical preparation for ERT known as Myozyme; it was a gift from Dr. 
Parenti and was obtained from residual solution after clinical infusions.  
To determine the pH optimum of the rhGAA activity, we have evaluated the 
enzymatic hydrolysis of 4NP-α-Glc in the range of pH 3.0−7.0. As expected for 
a lysosomal enzyme, the maximal activity (3.8 U/mg) was obtained at pH 4.0, 
then, all the subsequent assays were performed at these conditions. 
The steady state kinetic constants! on 4NP-α-Glc were determined at standard 
conditions as described in Experimental procedures (section 3.7), and were: 
KM=6.3±0.9 mM; kcat= 7.9±0.3 s-1; kcat/KM= 1.26 s-1mM-1. 
Figure 3.8.1: pH profile of rhGAA activity on 4NP-α-Glc 
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Identification of the parameters to test the chaperoning action of new 
ligands 
Pharmacological chaperones (PCs) are generally small molecules which have 
demonstrated to be promising for the treatment of diseases due to protein 
misfolding (Sampson et al., 2011; Valenzano et al., 2011). The efficacy of PCs 
is commonly monitored by evaluating the resistance of wild-type enzymes to 
physical stresses, such as modifications of temperature and pH (Tropak et al., 
2007). Resistance to pH variations is of utmost interest, especially for the 
recombinant enzymes administered in ERT, as neutral pH may be 
representative of some of the environmental conditions encountered by these 
enzymes in plasma and in certain cellular compartments. To evaluate how 
rhGAA activity is affected by pH changes, the enzyme (0.75 mg ml-1) was 
incubated in 50 mM citrate phosphate buffer in the range of pH 3.0–7.0 and 
the residual activity on 4NP-α-Glc was calculated in standard conditions. As 
expected for an acidophilic lysosomal enzyme, at pH 5.0, rhGAA was highly 
stable for up to 24 hours. At non-physiological pH representative of non-
lysosomal cellular compartments, either extremely acidic (3.0) or neutral 
(7.0),!the enzyme was unstable and rapidly lost its activity (Fig. 3.8.2). 
The thermal stability of the rhGAA structure at pH 5.2 and 7.4 was acquired 
by differential scanning fluorimetry (DSF) and confirmed to be greater at 
acidic pH compared to neutral pH. In fact the melting temperature (Tm) 
measured for the enzyme exposed at pH 5.2 is 65.6±0.2°C while at pH 7.4 is 
50.2 ±0.1°C (Fig. 3.8.3). 
Figure 3.8.2: rhGAA stability in the range of pH 3.0-7.0 
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In addition, the thermal stability of rhGAA activity was monitored by incubating 
the enzyme (0.75 mg ml-1) in 50 mM citrate phosphate buffer pH 5.0 in the 
range of temperature 60-65°C and, at interval times, the residual activity was 
measured in standard conditions (Fig. 3.8.4). rhGAA is stable for 40 min at 
60°C (residual activity≈100%), but its activity is drastically reduced after 20 min 
at 62.5°C (residual activity≈53%), and 10 min at 65°C (residual activity≈46%). 
We concluded that both temperature and pH can be used as parameters to test 
the efficacy of new PCs. In particular, we can estimate the chaperoning action 
of new compounds by evaluating their influence on the stability of enzyme 
exposed at different temperatures and pHs. 
Figure 3.8.3: Temperature profile of rhGAA at pH 5.2 and 7.4 
Figure 3.8.4: Thermal stability of rhGAA at pH 5.0 
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DNJ: inhibitory and chaperoning action 
1-Deoxynojirimycin (DNJ) is a compound belonging to the class of imino sugars 
that act as competitive inhibitors of rhGAA (Yoshimizu et al. 2008) and have 
showed a potential as PCs for PD (Parenti et al. 2007) . We evaluated the 
kinetics of DNJ inhibition by assaying rhGAA in the presence of 2, 8 or 16 µM 
inhibitor. The initial rate of rhGAA inhibition at various DNJ concentrations was 
fit to the Lineweaver-Burk (LB) equation (Fig. 3.8.5). As expected, the LB plot 
showed that the Vmax is unaffected by the presence of DNJ while the effective 
KM on 4NP-α-Glc is increased, confirming a competitive inhibition. The slopes of 
the LB graphs were then plotted as function of the DNJ concentration with the 
linear regression analysis (secondary plot). The x-intercept represents the Ki 
value (Fig. 3.8.5) of 3.4 µM, which is 7-fold higher than that reported on MU-α-
Glc (Yoshimizu et al., 2008), probably due to the different affinity of enzyme for 
the two synthetic substrates or to the diverse sensitivity of the assay procedures 
adopted. 
It has been reported that DNJ is able to rescue the activity of some GAA 
mutants, as observed in fibroblasts deriving from PD patients or in COS7 cells 
Figure 3.8.5: Kinetics of rhGAA inhibition by DNJ 
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transfected with GAA mutants (Flanagan et al., 2009; Parenti et al., 2007). 
Moreover, DNJ can function in synergy with ERT enhancing the stability of the 
wild-type rhGAA (Flanagan et al., 2009). In fact, DSF analysis indicated that 
100 µM DNJ increased the thermal stability of rhGAA at pH 7.4 to a similar level 
to that observed at pH 5.2 in the absence of DNJ (Flanagan et al., 2009). 
On the basis of these observations, we have analysed the effect of DNJ on the 
activity of rhGAA subjected to various chemical-physical stresses. In particular, 
we have evaluated the residual activity of rhGAA incubated at pH 5.0 and 7.0 or 
at 65°C in absence or presence of various concentrations of DNJ (in the range 
3×10-3 - 32 µM). As depicted in the Fig. 3.8.6A (left panel), the enzyme 
maintained its activity for at least 4 hours at pH 5.0 both in absence and in 
presence of DNJ. In the presence of 32 µM DNJ the residual activity of rhGAA 
increased by about 3-fold, but at this concentration, which is 10-fold the 
measured Ki, DNJ severely inhibited the enzyme (Fig. 3.8.6A, right panel). The 
stabilizing effect of DNJ on rhGAA is clearly observable at pH 7.0 (Fig. 3.8.6B; 
left panel). At these conditions, the enzymatic activity of the control was 
reduced after 4 hours of about 50%, but 32 µM DNJ clearly stabilizes the 
enzyme (Fig. 3.8.6B; left panel). But, also in this case, remarkable inhibition of 
DNJ is observed (Fig. 3.8.6B; right panel). 
The protective effect of DNJ can be observed also on rhGAA incubated at 65°C. 
At these conditions, 0.03 µM of the inhibitor had no protective effect while 32 
µM DNJ clearly stabilize the enzyme (Fig. 3.8.6C; left panel), even if at the cost 
of a severe inhibition (Fig. 3.8.6C; right panel). These data confirmed the 
stabilizing effect of DNJ as observed in cultured fibroblasts and transfected 
COS7 cells (Flanagan et al., 2009; Parenti et al., 2007). On the other hand it is 
worth mentioning the inhibitory action exerted by this compound, which could 
contribute to reduce its chaperoning effect. Additionally, the informations 
achieved by our experiments support the use of rhGAA stability at various pHs 
and temperatures as the correct parameters to follow the chaperoning action of 
new compounds. 
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Identification of NAC as new potential PC 
PCs identified so far, such as DNJ and derivatives, act as inhibitors of the 
enzyme target (Valenzano et al., 2011) and are effective in rescuing only some 
disease-causing missense mutations. For PD, it is possible to speculate that 
~10-15% patients may be amenable to PCT (Flanagan et al., 2009). 
Accordingly, it emerges the need to identify a second generation of PCs with 
better enhancing effect and without inhibitory action. 
Figure 3.8.6: Stability of rhGAA at pH 5.0 (A), pH 7.0 (B) and at 65°C (C) in presence 
or absence of DNJ (range 3×10-3-32µM). Left panels report on the 
residual activity of rhGAA while right panels, depicting the specific 
activity of rhGAA at the various conditions, show the inhibitory effect of 
the different concentrations of DNJ 
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It has been reported that the clinical course of some LSDs is associated with a 
condition of cellular oxidative stress (Vázquez et al., 2011) and it has been 
suggested that chaperones might be beneficial for its treatment (Wei et al., 
2008). In this framework, our collaborators of Parenti’s group tested the effect of 
some antioxidant drugs (resveratrol, epigallo chatechingallate and N-
acetylcysteine) on PD fibroblasts (Porto et al., 2012). Among the compounds 
tested, only N-acetylcysteine (NAC), a known antioxidant currently used as a 
mucolytic drug, has proved to be effective (Porto et al., 2012). In particular, 
Parenti’s group has investigated the effect of NAC in cultured fibroblasts 
deriving from five PD patients that carry different mutations and with different 
phenotypes (Table 3.8.1). 
At the concentration of 10 mM, NAC enhanced the residual activity of mutated 
GAA in fibroblasts from patients 3 and 4 (Fig. 3.8.7).  
Table 3.8.1: Genotype and phenotype of PD fibroblasts used in this study 
pt No Phenotype Genotype 
1 Severe p.W367X / p.G643R 
2 Severe p.H612_D616del- insRGI / p.R375L 
!
3 Intermediate p.L552P / aberrant splicing 
4 Intermediate c.-32-13T>G - S619N / L552P 
5 Intermediate G549R / aberrant splicing 
!
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To determine which mutations are responsive to NAC, Parenti’s group 
expressed a panel of mutated GAA gene constructs in COS7 cells and 
evaluated the effect of NAC in rescuing the activity of these mutants. As 
illustrated in Fig. 3.8.8A, NAC rescued the GAA activity of mutants carrying the 
mutations L552P, A445P, and Y455F. Moreover, the responsive mutants also 
showed an improved processing into 76 and 70 kDa active isoforms as 
observed by western blot analysis (Fig. 3.8.8B). Since the GAA precursor is 
converted into the active forms in the late-endosomal/lysosomal compartment 
(Wisselaar et al., 1993), this also indicates that NAC improved the trafficking of 
the enzyme to the lysosomes. 
Figure 3.8.7: Effect of NAC on the activity of mutated GAA in PD fibroblasts 
Figure 3.8.8: NAC rescued the activity (A) and improved the maturation (B) of 
mutated GAA expressed in COS7 cells 
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To assess if the enhancing effect of NAC observed in cell system was due to a 
correction of oxidative stress or to a direct stabilizing action on GAA, we 
evaluated the chaperoning action of NAC in a cell-free system by testing the pH 
and temperature stability of rhGAA as parameters. In particular, we incubated 
for 5 hrs rhGAA at pH 7.0 in the presence of increasing concentrations of NAC 
(0.1-10mM). As illustrated in Fig. 3.8.9A, NAC enhanced rhGAA activity at pH 
7.0 in a dose-dependent manner and at the concentration of 10 mM about 90% 
of the activity is maintained even after 48 hours of incubation (Fig. 3.8.9B). 
The pH of solution containing 10 mM NAC was 7.0, the same value measured 
in absence of NAC; thus, the stabilization of rhGAA observed in presence of 
NAC was not due to changes of pH. 
NAC demonstrated also to be able to increase the thermal stability of rhGAA 
structure at pH 7.0. In fact, DSF analysis showed that the Tm of enzyme co-
incubated with 10 mM NAC is 10.5 ± 0.6°C higher than Tm of rhGAA alone (Fig. 
3.8.10). 
These data suggest that NAC could act as molecular chaperone. To support 
and validate this hypothesis, and to try to have hints on the stabilization 
mechanism at molecular level, we tested other compounds. 
Figure 3.8.9: NAC stabilized rhGAA in a dose-dependent manner (A) and the 
protective effect persisted even after 48 hours at the concentration of 10 
mM (B)  
3.8 Results and discussion !
!
 147 
Understanding the molecular determinants of NAC stabilizing effect!
To understand which are the structural features of NAC responsible for its 
stabilizing action on rhGAA, we tested other compounds. In particular, we 
evaluated the stabilizing effect of structurally similar acetylated amino acids, 
such as N-acetylserine (NAS) and N-acetylglycine (NAG), the non-acetylated 
counterparts, such as cysteine (Cys), serine (Ser) and glycine (Gly) and the 
structurally unrelated compound 2-mercaptoethanol (2ME). NAS and NAG 
behaved as NAC enhancing rhGAA stability at pH 7.0 in a dose-dependent 
manner and the stabilizing effect persisted even after 48 hours of incubation at 
the concentration of 10 mM (Fig. 3.8.11).  
Figure 3.8.10: DSF analysis showing that NAC increased the thermal stability of    
rhGAA!
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Moreover, DSF analysis showed that NAS and NAG improved the thermal 
stability of rhGAA structure like NAC (Fig. 3.8.12), increasing the Tm of the 
enzyme of 10.2± 0.2°C and 5.1± 0.2°C, respectively.!
By contrast, the non-acetylated homologs, Cys, Ser and Gly, and the unrelated 
compound 2ME did not prevent enzyme inactivation at pH 7.0 at all 
concentrations tested (0.1-10 mM) (Fig. 3.8.13). 
Figure 3.8.11: NAS and NAG stabilized rhGAA in a dose-dependent manner (graphs 
on the left) and the protective effect persisted even after 48 hours at 
the concentration of 10 mM (graphs on the right)  
Figure 3.8.12: NAS and NAG thermally stabilized rhGAA increasing its melting 
temperature by 10.2±0.2°C and 5.1±0.2°C, respectively  
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Figure 3.8.13: The non-acetylated amino acids Ser, Cys and Gly and 2ME had no 
effect on rhGAA stability at all conditions tested 
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Also the thermal profile of rhGAA at neutral pH resulted unaffected by the non-
acetylated amino acids (Fig. 3.8.14). 
These data allowed us to assert that NAC acts as molecular chaperone rather 
than as antioxidant. NAS and NAG showed a chaperoning action like NAC, 
even though they lack the sulfhydryl group that is substituted by an hydroxyl 
and a hydrogen atom in NAS and NAG, respectively (Fig. 3.8.15). Moreover, 
2ME and Cys, which carry a sulfhydryl group (Fig. 3.8.15), did not showed any 
protective effect on rhGAA. Thus, the stabilizing effect of NAC seems not due to 
the presence of sulfhydryl group and neither is associated to an antioxidant 
action. This last concept is also supported by the results achieved by Parenti’s 
group in cell-system, where the other antioxidants studied did not produced any 
chaperoning effect. Instead, the chaperoning action of NAC seems correlated to 
the acetyl moiety which is a common feature of NAC, NAS, and NAG, while it is 
missing in Cys, Ser, and Gly. The identification of chaperoning activity in these 
molecules was somewhat surprising because they are structurally very different 
from imino sugars, the only PCs of GAA known so far, which resemble the 
natural substrates/products of the enzyme. 
None Cys Ser Gly 
Tm [°C] 48.6 ± 0.1 50.6 ± 0.4 48.8 ±  0.1 48.7 ±  0.1 
ΔTm [°C] +2 ± 0.5 +0.2 ± 0.2 +0.1 ± 0.2 
Figure 3.8.14: DSF analysis of rhGAA thermal profile in presence of 10 mM Cys, Ser 
or Gly 
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To assess if the new molecular chaperones identified here act as rhGAA 
inhibitors, we have evaluated the basal activity of enzyme in presence of 
increasing concentrations of NAC, NAS and NAG (0.1-10 mM). It is worth 
noting that none of these ligands inhibited rhGAA by concentrations up to 10 
mM. In contrast to DNJ whose stabilizing effect produced also a severe 
inhibition of the α-glucosidase activity, the new PCs stabilized rhGAA and never 
interfered with its basal activity at all the conditions tested (Fig. 3.8.16). These 
data suggest that NAC and the related compounds, NAS and NAG, are the first 
molecular chaperones that did not interact with the active site of rhGAA. 
 
Figure 3.8.15: Structures of the compounds analyzed. Green box encloses 
compounds active as molecular chaperones while the red box 
delimits the inactive molecules 
Figure 3.8.16: Analysis of rhGAA basal activity in presence of NAC, NAG and NAS 
(0.1-10 mM) and DNJ (1-100 µM) 
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NAC/NAS/NAG and DNJ: comparison and combination 
The data acquired in the previous paragraph led us to suppose that the new 
molecular chaperones and the imino sugars could bind to different domains of 
rhGAA. To test this hypothesis we evaluated how the combination of NAC and 
DNJ affects the thermal stability of rhGAA. These compounds individually 
increased the Tm of rhGAA at neutral pH, with DNJ alone apparently causing 
the best shift in Tm (Fig. 3.8.17A) but at the cost of an almost complete 
inhibition (Fig. 3.8.17B).!Interestingly, the combination of NAC and DNJ resulted 
in the highest stabilization of the enzyme (Tm=75.9±0.3°C) (Fig. 3.8.17A). The 
stabilizing effect of the two PCs was additive indicating that NAC and DNJ 
interact with a non-catalytic and the catalytic domain of rhGAA, respectively.  
Figure 3.8.17: Effect of the combination of NAC and DNJ on the thermal stability of 
rhGAA (A). Basal activity of rhGAA in presence of 10 mM NAC or 32 
µM DNJ (B) 
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The cumulative effect was also observed with the combination of NAS or NAG 
and DNJ (Fig. 3.8.18). 
!
Figure 3.8.18: Effect of the combination of NAS or NAG and DNJ on the thermal 
stability of rhGAA 
Moreover, the combination of NAC with the imino sugars gave similar results 
also in fibroblasts from two PD patients, as observed by Parenti’s group. These 
cell lines were incubated with rhGAA, with rhGAA plus either NAC or NB-DNJ, 
and with rhGAA plus the combination of the two chaperones. In both cell lines 
the combination of NAC and NB-DNJ resulted in the highest enhancement of 
GAA activity by rhGAA (Fig. 3.8.19).  
These data support the hypothesis that NAC, NAS, and NAG interact with a 
protein domain different to that bound by the imino sugars. Accordingly, the 
combination of the two molecular chaperones might represent an additional 
advantage for the treatment of PD patients, in order to obtain the best 
stabilization of rhGAA and the highest synergy with ERT.  
Figure 3.8.19: Combination of NAC and DNJ in PD fibroblasts 
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Synergy between NAC and Myozyme in cell system and in vivo 
The experiments in cell-free system have demonstrated that NAC and the 
related compounds NAS and NAG enhanced the activity/stability of rhGAA. The 
synergy between these molecular chaperones and ERT has been validated 
also in cell-system and in vivo by Parenti’s group.  
The synergistic effect between rhGAA and NAC was evaluated in fibroblasts 
from five PD patients. When these cell lines were co-incubated with 50 µM 
rhGAA and 10 mM NAC, the correction of GAA deficiency improved with 
increments in GAA activity ranging from ~3.7 to 8.7-fold, if compared to the 
activity of cells treated with rhGAA alone (Fig. 3.8.20A). As already observed in 
cell free-system (Fig. 3.8.8), also in PD fibroblasts NAC showed a dose-
dependent enhancing effect with the maximal increase of 3.3-fold at the 
concentration of 10 mM (Fig. 3.8.20B). The enhancing effect of GAA activity 
largely exceeded that due to the rescue of the native mutated enzyme (patients 
3 and 4) and was observed also in cell lines non-responsive to NAC alone 
(patients 1, 2, and 5). These data suggest that NAC acts as chaperone of the 
wild-type recombinant enzyme also in cell-system. Further indications 
supporting this hypothesis derive from immunofluorescence analysis and 
confocal microscopy performed by Parenti’s group. This approach allows to 
detect only the fluorochrome-labeled exogenous enzyme. In the presence of 
NAC the amounts of fluorochrome-labeled GAA increased compared to cells 
incubated with fluorescent GAA alone (Figure 3.8.20C). Moreover, western blot 
analysis (Fig. 3.8.20D), showed increased amounts of GAA active isoforms in 
the cells treated with NAC and rhGAA, compared to cells treated with the 
recombinant enzyme alone. Since the GAA precursor is converted into the 
active forms in the late-endosomal/lysosomal compartment (Wisselaar et al., 
1993) this indicates improved lysosomal trafficking of the enzyme.  
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Parenti’s group also evaluated the combination of NAC and rhGAA in a mouse 
model of PD (N Raben et al., 1998). Mice were treated with a single injection of 
rhGAA at high doses (100mg/kg) in combination with oral NAC for 5 days (Fig. 
3.8.21A). Forty-eight hours after rhGAA injection the animals were euthanized 
and GAA activity was assayed in different tissues. In all tissues examined (liver, 
heart, diaphragm and gastrocnemium) the combination of NAC and rhGAA 
resulted in higher levels of GAA compared to rhGAA alone (Fig. 3.8.21B). 
Figure 3.8.20: Synergy between NAC and rhGAA in PD fibroblasts. Improved GAA 
deficiency in cell lines co-incubated with rhGAA and NAC (A). NAC 
enhanced rhGAA efficacy in fibroblast of patient 3 in a dose-dependent 
manner (B). Increased amounts of fluorochrome-labelled GAA in the 
presence of NAC (C). Western blot analysis showing an improved 
processing of GAA precursor in cells treated with rhGAA and NAC 
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Modelling the interaction of NAC with the rhGAA 
The following computational biology studies, including molecular dynamics 
simulations and docking experiments, were performed by the group of Dr. 
Giorgio Colombo of Istituto di Chimica del Riconoscimento Molecolare, 
Consiglio Nazionale delle Ricerche (ICRM-CNR). The 3D structure of rhGAA is 
not yet available, so an homology model of GAA was constructed by using the 
structure of the human maltase-glucoamylase (pdb code 3L4Z) as a template 
(Sim et al., 2010) (for more details see Porto et al. 2012). Molecular dynamics 
(MD) simulations in conditions mimicking pH 5.0 and 7.0 showed that the 
rhGAA structure was more stable at acidic than at neutral pH.  
Combining MD simulations with molecular docking experiments, Dr Colombo's 
group identified the regions of the protein surface that may be most frequently 
in contact with NAC (Fig. 3.8.22).! During the simulation it was observed that 
NAC bound on specific regions of the protein. A control simulation carried out 
with non-acetylated Gly in the same conditions showed that this amino acid, 
which has no chaperoning effect, had a much lower tendency to bind in the 
vicinity of the surface. Interestingly, one of the identified areas of favourable 
contact between NAC and GAA partially overlapped the region defined by 
residues Arg525, Gly793, Glu794, Ser795, Leu796, Glu797, and Gly802 that 
Figure 3.8.21: Synergy between NAC and rhGAA in vivo. Mice were treated with oral 
NAC for 5 days and received an rhGAA injection on day 3 (A). 
Improved correction of GAA deficiency in tissues of animals treated 
with NAC and rhGAA (black bars) compared to the controls treated 
only with rhGAA (grey bars) (B) 
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defines a stable pocket, which is at 35 Å distance from the active site (Fig. 
3.8.22).! This region is conserved among characterized GH31 α-glucosidases 
from humans and other mammals (Fig. 3.8.23), and is located at the boundary 
between two domains (one of which contains the active site). 
Remarkably, the binding energies for NAC at this site were comparable to the 
binding energies calculated for the docking of maltose or DNJ to the GAA active 
site and similar results were obtained also with NAS and NAG (Tab. 3.8.2).  
Figure 3.8.23:! Multiple sequence alignment of GH31 α-glucosidases.! Red boxes 
indicate residues of GAA that are predicted in-silico to interact with 
NAC (R525; G793; E794; S795; L796; E797; G802) 
Figure 3.8.22:! Identification of the areas of favorable NAC contact. The green surface 
indicated the pocket defined by residues Arg525, Gly793, Glu794, 
Ser795, Leu796, Glu797, and Gly802.The cyan surfaces indicate 
alternative NAC contact sites; it is possible to appreciate that they are 
all superficial and do not define cavities suitable for small-molecule 
binding. The active site is indicated by yellow van der Waals 
representations of the atoms 
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Moreover, in the model of the best-ranked pose, the -SH group is directed 
toward the surface of the protein whereas the acetyl group interacts with the 
allosteric GAA pocket described above (Fig. 3.8.24) providing further indication 
that the SH group was not crucial for the binding of the molecule to the enzyme.!
A control docking run was carried out with DNJ. Importantly, the minimum free 
energy and most populated docking solution shows DNJ binding preferentially 
in the active site of GAA, with a lower energy than that measured for the 
pharmacological chaperone in the allosteric pocket, showing the high affinity of 
this ligand for the active site and supporting the validity of model used in this 
study.  
Finally, the GAA-NAC complex refined by MD simulations showed that the 
presence of NAC at pH 7.0 confers to GAA a local flexibility profile similar to the 
one of unbound GAA at pH 5.0. Additionally, this effect is not limited to the 
Figure 3.8.24: Detail of the GAA model with NAC bound to the hot spot: the sulfur 
atom is highlighted in yellow and the binding site is in red filled spaces 
 
Molecule Score Site
NAC -4,3342 Allosteric
NAG -4,0682 Allosteric
NAS -4,4576 Allosteric
MAL -4,9417 Active Site
DNJ -6,6378 Active Site
Table 3.8.2: Grid Docking scores (arbitrary units) of acetylated compounds to the 
allosteric site, and of maltose and DNJ to the active site 
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immediate vicinity of the NAC-binding site, but extends to distal regions of the 
protein. As a control, the same procedure was carried out using Gly as a 
possible ligand, but Gly appears to non-specifically sample many regions of the 
protein surface with very low affinity. These observations give support to the 
molecular mechanism of the chaperoning activity of NAC.  
Overall the computational data validated the results of in vitro experiments 
concerning both the stabilization through an allosteric pocket rather than active 
site and the involvement of acetyl group rather than -SH in the binding to the 
target enzyme. 
Concluding remarks 
We have identified the first molecular chaperones, NAC, NAS and NAG, direct 
to an allosteric site rather than to active site of GAA. These compounds have 
proved to enhance the stability/activity of rhGAA at neutral pH in cell-free 
system, to rescue the activity of some GAA mutants and to improve the efficacy 
of ERT in cell system and in vivo. The synergy between PCT and ERT has 
important clinical implications. First, it has to consider that in most cases the 
use of PCT alone, enhancing the endogenous defective enzymes, resulted in 
minor rescue of enzymatic activity (likely with a modest impact on patients’ 
outcome). By contrast, when the PCs are used in synergy with ERT, the 
correction of the defective activity is remarkably improved. An additional 
advantage of the combination of PCT and ERT is that the effect of chaperones 
is directed towards the wild-type recombinant enzyme and does not depend on 
the type of mutation carried by patients. This allows to expand the spectrum of 
treatable patients, including those carrying mutations not or poorly responsive 
to PCT alone. 
The data obtained in PD mice appear promising, although treatment protocols 
with NAC need to be carefully optimized in studies on a larger number of 
animals. The concentrations of NAC used in our studies may appear relatively 
high and difficult to translate into human therapy. However, toxicity of NAC is 
reported to be low and plasma concentrations in the range of 2-3 mM are 
usually reached for the treatment of paracetamol overdose (Walsh et al., 1998). 
Moreover, long-term treatment with NAC doses of 5g/kg/day (higher than doses 
used in the in vivo experiments in our study) has been used in the mouse model 
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of ethylmalonic encephalopathy and resulted in improved survival of treated 
animals (Viscomi et al., 2010). It worth mentioning that, for a possible clinical 
translation of our data, a therapeutic protocol would be based on the 
administration of the chaperone at the time of ERT infusion, and not on a long-
term daily administration of the chaperone. By using such an approach the risk 
of adverse events would likely be reduced. It is also possible that modifications 
to NAC might be required to have the stabilizing effect at lower concentrations.!
The identification of NAC and derivatives, which are structurally very different 
from the other known PCs identified in PD is promising. In fact, other molecules, 
whose chaperoning activity cannot be simply inferred from their structure, may 
be effective in several LSDs, thereby opening new and wider opportunities for 
the identification of novel therapeutic drugs.  
Future perspectives 
NAC, NAS and NAG are the first example of molecular chaperones able to 
stabilize GAA without interfering with its catalytic activity. The finding that 
molecules structurally different from the natural substrate can act as molecular 
chaperones delineates new scenarios in the research of PCs.  
Nonetheless, there are still some aspects to be elucidated: 
! determination of the site bound by NAC, NAS and NAG 
! characterization of the molecular mechanism through which the new PCs 
exert their chaperoning action 
! identification of new PCs effective on a larger number of GAA mutants 
and with a better affinity for enzyme. These last issues could be 
addressed by using NAC, NAS and NAG as lead molecules and 
improving their chaperoning action, for instance through their structural 
variations.
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Molecular Therapy 1
Pompe disease (PD) is a metabolic myopathy due to 
the deficiency of the lysosomal enzyme ?-glucosidase 
(GAA). The only approved treatment for this disorder, 
enzyme replacement with recombinant human GAA 
(rhGAA), has shown limited therapeutic efficacy in some 
PD patients. Pharmacological chaperone therapy (PCT), 
either alone or in combination with enzyme replacement, 
has been proposed as an alternative therapeutic strategy. 
 However, the chaperones identified so far also are active 
site-directed molecules and potential inhibitors of target 
enzymes. We demonstrated that N-acetylcysteine (NAC) 
is a novel allosteric chaperone for GAA. NAC improved 
the stability of rhGAA as a function of pH and tempera-
ture without disrupting its catalytic activity. A computa-
tional analysis of NAC–GAA interactions confirmed that 
NAC does not interact with GAA catalytic domain. NAC 
enhanced the residual activity of mutated GAA in cul-
tured PD fibroblasts and in COS7 cells overexpressing 
mutated GAA. NAC also enhanced rhGAA efficacy in PD 
fibroblasts. In cells incubated with NAC and rhGAA, GAA 
activities were 3.7–8.7-fold higher than those obtained 
in cells treated with rhGAA alone. In a PD mouse model 
the combination of NAC and rhGAA resulted in better 
correction of enzyme activity in liver, heart, diaphragm 
and gastrocnemia, compared to rhGAA alone.
Received 12 May 2012; accepted 3 July 2012; advance online 
publication 18 September 2012. doi:10.1038/mt.2012.152
INTRODUCTION
Pompe disease (PD, OMIM 232300) is an inborn metabolic dis-
order caused by the functional deciency of ?-glucosidase (GAA, 
acid maltase, E.C.3.2.1.20), an acid glycoside hydrolase involved 
in the lysosomal breakdown of glycogen. GAA deciency results 
in glycogen accumulation in lysosomes and in secondary cellular 
damage, through mechanisms not fully understood.1,2 Although 
GAA deciency in PD is generalized, muscles are particularly vul-
nerable to glycogen storage. e disease manifestations are thus 
predominantly related to the involvement of cardiac and skeletal 
muscles. e phenotypic spectrum of the disease is wide and varies 
from a devastating classical infantile-onset form, to attenuated late-
onset phenotypes. e manifestations related to progressive muscle 
hypotonia, which cause severe motor impairment and eventually 
respiratory failure, impact severely on the health of PD patients.1,3
Like for several other lysosomal storage diseases, an enzyme 
replacement therapy (ERT) with recombinant human ?-glucosidase 
(rhGAA) has become available for PD in the early 2000s. ERT was 
shown to improve patients’ survival and function and to stabilize 
the disease course.4–8 However, despite treatment, some patients 
experience limited clinical benet or show signs of disease progres-
sion and it is clear that reaching therapeutic concentrations of the 
recombinant enzyme in skeletal muscle is particularly challenging.9
Several factors concur in limiting therapeutic success of ERT, 
including the age at start of treatment,10,11 the immunological and 
cross-reactive material status of patients,12 the preferential uptake of 
rhGAA by liver and the insucient targeting of the enzyme to mus-
cles,13 the relative deciency of the mannose-6-phosphate receptor 
in muscle cells,14 and the “build up” of the autophagic compartment 
observed in myocytes.15,16 In addition, studies in other lysosomal 
storage diseases treatable by ERT, such as Gaucher disease (due to 
the deciency of ?-glucocerebrosidase) and Fabry disease (due to 
?-galactosidase A deciency), point to the role of factors intrinsi-
cally related to the recombinant enzymes used for ERT, and sug-
gest that these enzymes may be relatively unstable when exposed to 
stresses, like non-acidic pH, during their transit to lysosomes.17,18
In the recent years, pharmacological chaperone therapy (PCT) 
has been proposed as a strategy to increase physical stability of 
recombinant enzymes and to enhance the therapeutic action of 
ERT. is approach, based on using small-molecule ligands that 
increase stability of mutated proteins and prevent their degrada-
tion, was rst designed for the treatment of diseases due to protein 
misfolding.19 Recent studies, however, have shown that chap-
erones are not only able to rescue misfolded defective proteins, 
but may also potentiate the eects of the wild-type recombinant 
enzymes used for ERT.20 We and others have provided preclini-
cal evidence supporting this concept in two relatively prevalent 
lysosomal disorders, PD,21 and Fabry disease.18,22 In both disor-
ders, when recombinant enzymes were administered to mutant 
Correspondence: Giancarlo Parenti, Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131, Naples, Italy.  
E-mail: (parenti@tigem.it) or (parenti@unina.it)
Pharmacological Enhancement of ?-Glucosidase  
by the Allosteric Chaperone N-acetylcysteine
Caterina Porto1,2, Maria C Ferrara3, Massimiliano Meli4, Emma Acampora2, Valeria Avolio2, 
Margherita Rosa2, Beatrice Cobucci-Ponzano3, Giorgio Colombo4, Marco Moracci3, Generoso Andria2 
and Giancarlo Parenti1,2
1Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; 2Department of Pediatrics, Federico II University, Naples, Italy; 3Institute of Protein 
Biochemistry (IBP), Consiglio Nazionale delle Ricerche (CNR), Naples, Italy; 4Istituto Chimica del Riconoscimento Molecolare, Consiglio Nazionale delle 
Ricerche (CNR), Milan, Italy
!!
2 www.moleculartherapy.org 
© The American Society of Gene & Cell Therapy?-Glucosidase Enhancement by N-acetylcysteine
broblasts in combination with the chaperone molecules N-butyl-
deoxynojirimycin (NB-DNJ) and 1-deoxy-galactonojiirimycin, 
respectively, the lysosomal tracking, the maturation and the 
intracellular activity of the enzymes improved. A similar eect was 
also obtained in cultured macrophages treated with the recombi-
nant ?-glucocerebrosidase (the enzyme used for ERT in Gaucher 
disease), in the presence of the chaperone isofagomine.23
Although small-molecule chaperones have several advan-
tages, compared to ERT, in terms of biodistribution, oral avail-
ability, reduced impact on patients’ quality of life, a major reason 
of concern for the clinical use of these drugs is that the chaperones 
so far identied for the treatment of lysosomal storage diseases 
are active site-directed molecules and are reversible competitive 
inhibitors of the target enzymes.24 erefore, the identication 
of second-generation chaperones that protect the enzymes from 
degradation without interfering with its activity may be advan-
tageous. Extensive search for new chaperones is currently being 
done by high-throughput screenings with chemical libraries.25,26
Here we report on the identication of N-acetylcysteine (NAC), 
a known pharmaceutical drug, as a novel allosteric chaperone for 
GAA. e strategy used for the identication and characterization of 
NAC’s eects was based on the combination of biochemical studies, 
both in cell-free and in cellular systems, and a computational analy-
sis of NAC–GAA interactions. We found that this drug stabilizes 
wild-type GAA at nonacidic pH, enhances the residual activity of 
mutated GAA and improves the ecacy of rhGAA used for ERT in 
this disease. is novel chaperone does not interact with the catalytic 
domain of GAA, and consequently is not a competitive inhibitor of 
the enzyme.
RESULTS
NAC improves rhGAA stability in vitro
Resistance of wild-type enzymes to physical stresses, such as 
modications of temperature and pH, is commonly taken as 
an indicator to monitor the ecacy of pharmacological chap-
erones.24 rhGAA 6.8 µmol/l was stable at pH 5.0 for up to 24 
hours while rapidly lost its activity at nonphysiological pH (3.0 
and 7.0), representative of nonlysosomal cellular compartments 
(Figure 1a). Coincubation with 10 mmol/l NAC (compound 1 in 
Supplementary Figure S1) rescued rhGAA activity at pH 7.0 in a 
dose-dependent manner (Figure 1b), and persisted even aer 48 
hours of incubation (Figure 1c). e same concentration of NAC 
also thermally stabilized 0.95 µmol/l rhGAA increasing by 10.5 ? 
0.5 °C its melting temperature (Tm) (Figure 1d).
e related amino acids N-acetylserine and N-acetylglycine 
(NAS and NAG, compounds 2 and 3 in Supplementary Figure 
S1) also behaved as NAC by inducing remarkable stabiliza-
tion of rhGAA at pH 7.0 (Supplementary Figure S2a–b), while 
the nonacetylated homologs cysteine, serine, and glycine and 
2-mercaptoethanol (4–7 in Supplementary Figure S1) did not 
prevent enzyme inactivation (Supplementary Figure S2c–f), sug-
gesting that the stabilizing eect was due to the presence of the 
acetyl rather than to the suldryl group.
Modeling the interaction of NAC with the rhGAA 
protein
To rationalize the interaction of NAC with the enzyme, a homol-
ogy model of rhGAA was built based on its amino acid sequence 
and the 3D-structure of the highly homologous human enzyme 
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Figure 1 Characterization of recombinant human ?-glucosidase (rhGAA) in vitro and analysis of pharmacological chaperones stabilization. 
(a) rhGAA was stable at pH 5.0 for up to 24 hours while rapidly lost its activity at pH 3.0 and 7.0. (b) Coincubation with 10 mmol/l N-acetylcysteine 
(NAC) rescued rhGAA activity at pH 7.0 in a dose-dependent manner, and (c) persisted even after 48 hours of incubation. (d) NAC thermally stabi-
lized rhGAA increasing by 10.5 ± 0.5 °C its melting temperature.
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maltase-glucoamylase (pdb code 3L4Z) showing 44% identity 
over the aligned 868 residues of GAA. Molecular dynamics (MD) 
simulations in conditions mimicking pH 5.0 and 7.0 showed that 
the rhGAA structure was more stable at pH 5.0 than at neutral 
pH (Figure 2a) and the analysis of the protein’s pH-dependent 
geometric strain27 further conrmed that rhGAA was, in general, 
more rigid at pH 5.0 than at pH 7.0 (Supplementary Figure S3a). 
en, we searched for sites (hot spots) of the protein whose local 
exibility and structural organization changed upon passing from 
pH 5.0 to 7.0 (Supplementary Figure S3b). Projecting the results 
on the 3D structural model, the region dened by residues Arg525, 
Gly793, Glu794, Ser795, Leu796, Glu797, and Gly802 emerged 
as a possible target (Figure 2b). is region, which is conserved 
among characterized GH31 ?-glucosidases from humans and 
other mammals (Supplementary Figure S3c), is located at the 
boundary between two domains (one of which contains the active 
site) dening a stable pocket, which is at 35 Å distance from the 
active site (Supplementary Figure S3d). us, a putative ligand, 
stabilizing the interdomain interface, might confer to rhGAA 
at neutral pH the same properties showed by the apoenzyme at 
acidic pH.
NAC-binding mechanism and binding site
To identify the regions of the protein surface that may be most fre-
quently in contact with NAC, we combined MD simulations with 
molecular docking experiments. In a rst, “coarse-grained” explo-
ration of binding spots on the protein surface, multiple copies of 
NAC were simulated in the presence of GAA. e resulting den-
sity maps report on the areas of GAA where NAC clusters most 
favorably. NAC was observed multiple times during the simula-
tion to bind with favorable interactions on specic regions of the 
protein. A control simulation was carried out with nonacetylated 
Gly in the same conditions and the results showed that this amino 
acid, which has no chaperoning eect, had a much lower tendency 
to bind in the vicinity of the surface. e list of residues dening 
the surface on which NAC makes favorable contacts is reported in 
Supplementary Table S1. Interestingly, one of the identied areas 
of favorable contact between NAC and GAA partially overlapped 
with the hotspot region located at the boundary between the cata-
lytic domains and the anking one identied through geometric 
strain analysis (Figure 2b). e list of identied possible binding 
regions was further ltered by the application of the “Site Map” 
function of the Maestro suite of programs, which aims to iden-
tify possible sites on a protein that fulll structural and functional 
requirements optimal for binding a small, drug-like molecule thus 
being identied as druggable sites. e application of this further 
lter on rhGAA surface returned the pH responsive hot spot 
region identied earlier as the only one showing the stereochemi-
cal properties needed by a putative receptor site to bind a small-
molecule (Figure 2b).
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Figure 2 Modeling the structural determinants of ?-glucosidase (GAA) stability and mapping the N-acetylcysteine (NAC)-binding sites. 
(a) Comparison of the molecular dynamics (MD) simulations of the GAA model at pH 5.0 (red) and 7.0 (black). (b) Identification of the NAC cluster-
ing regions: the surfaces indicate the areas of favorable NAC contact calculated from the simulations of GAA in the presence of 10 copies of NAC. 
The green surface indicated the surface identified as a possible allosteric-binding site as explained in the results (combined analysis of NAC-binding 
regions, changes in the dynamics of the residues in response to pH, SiteMap screening to define the suitability of the pocket to host a small molecule). 
The cyan surfaces indicate alternative NAC contact sites. It is possible to appreciate that they are all superficial and do not define cavities suitable 
for small-molecule binding. The active site is indicated by yellow van der Waals representations of the atoms. (c) Detail of the GAA model with NAC 
bound to the hot spot: the sulfur atom is highlighted in yellow and the binding site is in red filled spaces. (d) The residue-based profile of average 
strain calculated over the simulation time for the three GAA conditions; from top to bottom: isolated protein at pH 5.0, 7.0, and 7.0 plus NAC.
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A rened docking analysis using the Grid program from the 
Maestro suite was next carried (see Materials and Methods section) to 
investigate the pose and the energy of NAC in the putative allosteric 
site. Interestingly, the binding energies for NAC at this site were com-
parable to the binding energies calculated for the docking of maltose 
or DNJ to the active site of GAA and similar results were obtained 
also with NAS and NAG (Supplementary Table S2). Moreover, in 
the model of the best-ranked pose, the -SH group is directed toward 
the surface of the protein whereas the acetyl group interacts with the 
allosteric GAA pocket described above (Figure 2c), providing further 
indication that the SH group was not crucial for the binding of the 
molecule to the enzyme. A control docking run was carried out with 
DNJ. DNJ was le free to move on the whole surface of GAA, with-
out imposing restraints. Importantly, the minimum free energy and 
most populated docking solution shows DNJ binding preferentially 
in the active site of GAA, with a lower energy than that measured 
for the pharmacological chaperone in the allosteric pocket, showing 
the high anity of this ligand for the active site and supporting the 
validity of our model (see Supplementary Table S2).
Finally, the GAA–NAC complex was rened by MD simula-
tions as described above for the apoenzyme at the two dierent 
pHs. Interestingly, the presence of NAC at pH 7.0 confers to GAA a 
local exibility prole similar to the one of unbound GAA at pH 5.0, 
thereby suggesting that NAC may actually act as a pharmacologi-
cal chaperone of the enzyme (Figure 2d). is eect is not limited 
to the immediate vicinity of the NAC-binding site, but extends to 
distal regions of the protein. As a control, the same procedure was 
carried out using Gly as a possible ligand, but the resulting maps 
did not show any specic feature and Gly appears to nonspecically 
sample many regions of the protein surface with very low anity.
NAC and related compounds, binding reversibly to allosteric 
sites remote from the catalytic site, may act by blocking confor-
mational uctuations leading to a destabilized state of GAA, thus 
rescuing its functional state. is suggests that these molecules 
would be the rst pharmacological chaperones that do not work 
as competitive inhibitors of the enzyme, expanding the molecu-
lar diversity of GAA pharmacological chaperones beyond imino 
sugar molecules. e modeling data were further supported by in 
vitro experiments showing that dierent concentrations of NAC 
and derivatives (up to 10 mmol/l) did not aect rhGAA activity 
(Figure 3a). Instead DNJ acted as a competitive inhibitor with a 
Ki of 3.4 µmol/l (Figure 3b).
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NAC rescues mutated GAA in PD fibroblasts  
and transfected COS7 cells
We investigated the eect of NAC in cultured broblasts from 
ve PD patients that carry dierent mutations and with dierent 
phenotypes (Table 1). e concentration of 10 mmol/l used for 
this purpose was in the same range as that used in studies on the 
antioxidant eect of NAC.28,29
NAC enhanced the residual activity of mutated GAA in bro-
blasts from patients 3 and 4 (Figure 4a). Both patients carried on 
one allele the mutation p.L552P, previously reported to be respon-
sive to NB-DNJ and DNJ.30,31
e response of individual mutations to NAC was further 
evaluated by expressing a panel of mutated GAA gene constructs in 
COS7 cells (Figure 4b). e mutated constructs were chosen to be 
representative of both imino sugar-responsive and non-responsive 
mutations, in order to compare the chaperoning prole of NAC 
with that of imino sugars. e mutations p.L552P, p.A445P, and 
p.Y455F showed signicant enhancement of GAA activity in the 
presence of 10 mmol/l NAC. e enhancement of enzyme activity 
for responsive mutations paralleled the increase in the amounts of 
the 76 and 70 kDa active isoforms of GAA on western blot analysis. 
Figure 4c shows a western blot analysis of COS7 cells overexpress-
ing two of the responsive (p.L552P, p.A445P) and one non-respon-
sive (p.G549R) mutation. For this latter mutation no change was 
seen in the amounts of the GAA active isoforms, already detectable 
in the absence of NAC, as previously reported.31 ese results sug-
gest that NAC has a dierent chaperoning prole compared to the 
active site-directed chaperones DNJ and NB-DNJ (Figure 4d).
NAC enhances rhGAA efficacy in PD fibroblasts  
and in the mouse model of PD
We tested whether NAC is able to synergistically enhance the e-
cacy of rhGAA. In broblasts from patient 3 coadministration of 
rhGAA and NAC (0.02–10 mmol/l) resulted in improved GAA 
activity with a dose-dependent eect (Figure 5a). Increases of 1.3-, 
1.7- and 2.0-fold were already observed at NAC concentrations 
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Figure 4 Effect of N-acetylcysteine (NAC) on the residual activity of mutated ?-glucosidase (GAA) in fibroblasts and COS7 cells. (a) Incubation 
of Pompe disease (PD) fibroblast with 10 mmol/l NAC resulted in enhanced residual GAA activity in 2 of the 5 cell lines (from patients 3 and 4). The 
response of mutated GAA to NAC was also evaluated by expressing mutated GAA gene constructs in COS7 cells. (b) The mutations p.L552P, p.A445P, 
and p.Y455F, showed increases of GAA activity in the presence of NAC, and increased amounts of 76 and 70 kDa active GAA isoforms by western blot 
(c). These results indicate that NAC (10 mmol/l) has a different chaperoning profile, in terms of enhancement of GAA activity, compared to the imino 
sugar chaperone N-butyl-deoxynojirimycin (NB-DNJ) (20–100 µmol/l).31
Table 1 PD fibroblast cell lines studied
pt No Phenotype Genotype Average GAA residual activitya Studies in which the same cell line was used
1 Severe p.W367X/p.G643R 0.20 Parenti et al.30; Cardone et al.32; Porto et al.21
2 Severe p.H612_D616del-insRGI/p.R375L 0.14 Not reported in previous studies
3 Intermediate p.L552P/aberrant splicing 0.69 Rossi et al. 2007; Cardone et al.32; Porto et al.21
4 Intermediate c.-32-13T>G - S619N/L552P 0.15 Not reported in previous studies
5 Intermediate G549R/aberrant splicing 0.16 Rossi et al. 2007; Cardone et al.32; Porto et al.21
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of 0.1, 1, and 5 mmol/l, respectively, with a maximal increase of 
3.3-fold at 10 mmol/l. We then incubated ve PD broblast cell 
lines with 50 ?mol/l rhGAA in the absence and in the presence 
of 10 mmol/l NAC. e ecacy of rhGAA in correcting the enzy-
matic deciency varied among the dierent cell lines, as already 
reported in previous papers,22,32 possibly due to individual factors 
implicated in the uptake and intracellular tracking of the recom-
binant enzyme in each cell line. However, in all cell lines tested, 
coincubation of rhGAA with NAC resulted in an improved cor-
rection of GAA deciency, with increases in GAA activity ranging 
from ~3.7–8.7-fold compared to the activity of cells treated with 
rhGAA alone (Figure 5b).
e enhancing eect largely exceeded that due to the rescue 
of the native mutated enzyme (patients 3 and 4) and was observed 
also in non-responsive cell lines (patients 1, 2, and 5). We also 
observed an increase in the amounts of uorochrome-labeled 
GAA in the presence of the chaperone NAC, compared to cells 
incubated with uorescent GAA alone (Figure 5c). Using this 
approach only the uorescent exogenous enzyme is detectable and 
variations in the intensity of uorescence only reect the eects 
on the recombinant enzyme. e combination of these results 
supports the concept that the enhancing eect of chaperones is 
directed towards the wild-type recombinant enzyme.
A western blot analysis (Figure 5d) and the quantitative analysis 
of each band (Figure 5e) showed increased amounts of GAA-related 
polypeptides in the cells treated with NAC and rhGAA, compared 
to cells treated with the recombinant enzyme alone. e processing 
of rhGAA into the active isoforms was also improved in the pres-
ence of NAC with a relative increase of the intermediate (95 kDa) 
and mature (76–70 kDa) GAA molecular forms, compared to the 
110 kDa precursor. Since the GAA precursor is converted into the 
active forms in the late-endosomal/lysosomal compartment,33 this 
indicates improved lysosomal tracking of the enzyme.
Other antioxidant drugs (resveratrol, epigallo chatechin-
gallate) did not enhance rhGAA in PD cultured broblasts 
(Supplementary Figure S4). ese results, together with the 
analysis of NAC–GAA interaction, with the data in cell-free sys-
tems, and with the lack of eect on another lysosomal glycosi-
dase, ?-galactosidase A that is defective in Fabry disease and 
belongs, like GAA, to the GH-D superfamily (Supplementary 
Figure S5), exclude that the eect of NAC is due to its antioxi-
dant properties.
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Figure 5 Synergy between N-acetylcysteine (NAC) and recombinant human ?-glucosidase (rhGAA) in Pompe disease (PD) fibroblasts. 
(a) The efficacy of rhGAA was enhanced by different concentrations (0.02–10 mmol/l) of NAC in patient 3, showing a dose-dependent effect. Five PD 
fibroblast cell lines were incubated with 50 µmol/l rhGAA in the absence and presence of 10 mmol/l NAC. (b) In all cell lines coincubation of rhGAA 
with the chaperone resulted in an improved correction of GAA deficiency, with increases in GAA activity ranging from ~3.7–8.7-fold the activity of 
cells treated with rhGAA alone. (c) In the presence of NAC also the amount of fluorochrome-labeled GAA increased, compared to cells incubated 
with fluorescent GAA alone. (d) The amounts of GAA polypeptides in the cells treated with NAC and rhGAA were also increased, compared to cells 
treated with the recombinant enzyme alone. Density scans of GAA bands show a relative increase of mature 76 and 70 kDa GAA isoforms in the 
presence of NAC (e).
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We also tested the combination of NAC and rhGAA in a 
mouse model of PD.34 Mice were treated with a single injec-
tion of rhGAA at high doses (100 mg/kg) in combination with 
oral NAC for 5 days (Figure 6a). Mice treated with the recom-
binant enzyme alone were used as controls. Forty-eight hours 
aer rhGAA injection the animals were euthanized and GAA 
activity was assayed in dierent tissues. In all tissues examined 
(liver, heart, diaphragm and gastrocnemium) the combination 
of NAC and rhGAA resulted in higher levels of GAA compared 
to rhGAA alone (Figure 6b).
Combined effect of NAC and imino sugar chaperones
A corollary of the fact that NAC and imino sugar chaperones 
interact with dierent protein domains, is that their eect may be 
cumulated. is hypothesis was supported by the results of ther-
mal denaturation of rhGAA performed in the presence of NAC, 
of the imino sugar DNJ, and of both molecules. Both NAC and 
DNJ increased rhGAA thermal stability, with DNJ causing the 
best shi in Tm (65.9 ? 0.3 °C). e combination of NAC and DNJ 
(Tm = 75.9 ? 0.3), however, resulted in the highest stability of the 
enzyme (Figure 7a).
A similar cumulative eect was also seen in PD broblasts from 
patients 2 and 4 incubated with rhGAA. e cells were incubated 
with rhGAA, with rhGAA plus either NAC or NB-DNJ, and with 
rhGAA plus the combination of the two chaperones. In both cell 
lines the combination of NAC and NB-DNJ resulted in the greater 
enhancement of GAA activity by rhGAA (Figure 7b). is might 
represent an additional advantage for the treatment of patients, in 
order to obtain the best stabilization of rhGAA and the highest syn-
ergy with ERT.
DISCUSSION
PCT is an attractive strategy to improve enzyme stability and is 
rapidly evolving towards clinical applications. However, con-
cerns have been raised on its clinical translation. First, known 
chaperones are active site-directed molecules and thus potential 
inhibitors of target enzymes.24 In addition, it has been shown that 
chaperones are eective in rescuing only some disease-causing 
missense mutations, mainly located in specic enzyme domains, 
and are thus potentially eective in a limited number of patients. 
For PD, it is possible to speculate that ~10–15% patients may be 
amenable to PCT.31
ese problems can be addressed by the identication of novel 
and allosteric noninhibitory chaperones. In this study, we have 
shown that NAC, and the related compounds NAS and NAG, are 
able to stabilize GAA without interfering with its activity and have 
a dierent chaperoning prole, compared to known chaperones. 
NAC is a known antioxidant that was evaluated in our laboratory, 
together with other related drugs (resveratrol, epigallo catechin-
gallate) in PD broblasts for possible eects on rhGAA intracellu-
lar tracking. e characterization of NAC’s mechanism of action 
on rhGAA, however, indicated that molecular interactions with 
the enzyme, rather than the antioxidant eect, were responsible 
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plus either NAC or NB-DNJ, and with rhGAA plus the combination of the 
two chaperones. In both cell lines the combination of NAC and NB-DNJ 
resulted in the highest enhancement of GAA activity by rhGAA (b).
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for rhGAA stabilization and that the other antioxidants stud-
ied did not stabilize the enzyme. is was somewhat surprising 
because NAC is structurally very dierent from the imino sugars, 
the only known pharmacological chaperones of GAA so far, that 
resemble the natural substrates/products of the enzyme.
We showed that NAC improved stability of GAA in response to 
physical stresses such as temperature and pH changes. Resistance 
to pH variations is of interest, as neutral pH may be representative 
of some of the environmental conditions encountered by recom-
binant enzymes in plasma and in certain cellular compartments. It 
has been shown that pH induces conformational changes in other 
lysosomal enzymes, such as ?-glucocerebrosidase,35 and that bind-
ing with pharmacological chaperones may favor the most stable 
conformations of the enzyme.
Here, NAC, and the structurally related amino acids NAS and 
NAG, prevented the loss of GAA activity as a function of pH and 
increased the enzyme thermal stability with no inhibition, while 
the nonacetylated counterparts had no eect. To rationalize these 
data at molecular level, we analyzed the conformational dynamics 
of a 3D model of GAA through MD simulations. Although a high-
resolution 3D-structure would certainly be the most accurate 
tool to perform these studies, structural models based on X-ray 
crystallography are not available for many glycosidases similar 
to GAA. According to these simulations, interaction with NAC 
favored a more stable conformation of the enzyme. Interestingly, 
the integrated analysis of the results of GAA simulations carried 
out in dierent conditions showed that a possible binding site 
for NAC could be located at 35 Å distance from the active site, 
thereby validating the allosteric stabilization observed in vitro. 
e binding site was dened based on the combined character-
ization of the variations in the local dynamics of specic protein 
sites in response to dierent pH conditions and to the presence/
absence of possible small-molecule ligands. Such analyses were 
next combined to the investigation of the druggability of possible 
identied binding pockets. e integrated analysis of the data 
eventually returned one solution that we dened as the putative 
allosteric pocket. Docking of NAC and its analogues to the allos-
teric pocket helped dene the most favorable pose for the chaper-
one in complex with the protein. A control docking run with DNJ 
proved that this molecule strongly favors binding to the active site 
(Supplementary Table S2).
ese observations were largely conrmed by the analyses 
performed in cellular systems (broblasts from PD patients and 
COS7 cells overexpressing mutated GAA constructs). In COS7 
cells that overexpress mutated GAA incubation with NAC resulted 
in signicantly increased residual GAA activity for three of the 
seven mutations studied. Remarkably, the chaperoning prole of 
NAC showed dierences compared to that of NB-DNJ and DNJ. 
is may translate into an expansion of the number of chaperone-
responsive mutations, and should be further investigated in large-
scale studies. It would be tempting to envisage that preliminary 
screenings in vitro on a number of chaperones would allow per-
sonalization of treatment protocols aimed at obtaining the great-
est benecial eect in dierent PD patients.
NAC also increased the ecacy of rhGAA in correcting the 
enzyme defect in PD broblasts. Compared to the eect of NAC, 
and of chaperones in general, on the mutated enzymes, this eect 
holds greater promise for the cure of patients aected by PD, and 
possibly of other lysosomal disorders. It should be considered that, 
while the enhancement of endogenous defective enzymes by chap-
erones in most cases resulted in minor changes in terms of resid-
ual activity (likely with a modest impact on patients’ outcome), 
the synergy of these drugs with ERT induced in PD broblasts 
remarkable increases in specic activity. In this study, coadminis-
tration of NAC and rhGAA resulted in complete correction of the 
enzymatic defect. An additional advantage of the combination of 
PCT and ERT is that the eect of chaperones is directed towards 
the wild-type recombinant enzyme and does not depend on the 
type of mutation carried by patients. us, any patient on ERT 
may benet from the coadministration of PCT.
e results that support a synergy between chaperones and 
recombinant enzymes have important clinical implications and 
may translate into improved clinical ecacy of ERT. e data 
obtained in our proof-of-concept in vivo experiments in PD mice 
appear promising in this respect, although treatment protocols 
with NAC need to be carefully optimized in studies on a larger 
number of animals. e concentrations used in our studies may 
appear relatively high and dicult to translate into human ther-
apy. However, toxicity of NAC is reported to be low and plasma 
concentrations in the range of 2-3 mmol/l can be reached for the 
treatment of paracetamol overdose.36 Long-term treatment with 
NAC doses of 5 g/kg/day (higher than those used in the in vivo 
experiments our study) has been used in the mouse model of eth-
ylmalonic encephalopathy and resulted in improved survival of 
treated animals.37 NAC therapy was also used in patients aected 
by this metabolic disorder, albeit at lower doses, and again resulted 
in improved clinical and neurological course and in improvement 
of biochemical markers. In addition it must be taken into account 
that, for a possible clinical translation of our data, a therapeutic 
protocol would be based on the administration of the chaperone 
at the time of ERT infusion, and not on a long-term daily admin-
istration of the chaperone. By using such an approach the risk 
of adverse events would likely be reduced. It is also possible that 
modications to NAC might be required to have the same stabiliz-
ing eect at lower concentrations.
It should be mentioned that clinical trials based on the com-
bination of imino sugar competitive chaperones and ERT are 
already in progress (see trials NCT00214500 and NCT01196871 
at http://clinicaltrials.gov; Telethon foundation trial GUP09017, 
http://www.telethon.it/ricerca-progetti/progetti-nanziati).
e identication of NAC and derivatives, which are structur-
ally very dierent from the other known pharmacological chap-
erones identied in PD is promising. In fact, other molecules, 
whose chaperoning activity cannot be simply inferred from their 
structure, may be eective in several lysosomal storage disease, 
thereby opening new and wider opportunities for the identica-
tion of novel therapeutic drugs.
MATERIALS AND METHODS
Fibroblast cultures. Fibroblasts from PD and Fabry disease patients 
were derived from skin biopsies performed for diagnostic purposes aer 
obtaining the informed consent from patients or from their parents. All 
cell lines were grown at 37 °C with 5% CO2 in Dulbecco’s modied Eagle’s 
medium (Invitrogen, Grand Island, NY) and 10% fetal bovine serum 
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(Sigma-Aldrich, St Louis, MO), supplemented with 100 U/ml penicillin 
and 100 mg/ml streptomycin.
Reagents. rhGAA (algucosidase, Myozyme) and rh-?-Gal A (agalsidase-?, 
Fabrazyme, for the experiments shown in Supplementary Figure S5) were 
from Genzyme, Cambridge, MA. As source of enzyme we used the residual 
amounts of the reconstituted recombinant enzymes prepared for the treat-
ment of PD and Fabry patients at the Department of Pediatrics, Federico 
II University, Naples, Italy. NAC, NAS, NAG, cysteine, serine, glycine, 
2-mercaptoethanol, 4-nitrophenyl-?-glucopyranoside (4NP-Glc), DNJ, 
NB-DNJ, and 1-deoxy-galactonojiirimycin were from Sigma-Aldrich.
The rabbit anti-GAA primary antibody used for immunofluorescence 
and western blot analysis was a gift from Dr Bruno Bembi and Dr Andrea 
Dardis, Centro di Coordinamento Regionale per le Malattie Rare, Udine, 
Italy; the anti-?-actin mouse monoclonal antibody was from Sigma-
Aldrich. The anti-rabbit secondary antiserum were from Molecular 
Probes, Eugene, OR; horseradish peroxidase-conjugated anti-rabbit or 
anti-mouse immunoglobulin G were from Amersham, Freiburg, Germany. 
Labeling of rhGAA was performed using the Alexa Fluor 546 labeling kit 
(Molecular Probes) according to the manufacturer instructions.
Enzyme characterization. The standard activity assay of rhGAA was per-
formed in 200 µl by using 5 µg of enzyme at 37 °C in 100 mmol/l sodium 
acetate pH 4.0 and 20 mmol/l 4NP-Glc. The reaction was started by adding 
the enzyme; after suitable incubation time (1-2 minutes) the reaction was 
blocked by adding 800 µl of 1 mol/l sodium carbonate pH 10.2. Absorbance 
was measured at 420 nm at room temperature, the extinction coefficient to 
calculate enzymatic units was 17.2 mmol/l–1 × cm–1. One enzymatic unit 
is defined as the amount of enzyme catalyzing the conversion of 1 ?mol 
substrate into product in 1 minute, under the indicated conditions.
Effect of pH on rhGAA. The effect of different pHs on the rhGAA stabil-
ity was measured by preparing reaction mixtures containing 0.75 mg ml–1 
of enzyme in the presence of 50 mmol/l citrate/phosphate (pH 3.0–7.0) at 
a certain pH. rhGAA mixture was kept at 37 °C and aliquots were with-
drawn at the times indicated (0–24 hours) and the residual GAA activity 
was measured with the standard assay.
To test the effect on the pH stability of rhGAA of pharmacological 
chaperones and other molecules and to test the effect of chaperones on 
rhGAA activity, experiments were performed as described above by adding 
to the reaction mixtures 0.1, 1, 10 mmol/l of the different compounds 
indicated in the text.
Analysis of thermal stability of rhGAA. Thermal stability scans of rhGAA 
were performed as described in ref. 38; briefly, 2.5 µg of enzyme were 
incubated in the absence and in the presence of NAC and DNJ, 10 and 
0.1 mmol/l, respectively, SYPRO Orange dye, and sodium phosphate 
25 mmol/l buffer, 150 mmol/l NaCl, pH 7.4 or sodium acetate 25 mmol/l 
buffer, 150 mmol/l NaCl, pH 5.2. Thermal stability scans were performed 
at 1 °C/minute in the range 25–95 °C in a Real-Time Light Cycler (Biorad, 
Milan, Italy). SYPRO Orange fluorescence was normalized to maximum 
fluorescence value within each scan to obtain relative fluorescence.
Modeling and molecular dynamics studies of GAA. The atomic struc-
tural model of GAA was constructed via homology modeling. The homol-
ogy module of the ICM software (Molsoft, San Diego, CA; www.molsoft.
com) was used for this purpose. The structure of the human maltase-
 glucoamylase,39 showing 44% identity over the aligned 868 residues of 
GAA, was used as a template. After alignment of the target sequence with 
the related 3D structure the modeling proceeded through the following 
steps: (i) a starting model was created based on the homologous struc-
ture with the conserved portion fixed and the nonconserved portion hav-
ing standard covalent geometry and free torsion angles; (ii) the Biased 
Probability Monte Carlo procedure was applied to search the subspaces of 
either all the nonconservative side-chain torsion angles or torsion angles 
in a loop backbone and surrounding side chains. The Biased Probability 
Monte Carlo procedure globally optimizes the energy function consisting 
of ECEPP/3 and solvation energy terms. Next, the structure was refined 
through energy minimization with the Gromos96 force-field and the good 
quality of the model was assessed using ICM, the WHAT_CHECK module 
of the program WHAT_IF and the program PROCHECK. This model was 
compared with previous modeling studies and the results appeared to be 
consistent with what reported by other authors.31,40
The structure obtained after the modeling step was subjected to MD 
simulation analysis. Three sets of MD simulations were run using the same 
protocol: one simulation for the isolated apo-GAA, one for GAA bound to 
NAC, and one for GAA surrounded by multiple copies of NAC or NAG. 
pH variations were mimicked by protonating ionizable groups according 
to their pKa values.
In each MD run, the system was solvated in a tetrahedral solvation 
box with a size allowing the presence of a 1.2-nm layer of water on each 
side of the protein. All simulations and the analysis of the trajectories were 
performed using the 4.0.3 version of the GROMACS software package41 
using the GROMOS96 force field42,43 and the SPC water model.44 In the case 
of the simulation with multiple copies of NAC or NAG, 10 molecules of co-
solute were randomly placed in the simulation box at a distance of 1.0 nm 
from GAA.
Each system was first energy relaxed with 2,000 steps of steepest descent 
energy minimization followed by another 2,000 steps of conjugate gradient 
energy minimization, in order to remove possible bad contacts from the 
initial structures. Next, the systems were first equilibrated by 50 ps of MD 
runs with position restraints on the protein and ligand to allow relaxation of 
the solvent molecules. These first equilibration runs were followed by other 
50 ps runs without position restraints on the solute. The first 20 ns of each 
trajectory were not used in the subsequent analysis in order to minimize 
convergence artifacts. Equilibration of the trajectories was checked by 
monitoring the equilibration of the root mean square deviation with respect 
to the initial structure, and of the internal protein energy.
Production runs span 100 ns each system studied. The electrostatic term 
was described by using the particle mesh Ewald algorithm. The LINCS45 
algorithm was used to constrain all bond lengths. For the water molecules 
the SETTLE algorithm46 was used. A dielectric permittivity, є = 1, and a 
time step of 2 fs were used. All atoms were given an initial velocity obtained 
from a Maxwellian distribution at the desired initial temperature of 300K. 
The density of the system was adjusted performing the first equilibration 
runs at NPT condition by weak coupling to a bath of constant pressure (P0 
= 1 bar, coupling time ôp = 0.5 ps).47 In all simulations the temperature was 
maintained close to the intended values by weak coupling to an external 
temperature bath with a coupling constant of 0.1 ps. The proteins and the 
rest of the system were coupled separately to the temperature bath.
The structural stability was initially monitored by analyzing the time 
evolution of structural parameters such as the root mean square deviation 
of each conformation visited from the starting structure.
The mechanistic determinants of GAA structural stability at different 
pHs was obtained by analyzing the protein’s pH-dependent geometric 
strain.27 This quantity reports on the variations of the local deformations 
of the residues’ contact networks as a consequence of the changes in their 
respective local structural environment. This parameter thus reflects the 
extent of conformational changes throughout the protein structure in 
response to specific perturbations.
Analysis of internal dynamic properties from MD trajectories. For each 
MD trajectory we computed the regions in which the geometric deforma-
tion accumulates. Such quantity, defined as geometric strain accumulates 
can be characterized by defining the strain of a given amino acid, i, as
where j runs over all protein amino acids, and f is a sigmoidal function 
that restricts the contribution to the sum to amino acids that are within 
p i A f dij ij( ) = å∑ ( )
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about 5 Å from amino acid i: f(x) = [1−tanh(x−5)]/2, where x is expressed 
in Ångstroms. Regions that respond dierently to a certain perturbation 
(such as the pH change, the presence of a certain ligand) are characterized 
by dierent values of p because in the course of the dynamical evolution 
their local network of contacts appreciably changes due to the relative 
motion of neighboring substructures.
To identify the regions of the protein surface that may be most frequently 
in contact with NAC, we combined MD simulations with molecular 
docking experiments. e density maps report the areas on the protein 
where NAC molecules cluster for most of the time. It is worth mentioning 
that this simulation should be intended as a coarse-grained exploration of 
the surface rather than a docking calculation. We ran an additional 100 ns 
MD simulation with one copy of GAA surrounded by 10 copies of NAC 
molecules, initially placed at random positions in the simulation box.
In order to generate a rened and optimized model of the possible 
NAC–GAA complex, the surface of the protein was further scanned for 
possible small-molecule binding sites with the “Site Map” function of 
the Maestro suite of programs. is function identies possible sites on 
a protein that have the structural and functional requirements that are 
optimal for binding a small molecule. e pH responsive hot spot region 
identied earlier was thus used as a target for a set of unrestrained docking 
calculations, using a large receptor 3-D grid of 20 Å of length on each 
side around the hot spot, which also included the residues that resulted to 
contact NAC in the aforementioned MD exploration.
Effect of NAC in COS7 cells and PD fibroblasts. Cultured PD broblasts 
and COS7 cells were treated with 10 mmol/l NAC for 24 hours before 
being harvested and used for GAA assay. COS cells were transfected with 
mutated GAA gene constructs as indicated in refs. 30,31.
GAA activity was assayed by using the uorogenic substrate 
4-methylumbelliferyl-?-D-glucopyranoside (Sigma-Aldrich) as described 
in ref. 22. Briey, 25 µg of protein were incubated with the uorogenic 
substrate (2 mmol/l) in 0.2 mol/l acetate buer, pH 4.0, for 60 minutes in 
incubation mixtures of 100 µl. e reaction was stopped by adding 700 µl 
of glycine-carbonate buer, pH 10.7. Fluorescence was read at 365 nm 
(excitation) and 450 nm (emission) on a Turner Biosystems Modulus 
uorometer. Protein concentration in cell homogenates was measured by 
the Bradford assay (Biorad, Hercules, CA).
Western blot analysis. To study GAA immunoreactive material, broblast 
extracts were subjected to western blot analysis as described in ref. 21. e 
cells were harvested, washed in phosphate-buered saline, resuspended in 
water, and disrupted by ve cycles of freeze-thawing. Equal amounts (20 µg 
protein) of broblast extracts were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and proteins were transferred to PVD 
membrane (Millipore, Billerica, MA).An antihuman GAA antiserum was 
used as primary antibody to detect GAA polypeptides; to detect ?-actin, 
a monoclonal mouse antibody was used. Immunoreactive proteins were 
detected by chemiluminescence (ECL; Amersham). To quantitate the 
amounts of GAA-related bands western blots were analyzed by ImageJ.
Immunofluorescence analysis and confocal microscopy. To study the dis-
tribution of AlexaFluor546-labeled GAA, PD broblasts grown on cover-
slips were xed using methanol, permeabilized using 0.1% saponin and 
locked with 0.01% saponin, 1% fetal bovine serum diluted in phosphate-
buered saline for 1 hour. e cells were incubated with the primary anti-
bodies, with secondary antibodies in blocking solution and then mounted 
with vectashield mounting medium (Vector Laboratories, Burlingame, 
CA). Samples were examined with a Zeiss LSM 5–10 laser scanning confo-
cal microscope.
In vivo studies. Animal studies were performed according to the European 
Union Directive 86/609, regarding the protection of animals used for 
experimental purposes. PD mice were housed in the TIGEM animal facil-
ity. Every procedure on the mice was performed with the aim of ensuring 
that discomfort, distress, pain, and injury would be minimal. Mice were 
euthanized following avertin anesthesia by cervical dislocation. To study 
the eects of the combination of NAC and rhGAA the animals were 
allowed to drink 138 mmol/l NAC in water ad libitum (4.2 g/kg/day) for 5 
days. On day 3 the animals received a single rhGAA injection. On day 5 the 
animals were euthanized and the tissues were homogenized with a tissue 
lyser and GAA activity was measured as described in ref. 21.
SUPPLEMENTARY MATERIAL
Figure S1. Molecular structures of the compounds analyzed in this 
study.
Figure S2. Effect of NAS, NAG, and nonacetylated amino acids on 
rhGAA at different concentrations (0, 0.1, 1, 10 mmol/l) and up to 48 
hours of incubation.
Figure S3. The analysis of the root mean square fluctuation (RMSF) 
per residue showed that the protein residues experience lower struc-
tural fluctuations at acidic pH than at neutral pH, suggesting a higher 
structural stability at the lower pH condition (data not shown).
Figure S4. Effect of the antioxidants epigallo catechingallate (EGCG) 
and resveratrol on the efficacy of rhGAA in cultured PD fibroblasts 
 (patient 3).
Figure S5. Molecular modeling data suggest that the interactions of 
NAC occur at a specific protein domain that shows sequence homol-
ogy within other glycosidases belonging to family GH31.
Table S1. The lists of residues reported in the table have been cal-
culated by running a simulation of GAA in the presence of 10 NAC 
molecules starting from random positions in the simulation box.
Table S2. Grid Docking scores of acetylated compounds to the 
 allosteric site, and of DNJ to the active site.
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